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Interferon gamma (IFN-γ) regulation of macrophages plays an essential role in innate immunity and 
pathogenicity of viral infections by directing large and small genome-wide changes in the transcriptional 
program of macrophages. Smaller changes at the transcriptional level are difficult to detect but can have 
profound biological effects, motivating the hypothesis of this thesis that responses of macrophages to 
immune activation by IFN-γ include small quantitative changes that are masked by noise but represent 
meaningful transcriptional systems in pathways against infection. To test this hypothesis, statistical 
meta-analysis of microarray studies is investigated as a tool to obtain the necessary increase in analysis 
sensitivity.  
 
Three meta-analysis models (Effect size model, Rank Product model, Fisher’s sum of logs) and three 
further modified versions were applied to a heterogeneous set of four microarray studies on the effect of 
IFN-γ on murine macrophages. Performance assessments include recovery of known biology and are 
followed by development of novel biological hypotheses through secondary analysis of meta-analysis 
outcomes in context of independent biological data sources. A separate network analysis of a microarray 
time course study investigate s if gene sets with coordinated time-dependent relationships overlap can 
also identify subtle IFN-γ related transcriptional changes in macrophages that match those identified 
through meta-analysis.   
 
It was found that all meta-analysis models can identify biologically meaningful transcription at 
enhanced sensitivity levels, with slightly improved performance advantages for a non-parametric model 
(Rank Product meta-analysis). Meta-analysis yielded consistently regulated genes, hidden in individual 
microarray studies, related to sterol biosynthesis (Stard3, Pgrmc1, Galnt6, Rab11a, Golga4, Lrp10), 
implicated in cross-talk between type II and type I interferon or IL-10 signalling (Tbk1, Ikbke, Clic4, 
Ptpre, Batf), and circadian rhythm (Csnk1e). Further network analysis confirms that meta-analysis 
findings are highly concentrated in a distinct immune response cluster of co-expressed genes, and also 
identifies global expression modularisation in IFN-γ treated macrophages, pointing to Trafd1 as a 
central anti-correlated node topologically linked to interactions with down-regulated sterol biosynthesis 
pathway members.  
 
Outcomes from this thesis suggest that small transcriptional changes in IFN-γ activated macrophages 
can be detected by enhancing sensitivity through combination of multiple microarray studies. Together 
with use of bioinformatical resources, independent data sets and network analysis, further validation 
assigns a potential role for low or variable transcription genes in linking type II interferon signalling to 
type I and TLR signalling, as well as the sterol metabolic network. 
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This chapter provides background for understanding the use of statistical meta-
analysis for the detection of subtle gene transcription changes in macrophage type 
II interferon signalling.  This covers macrophages, interferon gamma signalling in 
macrophages, microarray technology and meta-analysis. Also included is a final 
overview of the thesis rationale, research context and structure.  
 
1.1 Macrophage biology and interferon signalling 
 
Macrophages (MØ) are an important and highly heterogeneous component of the 
innate immune system, where their primary function is the first-instance 
recognition, ingestion and destruction of pathogens or tumour cells. Their immune 
functions include signalling and antigen-presentation to other immune cells (e.g. 
neutrophils, lymphocytes), therefore also giving them a function in the adaptive 
immune system. In line with their first-responder immune function, macrophages 
can be found throughout many tissues, their wide distribution aiding recognition of 
any foreign material. Apart from immune functions, macrophages have also site-
specific functions in wound repair and tissue organisation, steroid production, 
debris collection and homeostasis.  
 
Background. The role of macrophages in absorbing and digesting pathogens by 
phagocytosis was first comprehensively (for the time) described in 1905 
(Metchnikoff 1905). Subsequent research revealed much deeper levels of 
complexity in terms of function, location and development, leading to attempts at 
classifying macrophages within systems of cell types and subtypes (Aschoff 
1924). These were superseded by consensus at a 1969 conference and with some 
revisions published in 1972 (Vanfurth, Spector et al. 1972). The proposed 
“mononuclear phagocyte system” (MPS) is close to modern understanding and 
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includes the system from origin (bone marrow precursors) over circulation 
(peripheral blood monocytes) to local application (tissue-specific macrophages). 
The definition of this system is based on a shared origin (bone marrow), function 
(efficient internalisation of large particles), features (cell surface receptors for 
immunoglobulins and pathogens), distribution (as monocytes via peripheral 
blood). The authors acknowledged that this concise understanding of the MPS 
would undergo continuous revision in light of new research. 
In the decades since then, an overwhelming amount of knowledge has been 
generated (~288,000 macrophage-specific publications since 1972) on the 
development, distribution, morphology and function of macrophages. 
Phagocytosis in particular has been recognised as highly complex due to the wide 
range of different surface and internal receptors present in macrophages, as well as 
pathogen interactions with the macrophage itself (Aderem and Underhill 1999). 
This diversity of pathogen-recognition and -interaction routes accounts for 
complicated and interlinked signal transduction pathways. One of the most 
significant distinctions since made between macrophage subpopulations is that 
between classical activation and alternative activation, where either type has 
separate activating receptors (IFN-γ for classical; IL-4 and IL-13 for alternative) 
resulting in specific macrophage phenotypes with associated functionality. 
Classically activated and alternatively activated macrophages are also known as 
M1 and M2 macrophages, and the process of macrophages falling into either 
category as polarisation. In either case, these activation or pathways are usually 
balanced depending on type and time frame of infection, with a final macrophage 
deactivation stage applicable to both and induced by IL-10, TGF-β, 
glucocorticoids and other active molecules. 
 
Classical macrophage activation. In case of bacterial infections, it was recognised 
early (Mackaness 1964, Mackaness 1969, Tripathy and Mackaness 1969) that the 
macrophages response to both reinfection by the same bacteria and subsequent 
infection by other bacteria was more effective than a passive macrophage reaction 
(innate macrophage activation by pathogens only) to the presence of bacteria 
would suggest, and that there were other factors (lymphocytes such as T-cells) 
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rendering a macrophage hypersensitive to bacteria, leading to fast and specific 
macrophage responses. While these investigations revealed that macrophages were 
somehow activated not only by the pathogen but also by host-specific factors, the 
identity of this factor as IFN-γ was determined much later (Nathan, Murray et al. 
1983, Nathan 1991). This introduced the understanding of “classically activated” 
macrophages, where macrophages are primed (but not activated) by IFN-γ and 
activated by the presence of a pathogen (indicated by Lipopolysaccharides, LPS). 
In this model, T helper 1 cells (Th1) and natural killer cells (NK) produce the 
cytokine IFN-γ, which binds to macrophage IFN-γ receptors and keys them to 
enter a primed state that is associated with increased aptitude for antigen 
presentation, production of pro-inflammatory cytokines, chemokines and 
phagocytosis in reaction to LPS-sensing. Heightened macrophage immune 
functions are then triggered when bacteria are recognised through binding of LPS 
in their outer membrane to a corresponding receptor (TLR) on macrophages. IFN-
γ signal transduction is presented in more detail in chapter 5.  
 
 Alternative macrophage activation. If unchecked, classical activation of 
macrophages would lead to runaway immune responses to infection. This 
motivated the search for complementary signalling processes that might inhibit 
this excess. IL-4 (produced by Th2 cells rather than the IFN-γ producing Th1 
cells) was initially identified as macrophage-activating in 1987 (Crawford, 
Finbloom et al. 1987) and its function described in 1992 (Stein, Keshav et al. 
1992), where it was found to reduce macrophage production of pro-inflammatory 
cytokines, and to initiate a different activation state that results in expression of 
MHC class II antigens. As opposed to classical activation, no secondary 
(pathogen-provided) signal is required for macrophages to enter this state. In this 
model, Th2 cells produce IL-4 (and IL-13), which binds to MMR (macrophage 
mannose receptors) and initiates a different macrophage phenotype compared to 
that of classical activation, in this case resulting in reduction of pro-inflammatory 
cytokines, enhanced response to parasitic pathogens, and tissue repair. 
Macrophage phenotypes based on classical and alternative activation were 
summarised in 2003 (Gordon 2003), with the classical activation resulting in 
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enhanced macrophage sensitivity, pro-inflammatory responses, tissue damage, 
cell-mediated immunity and general microbicidal activity; and alternative 
activation resulting in anti-inflammatory responses, allergic responses, tissue 
repair, anti-parasite responses and macromolecule-mediated humoral immunity.  
 
Macrophage response to viral infection. Apart from their role in bacterial 
infection, interferons are also known for inducing and modulating an antiviral 
state, that is, the attack of the virus itself and induction of apoptosis in virus-
infected cells. This includes interferon alpha and beta (IFN-α/β), referred to as 
type I interferon (Bach, Aguet et al. 1997, Biron 1999, Taniguchi and Takaoka 
2002), as well as interferon gamma (IFN-γ), referred to as type II interferon 
(Muller, Steinhoff et al. 1994). Type I and type II interferon are described in a 
subsequent section. It has been noted that in this area the notion of macrophage 
polarisation into M1 or M2 type may be too restrictive. It is subject to large 
amounts of signal transduction crosstalk (Sica and Mantovani 2012), as various 
viruses are able to co-opt macrophage activity to their own ends. This increases 
the importance of identifying which factors can shift the balance between viral 
infection and host immune response. 
 
The above distinctions on activation and interferon signalling have remained intact 
in intervening years, but great detail has been added in terms of signal transduction 
pathways available through the application of microarray and other high-
throughput experiment platforms. Differences in whole-genome transcriptional 
profiles have been identified for M1 and M2 macrophages (Martinez, Gordon et 
al. 2006). 
 
Interferons. Of particular relevance to this thesis are transcriptional pathways 
related to interferon signalling in macrophages, and here microarray and other 
platforms have enabled the creation of databases specific to cell responses to type 
I, II or III interferon signalling (Samarajiwa, Forster et al. 2009), identifying 
around 2000 interferon stimulated genes. 
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The relevance of interferons to viral replication was noted in 1957 (Isaacs and 
Lindenmann 1957), when an unknown factor (later identified as type I interferon) 
released from membrane tissue infected with inactivated influenza virus 
subsequently interfered with live influenza infections. Since then, three families of 
interferon protein have been identified (type I, II, III), where type I comprises 
IFN-α, IFN-β, IFN-ε, IFN-κ, IFN-ω; type II comprises IFN-γ; type III comprises 
IFN-λ, IL-28 and IL-29. The role of interferons in the immune system is primarily 
seen as antiviral (Samuel 2001), with virus-infected cells producing type I 
interferons and antigen-stimulated cells producing type II interferons. Released 
interferon proteins engage with their respective receptors (IFNAR for type I, 
IFNGR for type II) in other host cells to start the signal transduction cascade, 
which results in the host’s antiviral response by directing the transcription of genes 
and translation of proteins (e.g. Zinc Finger antiviral protein (Karki, Li et al. 
2012)) that interfere with viral replication and attempts by viruses to subvert this 
response as well as modulating other immune responses. 
Macrophages possess distinct receptors for type I and II interferon, but the 
presence of type III interferon receptors has not been conclusively shown for 
mouse macrophages as yet, although it has been shown for human macrophages 
(Hou, Wang et al. 2009) and there is circumstantial evidence for macrophages 
responding to virus-induced IFN-λ (Melchjorsen, Siren et al. 2006). As described 
before, type II signalling is required for classical macrophage activation. Type I 
signalling is not a required signal for macrophage activation, but plays a 
prominent role in the induction of interferon stimulated genes and is required for 
the production of nitric oxide after microbe-triggered sensing of LPS (Vadiveloo, 
Vairo et al. 2000). 
The three interferon classes described above have distinctive signal induction 
pathways (although crosstalk between them can be substantive) and are described 
below. 
Type I interferon signalling is characterised by IFN-α or IFN-β (or all with the 
exception of IFN-γ) proteins binding to the interferon alpha receptor (IFNAR) on 
the cell membrane and activating the JAK-STAT pathway, resulting in 
STAT1/STAT2 heterodimers that can form a complex with IRF9 (then a 
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heterodimer), translocate to the nucleus and activate genes containing ISRE 
(Interferon Stimulated Response Element) motifs in their promoter. Type II 
interferon signalling is typified by IFN-γ binding to an IFN-γ receptor and also 
activating the JAK-STAT pathway, but where this results in the formation of 
STAT1 homodimers that translocate to the nucleus and activate genes containing 
GAS (Gamma Activated Sites) motifs in their promoter. Type III interferon 
signalling is less well characterised, and is assumed to share its function with type 
I interferon, but with JAK-STAT activation through IL28 or IL29 (and other 
cytokines) binding to an IFN-λ receptor. Both type I and type II interferon play a 
role in the activation of macrophages, although type II is regarded as the classical 
factor in this.  
For the purposes of this thesis, it is important to note that the included microarray 
studies are all concerned with the effect of IFN-γ on murine macrophages in the 
absence of any other factors (infections or treatments). The expected primary 
response is therefore type II interferon signalling in macrophages in the absence of 
signalling through other immune cells, although the length of treatment will allow 
for autocrine and paracrine effects within the macrophage cell population. The 
classical activation of macrophages requires stimulation by an extracellular IFN-γ 
signal, which engages a cell’s JAK-STAT pathway with the specific outcome of 
phosphorylating STAT1 proteins, which in turn dimerise, translocate to the 
nucleus and activate the transcription of genes containing a GAS (STAT1 
homodimer binding site) motif in their promoter region. With no particular focus 
on the type of interferon involved, these genes and those affected indirectly are 
referred to as Interferon Stimulated Genes (ISGs). The type II interferon pathway 
has been previously developed into a logic map representation (Raza, Robertson et 




Figure 1.1 Type II interferon signalling 1 
 
The pathway is arranged to flow from left to right. Components are coloured according to 
type (protein, complex or gene) and arranged within the sub-cellular compartments in 
which they are active. This pathway is initiated by IFNG binding to its receptor and a 
subsequent phosphorylation cascade involving a number of the JAK and STAT family of 
proteins. Several transcriptionally active complexes are formed (STAT1 homodimer, 
ISGF3 complex, STAT1:STAT1:IRF9 complex) and the pathway culminates with the 
transcriptional activation of target genes. 
(Figure 1 of Raza et al. BMC Systems Biology 2008, doi:10.1186/1752-0509-2-36, 
obtained under Creative Commons Attribution Licence) 
 
 
This canonical model does not include all possible modifiers of the type II 
immune response, and some of these are listed here. 
- Other genes or miRNAs positively or negatively regulating (via respective 
proteins) the JAK-STAT pathway, such as SOCS, PIAS (Greenhalgh and 
Hilton 2001) or miR-155 (Lu, Thai et al. 2009) targeting and potentially 
down regulating SOCS (at least in T-cells), or nitric oxide synthase 2 
(NOS2) associating with IFNGR1 in bacterial infection (Velez, Hulme et 
al. 2009). Other examples are Prn, Ptpn1, Cd45. 
- Complicated crosstalk with other signalling pathways like MAPK 
signalling or PI3K-AKT (Rane and Reddy 2000), particularly type I 
immune response and in newer research, with Ch25h in sterol metabolism 
(Blanc 2013).  
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- Activation/suppression of gene transcription that is not due to STAT1 
alone (such as activation of Irf1 only through joint activity of STAT1 and 
TNFα-activated NFκb (Ramana, Gil et al. 2002). Other examples are Jun, 
Cebpb, Hmga1, Myc. 
- Presence of a gamma-activated site in a gene may need to be 
complemented by both co-activators with STAT1, e.g. Brca1 (Ouchi, Lee 
et al. 2000) and other transcription factors like SP1 bound to other sites on 
that gene (Ramana, Gil et al. 2002). 
- In addition to interferon (or IFN-γ) related genes that are directly 
transcribed by STAT1, there are of course also genes (indeed, the majority 
of the interferon response) activated or suppressed further downstream and 




Microarrays are a physical substrate onto which nucleotide sequences are 
deposited as representation of genes, exons, or any other defined nucleotide 
sequence. When a biological sample is hybridised (binding of complementary 
nucleotide sequences) to a microarray, this allows the quantification of all genes’ 
transcription in that sample. 
 
1.2.1 Historical development 
 
“Southern blots” were developed by Ed Southern in 1975 (Southern 1975) as a 
method to detect specific DNA sequences in a given DNA target (DNA extracted 
from cells or tissues). These can be regarded as the earliest precursor of 
microarray technology, although the term “microarray” was not officially used in 
publications until 1995 (Schena, Shalon et al. 1995) in a gene expression context. 
By this time, gradual advances had led to the use of RNA instead of DNA, 
substrate-fixing of probes rather than the target, larger numbers of gene probes, 
and substrate improvements. Although larger cDNA libraries had been screened 
before using filter paper and labour intensive processes (Kulesh, Clive et al. 1987), 
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the concept of large-scale deposition of oligonucleotide sequences on a physical 
substrate was first patented1 in a series of patents by Ed Southern in 1998, 
although this has been subject to legal challenges (Rouse and Hardiman 2003). 
Various methodology papers followed (Maskos and Southern 1992, Maskos and 
Southern 1993, Southern, Casegreen et al. 1994), but Schena et al provide a first 
comprehensive application of microarrays in their use of glass slide substrates and 
high-density arraying robotics for dual-colour hybridisations, in this case 45 
probes were robotically deposited in a ~20mm2 area. While such glass-based 
oligonucleotide arrays were preceded by the earlier notion of photolithography 
(nucleotide sequences assembled base-by-base using masking technology) based 
sequence deposition (Fodor, Read et al. 1991), this technology did not become 
widespread until a larger number of gene sequences were known and could be 
included on more advanced versions, then known as Affymetrix2 microarrays. 
Following the availability of fully sequenced genomes, 1997 saw the first whole-
genome microarray study, an investigation of the yeast genome under multiple 
experiment conditions (Lashkari, McCusker et al. 1997). Since then, microarrays 
have become a mainstay of biological science, reflected in the number of newly 
published academic publications3 rising from 55 in the one year period 1997-1998 
to 5041 in the one year period 2011-2012. Although next-generation sequencing 
platforms (Metzker 2010) have since been developed into the next candidate for 
the collection of post-genomic data, the number of microarray data sets in public 
repositories (~34000 experiments in ArrayExpress4 as of April 2013) provides a 
large amount of raw data open for re-analysis or collective analysis. Microarray 
technology is also unlikely to disappear soon or completely until next-generation 
sequencing can achieve sufficient levels of standardisation in processing, analysis 
and data handling (Biesecker, Burke et al. 2012).  
 
                                                
1 United States Patent Office numbers: US6054270, US5700637 (note that these patents are later 
2 www.affymetrix.com 
3 Numbers obtained from Thomson Reuters Web Of Knowledge, searching for “microarray” in 
article title and “genes” in article topic (in order to exclude previous use of microarrays in 
electronic applications) and limiting period of search to the stated years. 
4 http://www.ebi.ac.uk/arrayexpress/ 
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1.2.2 Next-generation sequencing technology platforms 
 
Next generation sequencing (NGS) technology has been commercially available 
since 2006 and has found increasing use in obtaining complete snapshots of 
genomes or transcriptomes at single nucleotide resolution. The approach itself has 
many technological implementations (Mardis 2008), e.g. Roche/4545 sequencing, 
Illumina/Solexa 6  sequencing or SOLiDTM sequencing 7 . These differ in their 
sample processing protocols, labelling steps, data acquisition and performance; 
each platform also allows some degree of customising experimental protocols to 
highlight specific biological aspects (e.g. transcriptome sequencing). Generally, 
each method generates tens of thousands to billions of short reads. These are short 
sequences of nucleotide bases, the length and number of which is platform-
specific. The total number of all short reads represents the full DNA or RNA 
sequence of a given biological sample, albeit unordered. In order to interpret the 
complete genomic DNA snapshot of the sample, these short reads are either 
aligned to a known reference genome (“resequencing”) or aligned without a 
reference (“de novo sequencing”). Once aligned, the result is in theory the 
complete nucleotide sequence of all chromosomes in the original sample, although 
there are platform-specific limits and errors in the coverage and resolution of 
genomes. Platforms like RNA-seq 8  focus on the complete transcriptome by 
counting transcript abundance (frequency) of a given sequence in the sample.  
This provides similar outputs to microarray gene expression platforms, but in 
addition to providing expression level readings for known genes, it also allows the 
identification of novel genes or isoforms, splicing or single nucleotide 
polymorphisms. For analysis of RNA-seq transcriptome data, several challenges 
present themselves. The method and parameters of aligning short reads to a 
reference genome (as well as the choice of reference genome itself) affects the 
actual quantity measured, for example, one might measure splice variants of a 
gene independently or combined. Steps prior to statistical analysis therefore need 







appropriate consideration. Regarding numerical outcome measurements, it has 
been shown (Mortazavi, Williams et al. 2008) that both microarray and RNA-seq 
transcriptome analyses match true sample transcript levels. However, while 
microarrays give continuous intensity readings (usually within a 16-bit range) 
based on fluorescence levels, RNA-seq simply counts short reads mapped to a 
genome. The latter can be treated as discrete data or, after some normalisation 
steps, as continuous data. Preferred analysis methods for RNA-seq have not yet 
been settled, and discrete (Poisson, Negative Binomial distribution), continuous 
parametric (Normal, Log-Normal distribution) statistical models as well as non-
parametric models have all been used to similar effect in identifying gene 
differential expression (Anders and Huber 2010, Robinson, McCarthy et al. 2010, 
Busby, Stewart et al. 2013, Li and Tibshirani 2013, Soneson and Delorenzi 2013). 
While problems such as different signal ranges and sensitivity remain (Mortazavi, 
Williams et al. 2008), it is possible to combine or associate RNA-seq data with 
microarray data, and this has already been attempted  (Battke and Nieselt 2011, 
Chavan, Bauer et al. 2013, Mooney, Bond et al. 2013). Very recently, meta-
analysis methods were applied to multiple RNA-seq data sets (Jaffrezic 2013, 
Nikaido 2013), but the question of RNA-seq suitability for meta-analysis remains 
open, and combining RNA-seq data and microarray data within a meta-analysis 
may be possible but has not yet been explored. At this time, within the framework 
of this thesis any such exploration could only be theoretical, as no RNA-seq 
studies with the required experimental conditions currently exists, with the 
possible exception of a (albeit human) macrophage based study (Beyer, Mallmann 
et al. 2012). The meta-analyses in this thesis are therefore limited to microarray 
gene expression studies. 
 
 
1.2.3 Microarray technology overview 
 
Microarrays of the form relevant to this thesis (that is, discounting genotyping, 
exon, protein and other array types) consist of nucleotide sequences of assumed 
sufficient length to detect a complementary strand in the hybridised sample and to 
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be representative of a given gene. The sequence probes located on the microarray 
are referred to as probes, gene probes or features. The biological sample 
hybridised to a microarray is referred to as target sample. All technologies have in 
common that in order to detect a gene that is transcribed in the target sample, it 
has to be labelled (usually with a fluorescent tag) in the target sample prior to 
hybridisation to a microarray, and only binding of probe sequence and 
complementary labelled strand in the target cause this label to remain present on 
the microarray. This fluorescence is detectable by exposure to the correct light 
excitation frequency in a scanner instrument, providing for each gene a 
measurement of its transcription (“expression”) level in the target sample.  
Among the basic differences between microarray technologies are the method of 
probe deposition on a substrate and the required labelling of sequences in the 
target sample. In “spotted” or “printed” arrays, probe sequences (multiple copies 
thereof) are directly deposited onto a predetermined location on the substrate with 
a robotic array printer. In an Affymetrix array or “GeneChip” (figure 1.2), 
individual probe sequences are assembled nucleotide-by-nucleotide in-situ with a 
photolithographic masking process, with probe copies distributed across the array 
rather than at a single coordinate. A third and more recent option are bead arrays 
(Illumina9), where probe sequences (and copies thereof) are bound to microscopic 
silica beads that then get randomly arranged in microscopic wells etched into silica 
slides. Microarrays can also be distinguished by the number of channels, where 
this is the laser frequency used to quantitate hybridisation levels for a particular 
dye label. Array platforms are usually either single-channel (single-colour) or 
dual-channel (dual-colour). The ability to read out this number of channels often 
but not always corresponds directly to the number of samples (1 and 2, 
respectively) hybridised to an array. Affymetrix arrays are single-colour arrays in 
that only one channel (laser frequency) can be quantitated from them. This usually 
means one biological target sample at a time is hybridised to the full array of 
probes, resulting in a quantitative absolute measurement of expression for each 
gene. Printed arrays are commonly but not exclusively used in a dual-colour setup, 
with a test and a control target sample (differently dye labelled) co-hybridised to 
                                                
9 www.illumina.com 
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one probe array and two channels quantitated. This results in a quantitative 
relative measurement of expression for each gene. Illumina bead arrays can be 
quantitated as single-colour or dual-colour platforms, depending on the particular 
type. 
 
Figure 1.2 Affymetrix GeneChip processing 
  
Depicted are all laboratory procedures that are prior to confocal laser scanning of 
hybridised microarrays and subsequent to growing bone marrow derived macrophages in 
culture and either treatment or not with IFN-γ. 
 
 	  
Total RNA sample 
5’                                                       AAAAA        3’ 
5’                                                     AAAAA        3’ 
3’                                                     TTTTT –          5’ 
3’  TTTTT –          5’ 
Poly (A) – RNA controls  
T7 – oligo (dT) primer 
3’                                                     TTTTT –          5’ 
5’                                                     AAAAA –          3’ 






1.   Primer hybridisation 
2.   1st strand cDNA synthesis!
3.  2nd strand cDNA synthesis 
4.  Cleanup of double-stranded cDNA 
3’                                                   UUUUU 5’ 
5.  Amplification and biotin 
labelling of antisense cRNA!
6.  Cleanup of biotinylated cRNA 
7.  Fragmentation 




1.2.4 Microarray processing and analysis 
 
Subsequent to hybridisation of biological target samples to a microarray, a distinct 
number of steps are carried out before biological results are obtained. These are 
outlined in figure 1.3.  
 




This general workflow and methods applied at each step were introduced in the 
first few years after the introduction of microarray technology, with 
computational, statistical, bioinformatical and biological researchers applying their 
Hybridisation of biological target to microarrays 
Scanning of microarrays 
Image quantification algorithm 
Background noise correction data 
Data transformation (log2 or other) 
“Normalisation” of data distributions within 
arrays (dual-target) and/or across arrays 
(single-target) 
Non-specific filtering to remove genes of 
constant low expression or low variability 
Per-gene statistical hypothesis 
testing 
Gene pattern similarity 
clustering or classification 





existing expertise and specialisation to this new field. Although there are large 
numbers of later refinements and additions, the steps in this figure comprise the 
groundwork they are built on. A workflow based on sequential application of 
techniques is discussed in a paper on standard operating procedures for microarray 
analyses (Forster, Roy et al. 2003). Statistical issues regarding quantification of 
scanned microarray images are discussed in Glasbey et al (Glasbey, Forster et al. 
2007). Issues requiring early solutions were centred on several subject areas, 
which are outlined below. It should be noted that these were mostly concerned 
with printed arrays because the commercial availability and use of Affymetrix 
arrays dates later than the availability of the former. While procedures and 
algorithms for stages of a microarray study (data acquisition, pre-processing, 
experiment design and analysis) may differ for that platform, the stages 
themselves are the same. 
 
Data acquisition and storage. Microarray data provided amounts of data that 
limited the use of spreadsheets or text files for data handling and storage, making 
it necessary to develop and standardise methods for obtaining, identifying and 
storing data. Recognition of these issues was a primary motivator for establishing 
the Microarray Gene Expression Data society (MGED). From these efforts of 
developing standards came an early paper (Brazma, Hingamp et al. 2001) 
outlining the MIAME-standard (Minimum Information About Microarray 
Experiments) for characterising microarray studies and data, with the express 
purpose of making microarray data and their analyses reproducible within this 
framework of defined processes and terminology. This standard is still one of the 
underpinnings of the data collection and storage by the European Bioinformatics 
Institute’s ArrayExpress database and the National Centre for Biotechnology’s 
Gene Expression Omnibus database, two main providers of publicly available 
microarray data sets. It also paved the way for researchers to upload experimental 
data to a central resource, allowing easy and unprecedented access to data to re-
analyse them, or as is the case in this thesis, to combine them. 
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Data pre-processing. Numeric microarray gene expression data are based on the 
quantified (using image processing algorithms) fluorescence of images scanned at 
the excitation frequency of the label used for tagging sequences in the target 
sample. Before analysing these data, it was recognised that further processing had 
to be applied in order to address noise and variation introduced by prior steps (e.g. 
RNA extraction, RNA amplification, dye labelling, hybridisation, scanning, array 
imperfections). In this regard, “normalisation” is now the step that removes such 
systematic sources of variation based on assumptions. The goal is to centre data 
distributions on 0 (if using dual-colour arrays that result in log-ratio expression 
measurements) or to match overall array distributions between all arrays in the 
study (if using single-colour arrays). For printed arrays, an additional issue were 
expression differences introduced by robotic arraying, with different “print tip” 
groups possibly leading to different measurement levels. In either case, 
normalisation is based on one of two fundamental assumptions. One is that the 
effect of any sample treatment or measured condition is limited to a small set of 
genes and not the full genome represented on the array. In case this cannot be 
assumed, the second assumption is that a selected set of probes (spiked in or 
existing housekeeping genes) should not change expression in response to 
treatment or in different conditions. 
Although some early approaches (Kerr and Churchill 2001) suggested statistical 
analysis models (specifically, linear models incorporating variation sources) could 
account for all types of variation and error, independent normalisation alternatives 
were proposed and later incorporated into standard workflows. Although primarily 
concerned with gene expression profile clustering algorithms, normalisation 
strategies to address sources of systematic variation were usefully reviewed by 
Quackenbush in 2001 (Quackenbush 2001) and further expanded in 2002 
(Quackenbush 2002). These early normalisation approaches were focused on 
printed dual-colour arrays (with expression data obtained as ratios) and centering 
log-ratios for all genes on an array around 0. Although this methodology does not 
apply to single-colour microarray platforms like Affymetrix or Illumina, the 
underlying assumption of a majority of genes on an array being unaffected by any 
tested condition or applied treatment remains common. For dual-colour arrays, 
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non-linear normalisation methods (e.g. fitting a weighted smoother line in a 
regression of signal intensity to signal ratio) remain common due to dye-label bias, 
but more generic methods were developed specifically for single-colour platforms. 
Primary examples of those are Variance-Stabilising-Normalisation (VSN) 
introduced by Huber in 2002 (Huber, von Heydebreck et al. 2002) and the Robust-
Multiarray-Average (RMA) introduced by Irizarry in 2003 (Bolstad, Irizarry et al. 
2003, Irizarry, Bolstad et al. 2003, Irizarry, Hobbs et al. 2003). The former uses 
the verifiable assumption that the coefficient of variation at low expression levels 
is different from that at higher expression levels, motivating different data 
transformations along the range of expression values. The latter incorporates a 
background correction, log-transformation, robust multi-probe averaging and is in 
effect a quantile normalisation, that is, it matches all quantiles (as opposed to just 
the median or another single point estimate) across all arrays in the study.  
 
Experiment design and statistical analysis. Microarray technology initially had 
uncertain properties and characteristics, requiring re-establishment of common 
statistical procedures for this platform. This particularly concerned dealing with 
sources of variation, which included arrays, probes, dye labelling, RNA 
processing, hybridisation, target samples and numerous other potential sources. 
These questions were initially addressed 2001 (Kerr and Churchill 2001) and 2002 
(Churchill 2002, Yang and Speed 2002), discussing differences between technical 
and biological replication, arrangement of dye labelled samples amongst the full 
set of microarrays, utility of universal reference samples, and various statistical 
study designs already well-known outside the microarray community.  
The issue of study design is closely related to that of data analysis, and early work 
in this area still informs statistical microarray analysis models in use today. 
Concerns here included quantitative ways to characterise signal noise for inclusion 
in linear models, assumptions about the normal or lognormal data distribution of 
gene expression measurements, non-linear effects of dye labelling on gene 
expression, and the use of reference samples in a linear model. These were 
formally addressed in 2000 (Kerr, Martin et al. 2000) and resulted in the 
application of analysis of variance (ANOVA, already a well-established analysis 
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model in other areas of science) to microarray data. The linear model for 
determining the difference between group means (arithmetic or geometric) --given 
the measured within-group and across-groups variance and error-- was the 
theoretical foundation for applying per-gene hypothesis tests on differential 
expression. An important issue yet to be addressed were issues of “multiple 
testing”, which is inherent in microarray technology. It is statistically inevitable 
that the testing of multiple hypotheses at the same time will incur high false 
discovery rates (that is, false rejections of the null hypothesis in statistical 
inference test). For microarrays, genes were recognised to be the variables on 
which inference tests are performed, and their number exceeded that common to 
other applications (e.g. clinical trials, where maybe a handful of physiological 
variables might be tested). Dudoit et al recognised in 2002 (Dudoit, Yang et al. 
2002) that multiple testing adjustments to computed p-values for genes were a 
necessity in order to avoid large numbers of false positive results to validate. 
Investigations showed that the simplest approach (Bonferroni correction) would be 
extremely conservative in the presence of thousands of variables and presented 
several alternatives, including the less conservative and now frequently used 
methods of controlling the false discovery rate (FDR). These FDR methods were 
subsequently investigated in detail and confirmed as a viable choice (Reiner, 
Yekutieli et al. 2003). 
Also of interest in that period of time were suggested alternatives to simple linear 
models, specifically those based on Bayesian statistics. These were discussed by 
Efron as early as 2001 (Efron, Tibshirani et al. 2001) as well as Smyth in 2004 
(Smyth 2004) and laid the foundation for the now widely used “empirical Bayes” 
hypothesis tests, which -- instead of using information of one gene at a time – 
borrow information (in this case expression variance estimates) from other genes, 
resulting in more robust results for microarray studies consisting of small numbers 
of samples per group. A relatively late addition was the Rank Product method 
(Breitling, Armengaud et al. 2004), a simple yet robust statistical test focusing not 
on group mean expression differences, but on relative rankings of differential gene 
expression that take into account broad relationships between genes in terms of 
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their rank consistency across all samples (or rather, sample combinations of 
treated and control samples).   
In parallel to statistical hypothesis testing, the development of pattern recognition 
algorithms for gene expression profiles began in 1998 with Eisen’s seminal paper 
on cluster analysis (Eisen, Spellman et al. 1998). This began still on-going 
attempts to assess similarity (or dissimilarity) patterns between genes in their 
expression levels changes across multiple samples, usually multiple biological 
conditions or sequential time points. Using machine learning algorithms to 
identify such clusters of gene expression is aimed at identifying gene function 
modules on the basis of gene co-expression. Such measurements of similarity or 
association between genes are also used for generation of gene network graphs, 
where genes are drawn as nodes and the strength or nature of their relationship is 
indicated by a drawn edge between them (Freeman, Goldovsky et al. 2007). 
 
It was specifically the application of clustering algorithms that highlighted the 
issue of missing values in microarray data sets, since many algorithms require the 
presence of complete data matrices to calculate distances between genes or 
samples. This resulted in many algorithms designed to estimate replacement 
values (to “impute”) based on the values of other genes or samples, primarily 
through first finding genes or samples similar to the one with missing values. 
These are in common use, but they have never been explored in context of 
hundreds or thousands of missing values that are introduced when combining 
different microarray platforms (with differing genome coverage) for a meta-
analysis. Chapter 4 introduces and addresses the issue of missing values in detail. 
 
Microarray technology presented a necessity and opportunity in the measurement 
of full or large proportions of genomes. It provided a wealth of information 
previously unobtainable in smaller-scale experiment platforms, but it also required 
difficult large-scale validation of all positive results. Into this space fell the 
development of bioinformatics tools and resources. These provided existing 
knowledge in form of gene annotation, e.g. identities, functions, pathways, or 
related research. Increasingly, they also provided analytical tools for testing gene 
 32 
lists (usually resulting from prior statistical or machine learning analysis) for 
enrichment of particular gene functions, membership of known pathways or other 
properties. One important early resource providing existing annotation in form of a 
database was DAVID (Dennis, Sherman et al. 2003), tools like GOstat (Beissbarth 
and Speed 2004) added to the field the capacity to perform the above mentioned 
enrichment analysis of existing annotation. These tools have proven invaluable, 
undergone continuous development and now exist amongst a very large number of 
bioinformatics tools at the disposal of researchers to make sense of and create new 




DNA microarray technology is used to measure a biological sample’s 
transcriptome as a proxy for biological function carried out through the proteome. 
Since the conception of this technology, many discoveries have been made that 
highlight the its limitations. It is known that, firstly, mRNA (messenger RNA) 
expression levels in many cases do not have a proportional relationship with 
protein abundance or the magnitude of their biological effect (Ozbudak, Thattai et 
al. 2002, Watterson, Guerriero et al. 2013). Secondly, it is known that mRNA 
comprises only part of the transcriptome, and microarray technology by its design 
(with the exception of tiling arrays) will measure expression of protein-coding 
genes. However, there are a multitude of non-protein coding RNAs that have been 
found to interact with themselves or other RNAs and proteins (Wan, Kertesz et al. 
2011). Examples of these non-coding RNAs are miRNA (microRNA), siRNA 
(short interfering RNA), rRNA (ribosomal RNA) and tRNA (transfer RNA), and 
their total number (in the human genome) has been estimated at more than 
400,000 such RNA sequences (Willingham and Gingeras 2006), although it is 
unclear how many of them have an actual function (Rederstorff, Bernhart et al. 
2010).  
In the above context, RNA-seq as a full-genome coverage technology has been a 
useful tool (Forrest and Carninci 2009, Fasold, Langenberger et al. 2011) in 
identifying and characterising non-coding RNAs. 
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Within the framework of this thesis and for any meta-analysis on data obtained 
from databases, it is important to acknowledge that these data are often from older 
generations of microarrays and that this means the measured mRNA levels do not 
represent a complete picture of expression. The design of these arrays will miss 
both protein-coding (mRNAs not known or predicted at the time) and non-coding 
RNAs, and the gene sets identified through any analysis (including the meta-
analyses in this thesis) will only represent a limited starting point to understanding 




A detailed introduction to the specific meta-analysis models used in this thesis is 
provided in chapter 3, including historical context and equations. The introductory 
section here is therefore limited to providing the general context of meta-analysis 
and ultimately its relation to microarray studies. 
 
1.3.1 Definition and background 
 
A contemporary definition is provided by the Cochrane Collaboration10 glossary, 
with meta-analysis as “The use of statistical techniques in a systematic review to 
integrate the results of included studies”, where a systematic review is a “review 
of a clearly formulated question that uses systematic and explicit methods to 
identify, select, and critically appraise relevant research, and to collect and analyse 
data from the studies that are included in the review”. 
 
A more concise definition from a statistician’s point of view (Dersimonian and 
Laird 1986) is “the statistical analysis of a collection of analytic results for the 
purpose of integrating the findings”. 
 
                                                
10 www.cochrane.org (This is an international collaboration serving as a centralised 
resource for collecting officially registered randomised controlled clinical trials, meta-
analyses, support and information) 
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In either definition, it is of particular importance that meta-analysis is not 
concerned with combining the observed data from multiple studies, but with 
combining the results obtained in multiple studies. 
 
Background. The idea of combining several studies on a subject to obtain a better 
result is not new and has existed for centuries outside of any formalised 
framework, findings were anecdotally or selectively combined or limited to 
literature reviews. Although the latter are related and useful tools for combining 
the knowledge inherent in a field, they lack the quantitative and statistical 
framework to formally combine numerical findings across studies. The first 
documented use of a formal quantitative combination of results from multiple 
similar studies can be attributed to Karl Pearson, who combined typhoid 
inoculation studies on soldiers in order to assess correlation between typhoid 
disease, mortality, and inoculation (Simpson and Pearson 1904). The basic 
principle used in that report consists of computing estimates for the strength of 
association between two variables for each study, with an overall estimate then 
calculated across all similar studies. Pearson noted that the variation of per-study 
estimates had a large effect on the outcome and suggested formal investigation of 
such variation across studies. Although not named in the original report, this 
introduced the concept of study heterogeneity and is of primary importance in 
meta-analysis. This initial report has given rise to decades of research on this 
subject, and it inspired the concepts still in use for general meta-analyses today. 
The term “meta-analysis” itself was introduced in 1976 (Glass 1976) and it is one 
subtype of approaches collectively known as research synthesis (Chalmers, 
Hedges et al. 2002). “Meta-analysis” maintains its special definition, but if used 
by non-statisticians, “meta-analysis” is occasionally used as collective term for 
other forms of research synthesis, which include “data integration”, “data fusion”, 
and others that combine data rather than results or that are another form of data 
integration. This thesis is concerned with the statistical form of meta-analysis and 




Objectives. The main objective of many meta-analyses is to obtain a quantitative 
combined estimate of the effect of a treatment or condition on a measured variable. 
For clinical trials, this may be the observed size of the effect of aspirin (the 
treatment) on cancer patients’ mortality rate (the variable). It should be noted that 
in context of microarrays, each gene is a variable, which requires that as many 
meta-analyses are performed as there are genes. 
The underlying assumption is that any single study will provide limited statistical 
power to obtain meaningful results, or that a projected treatment effect is very 
small, or that the variable of interest is heterogeneous between study populations. 
A combined estimate in theory provides larger virtual sample sizes (where sample 
size here refers to the number of biologically independent samples, i.e. individual 
mice) and therefore a more powerful statistical representation of the treatment or 
condition under investigation, although this is subject to many caveats regarding 
selection and design of suitable studies and analysis methods. A secondary 
objective is often an active investigation into how different studies contribute to 
overall estimates of treatment effect, that is, study heterogeneity itself is the 
subject of interest. 
 
1.3.2 Meta-analysis key considerations 
 
For a meta-analysis to be successful, correct selection of studies and application of 
analysis is crucial but subject to many biases (Egger and Smith 1998, Walker, 
Hernandez et al. 2008). Key considerations are here detailed, also taking into 
account how these relate to meta-analyses based on microarray technology. 
 
Publication bias. Of foremost concern for meta-analysis is publication bias, in 
which the availability of studies is biased towards those with positive results, that 
is, studies with negative outcomes are often not published, severely limiting the 
interpretability of meta-analysis results. Interestingly, for microarray studies this 
problem is potentially alleviated for basic biological studies, because measuring 
full genomes can imply that at least some genes will observably respond to some 
intervention or show differences in some condition, increasing likelihood of 
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publication. Informal investigations (Ramasamy, Mondry et al. 2008) suggest that 
a small percentage (10%) of commercially purchased microarrays do not get 
published, although it is unclear if this is caused by negative results, technical 
array failures, or other reasons for non-completion of project.  
 
Search parameters. Even if a study has been published (and in case of microarray 
studies, data uploaded), a successful meta-analysis requires that the underlying 
investigative question is similar enough across studies. Initial searches depend on 
the tools used (literature databases, search engines, study registries) and the search 
criteria chosen (keywords). For microarray studies, biological domain knowledge 
is of crucial importance, as biological experiments are often removed from a 
(relatively constrained) human subject setting and the exact nature of organism, 
tissue types, cell types, treatment regimes and technology platform become very 
important.  
 
Study selection bias. Once search parameters are decided and candidate studies 
identified, a selection needs to be made on the basis of inclusion and exclusion 
criteria for studies to undergo meta-analysis. This concerns study design 
(randomised controlled trials, group sample sizes, the type of replicated samples 
(individual subjects, cell lines, pooled samples, technical replicates) source 
population, time frame and more), questions of data quality (inclusion of low 
quality studies will have an effect on combined meta-analysis outcomes) and 
processing and availability of data (are per study effect sizes of the same type and 
the same scale?). For microarray studies, study design is of the same importance, 
but with regard to data quality and data processing they present a sizeable 
advantage in the availability of all unprocessed data in public repositories. That is, 
for microarray meta-analyses one is not limited to effect size or p-value estimates 
listed in published articles, because the full unprocessed data sets can be 
downloaded and individually and identically processed and analysed.  
 
Study heterogeneity. It can be assumed that no two independent studies will return 
absolutely identical results. For meta-analyses, this poses a problem in terms of the 
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degree of the dissimilarity between study results (heterogeneity). Considerations 
here are how similar primary study results of the observed treatment effect have to 
be for a study to be included in a meta-analysis. In the absence of knowledge on 
the cause of any differences (which may be real differences, or issues with 
population sampling, treatments, analysis), a decision usually needs to be made 
based on a metric. One such method is a forest plot (Lewis and Clarke 2001), a 
reference example of which is shown in chapter 3 (figure 3.2). This plot depicts 
the effect size and its confidence interval (CI95, meaning the true population 
effect size will lie in this range with a probability of 95%) for each individual 
study, allowing a rough decision to be made based on the amount of overlap 
between these confidence intervals. That is, for studies to be selected, their 
confidence intervals should ideally overlap and share the same effect directionality 
(i.e. either a positive or negative effect size). However, this can only form the 
basis to visually identify extreme outlier studies. An alternative to this visual 
assessment is a statistical test for study heterogeneity (e.g. a 𝜒! test based on the 
null hypothesis of “no differences in effect size across all studies”), although this 
is also not free of risk: if there are too few studies, the statistic is flawed, if there 
are too many studies, the statistic is too good at identifying small heterogeneity 
levels. In terms of microarray studies, the issue of heterogeneity is difficult to 
address, because the number of studies and the size of studies are usually small 
(this is quantified in chapter 3).  
 
Study size. Small study sizes mean that the statistical power of individual studies 
to detect small expression changes is very limited and subject to error, increasing 
heterogeneity between studies. The limitation in numbers of studies prevents 
reasonable estimation of study heterogeneity as discussed above. This is a clear 
limitation compared to meta-analyses on randomised clinical trials, where studies 
are usually required to be sufficiently powered and where more studies may be 
available. The use of forest plots or heterogeneity tests is also limited because in 
addition to plotting per-study outcomes, this would also have to be done for each 
gene (variable) separately. An investigation into summary statistics (e.g. 
proportion of genes on array for which confidence intervals do not overlap across 
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studies, or for which a test indicates significant heterogeneity across studies) 
would be of worth, but for this thesis the issue is considered secondary to 
biological validation of meta-analysis usefulness. 
 
Multiple testing issue. Identical to the multiple testing issue described in section 
1.2.4, microarray meta-analyses in particular are subject to a large number of 
statistically significant but false positive results because many thousands of 
variables are tested simultaneously. A 1-in-20 accepted false positive rate for a 
single test implies 500 false positive results when testing 10000 genes, and if 
required for publication reasons, meta-analysis p-value thresholds can be adjusted 
downwards as explained in section 1.2.4. 
 
1.4 Microarray meta-analysis 
 
A detailed introduction to meta-analysis models used in this thesis is provided in 
the introduction to chapter 3, including historical context and equations. This 
section introduces the field of microarray meta-analysis, because this has 
advanced independently of the general concept. 
 
1.4.1 Literature summary 
 
The field of microarray meta-analysis is small compared to many other areas. 
Using strict search criteria requiring the title of a published article to contain both 
“meta-analysis” and “microarray” identifies 116 journal articles in a Thomson 
Reuter Web of Knowledge search across all publication years (as of 19 Mar 2013, 
shown in figure 1.4) The resulting body of publication begins in 2002, around the 
same time as research into general microarray analysis issues (section 1.2 above). 
There are clear indications that, as a research theme, this subject peaked in 2008 
and subsequently is associated with less primary research interest (although meta-
analyses continue to be applied and user-oriented software continues to be 
developed). It is unclear if this is related to statistical researchers changing their 
focus to analysis issues around next-generation sequencing platforms, although a 
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corresponding search for “next generation sequencing analysis” (as individual 
search terms) provides an indication that this may be a contributing factor (figure 
1.5), with this subject rising after microarray meta-analysis peaks. At the outset 
and during the development of a body of research for this thesis, the subject matter 
of microarray meta-analysis would have presented an ideal opportunity to 
contribute to the first wave of developments, it is therefore unfortunate that the 
extended part-time nature of this thesis prevented timely use of this opportunity. 
However, as shown in figure 1.4, this work will still fit into (albeit a reduced 
quantity of) contemporary research, and it is a positive that the actual use of 
microarray meta-analyses on biological data is still on the increase, assuming a 
search of the terms “microarray” and “meta-analysis” as a topic rather than as part 
of a publication title presents suitable proxy evidence for this (figure 1.6). 
 
Figure 1.4 Publications with “microarray” and “meta-analysis” in title 
 
 











It is possible to speculate that the relative scarcity of microarray meta-analyses 
(for reference, there are >30000 published papers on meta-analysis of clinical or 
other trials within the last 5 years alone) is not only due to insufficient numbers of 
research studies, high diversity of research hypotheses, and reluctance to recreate 
similar existing data, but also to the absence of sufficient numbers of statistical 
analysts within biological departments, or the absence of easy-to-use software for 
meta-analysis purposes. 
 
Despite the reduction of new content produced on meta-analysis methodology, this 
remains a current research subject (for microarray as well as next-generation 
sequencing technology) as well as an applied methodology. Current updates to the 
field are outlined in paragraph “Current Developments” in section 1.4.2. 
 
1.4.2 Development of meta-analysis for microarray data 
 
Earliest application to microarrays. The concept of applying statistical meta-
analysis to studies based on microarray data coincides with the increased 
availability and affordability of microarrays (both printed and in-situ deposition 
arrays) and one of the earliest suggestions for this can be found in a 1999 paper 
(Khan, Saal et al. 1999). However, the first attempt to formally apply a meta-
analysis by statistically combining the per-study significance test results was that 
performed by Rhodes et al in 2002 (Rhodes, Barrette et al. 2002). This study was 
Publica(ons,per,year, Cita(ons,per,year,
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based on microarray studies aimed at characterising (differential) gene expression 
profiles between healthy prostate tissue and prostate cancer tissue derived from 
human clinical biopsies. Four such studies had been carried out independently, 
with between 8 and 23 samples available in the cancer groups (and usually fewer 
control samples). Although the meta-analysis model was unnamed, the model used 
is Fisher’s sum of logs (Fisher 1932). This is one of the simplest and easily 
understandable methods (also used as a reference method in this thesis) in that it 
uses –for each gene— the per-study calculated p-values and constructs an overall 
meta-statistic by summing the log-transformed p-values. This statistic follows a 
chi-squared distribution and its statistical significance can be looked up in the 
relevant degrees-of-freedom table, although the authors here preferred to obtain 
significance by comparing to a permuted Null distribution based on the source 
data. The authors conclude that despite the presence of one outlier study, meta-
analysis increased the significance and number of “called” genes (genes 
significant at chosen alpha level). Importantly, they were able to identify (although 
no formal count of such genes is provided) biologically relevant genes whose 
lower expression changes were not identified as significant in individual studies. 
Apart from proving that in principle meta-analysis can be of real benefit, this study 
already has the features that are common to microarray meta-analyses: full 
microarray data sets can be obtained and individual studies newly and consistently 
processed and analysed “in-house”, a mapping of gene probes between arrays is 
necessary (here using UNIGENE IDs), and the resulting output requires new 
methods of visualisation and summary. As an early work in this area, some issues 
would require further discussion, such as the use of one-sided statistical tests in the 
individual studies, the use of UNIGENE IDs to ensure that gene probes on 
different microarray platforms represent the same gene, and of course the lack of 
reference meta-analysis methods. This study is therefore an early proof-of-concept 
by a biological research group, inviting more meta-analysis-centric research. 
 
Systematic testing of methodology. This line was taken by Choi et al in 2003 
(Choi, Yu et al. 2003), with the biological validation not the primary concern, but 
a systematic application of a more recent meta-analysis model (Hedges 1985) 
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based on a model-based combination of per-study effect sizes under fixed-effect-
model (FEM) or random effects model (REM) assumptions on the heterogeneity 
of studies. This approach is detailed in chapter 3; the following simply puts it into 
context. This study used the same prostate data sets as those used by Rhodes et al 
above, and the methodology obtained a modest improvement over Fisher’s method 
in identifying six additional and biologically relevant genes. This paper also 
proposed the introduction of an IDD (integration-driven discovery) metric and the 
related IDR (integration-driven discovery rate), highlighting that to assess the 
usefulness of a meta-analysis in a microarray context, one should compare how 
many discoveries (statistically significant genes) can exclusively be identified by 
meta-analysis and not by analysis of any individual study.  
 
New methodology. Another relevant contribution to the field was a method 
described by Breitling et al in 2004 (Breitling, Armengaud et al. 2004), although 
this was not explicitly proposed as a meta-analysis model. Briefly (this method is 
detailed in chapter 3), the proposed Rank Product method is a non-parametric 
approach to microarray analysis. Instead of using parametric group mean 
comparisons (e.g. t-test) that utilise gene variation information, Rank Product uses 
the more directly biological metric of fold-change between individual case and 
control samples. By computing all possible fold-changes (which depends on the 
number of case and number of control samples in a study) for a given gene and 
ranking this with respect to all other genes, a summary statistic (the product of 
these rankings, which can be assigned a statistical significance) is obtained for 
each gene that indicates how consistently it is top-ranked across the replicate 
samples. While this applies to replicated samples within a microarray study, it is 
not difficult to see that this can easily be extended to consider replicated samples 
across multiple microarray studies, by simply forming the rank product across all 
per-study ranks of differential expression. The authors later explicitly described 
the methodology as capable of meta-analysis in a 2006 paper (Hong, Breitling et 
al. 2006) on the implementation of their algorithm as an R analysis package. As 
with any non-parametric analysis, benefits of this approach lie in its robustness 
against outlier observations (with ranks impervious to particularly high or low 
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values), which has perceived advantages when dealing with small numbers of 
observations or a high level of noise, both of which are issues with small 
microarray studies. This independence from the assumption of underlying data 
distributions (normal or otherwise) is balanced by a lack of statistical power when 
compared to parametric methods correctly applied to low-noise data. Of additional 
interest with the Rank Product method is that the relative expression levels 
between genes have an influence on the outcome, whereas parametric methods 
usually mean that genes are analysed independently of one another. Rank Product 
analysis was applied as a meta-analysis to a set of two microarray studies (Vert, 
Nemhauser et al. 2005), although little information is provided on its 
effectiveness.   
 
Other “meta-analysis” methods. The microarray meta-analysis research described 
above informed the initial choices made in the hypothesis underlying this thesis. 
Separately, a wide variety of other types of research synthesis and meta-analysis 
continued to be advanced: Combining differential expression across studies 
(Ghosh 2003); combining expression profiles (Rhodes, Yu et al. 2004);  
correlating the within-study gene correlations across studies or “integrative 
correlation” Parmigiani’s (Parmigiani, Garrett-Mayer et al. 2004); using a 
Bayesian model of combining fold-change estimates by treating other studies as 
the modelled prior knowledge (Wang, Coombes et al. 2004); effect sizes 
combined by a random effects model (Grutzmann, Boriss et al. 2005); combining 
binary “votes” across studies for genes based on a set of genes with known 
biology or “election results” (Benedict, Geisler et al. 2006); relying on 
researchers’ published gene lists and simply assessing overlap of lists between 
studies (Cahan, Rovegno et al. 2007); cross-correlation and auto-correlation 
statistics between time-course studies of identical design (Keegan, Pradhan et al. 
2007). These publications have in common that they are not performed from a 
formal comparative point of view. That is, it is not the meta-analysis approach that 
is compared to other meta-analysis approaches, but the meta-analysis proposed is 
simply applied to a data set of choice and compared to individual study outcomes. 
In the context of this thesis, the above studies were lacking a basic comparison of 
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existing meta-analysis models (from other research domains) to a proposed new 
approach, as well as the biological follow-through in terms of detailed 
quantification of meta-analysis benefits on biological discovery.  
 
Comparative research into meta-analysis. This was the open research area into 
which this thesis was originally developed: given a specific biological problem 
(low-powered microarray studies on macrophage activation), can established 
meta-analyses make a quantifiable and verifiable biological contribution, how do 
methodologies compare and how can they be improved? These issues –with the 
exception of improvements to existing methodology-- were also recognised by 
Breitling et al and in 2008 they published a paper (Hong and Breitling 2008) 
addressing it, using the basic models described above (Fisher’s sum of logs, effect 
size model, and their own Rank Product meta-analysis). There is therefore a 
definitive need to highlight the areas in which this thesis differs, these being a) 
notional improvements to the actual meta-analysis models, b) inclusion of more 
studies (other papers use effectively two small studies, with a third used only as 
reference), c) a specific biological system, d) result validation against biological 
domain knowledge rather than simulation or reference studies, and e) an 
investigation of missing values and assessment of methods dealing with them. On 
the subject of meta-analysis, this thesis is therefore aimed at a comprehensive 
assessment of the statistical models and potential improvements, but also the 
biological context of their results. 
 
Current developments. While all literature discussed above describes the state of 
play in microarray meta-analysis that coincides with the main period of statistical 
work on this thesis, the field has not stalled and further developments have taken 
place. It is therefore important to assess how much of the relevance of this thesis 
can be retained in light of any more recent findings. The first comprehensive 
review of microarray meta-analysis has recently been published (Tseng, Ghosh et 
al. 2012), which considers 333 microarray meta-analysis papers, including those 
which do not develop methodology, but simply apply it to their biological area of 
interest. From these, they establish four classes of microarray meta-analysis 
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models: those based on combining p-values (42%), combining effect sizes (22%), 
combining ranks (9%) and those that merge data sets rather than combining results 
(27%). Three of these classes mirror those used in this thesis, with Fisher’s sum of 
logs, effect size model and Rank Product model falling into the first three classes, 
respectively. The last method, merging of data (co-normalising all samples from 
all studies) makes a very strong assumption about the similarity of study 
hypothesis, experiment design and laboratory procedures across multiple studies. 
These methods use and integrate data directly, while statistical meta-analyses use 
indirect study outcomes (p-values, effect sizes, differential expression). While 
direct data integration is worthy of discussion, it has not been considered as a 
meta-analysis method for this thesis. Findings from this review suggest that there 
have been no major changes to the three methods used in this thesis (with the 
exception of a weighted form of Fisher’s method) and that they remain in 
widespread use. The review also indicates that no “best” methods have as yet been 
established, due to lack of a large-scale and comprehensive comparative study. 
One interesting addition not covered in this thesis is a Bayesian approach (Choi, 
Shen et al. 2007, Scharpf, Tjelmeland et al. 2009) that does not use gene and study 
specific outcome representations (p-values, effect sizes, differential expression) 
that are then combined in a meta-analysis, but which uses a transformation 
(making use of all genes) of each microarrays’ raw expression values to a 
“Probability Of Expression” scale (-1 to +1), allowing the meta-analysis to 
become a form of regular microarray analysis by virtue of making a new data set 
that consists of all POE-transformed microarrays from all studies. Overall, the 
current body of work in microarray meta-analyses is incomplete and there is scope 
to allow this thesis to contribute novel outcomes and model improvements. 
 
1.4.3 Microarray meta-analysis workflow 
 
Although inherent in the structure of this thesis, as an introduction it may be useful 
to summarise the steps required. While this is discussed in a large proportion of 
microarray meta-analysis papers, a specific and comprehensive summary is 
provided by Ramasamy et al (Ramasamy, Mondry et al. 2008). Figure 1.7 is a 
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summary graph to illustrate the normal processes, and it does not include steps 
required in an investigation of the meta-analysis itself. Complications and issues 
around these steps are presented in the corresponding chapters. 
 





1.5 Thesis overview 
 
Background and hypothesis. Gene transcription pathways related to macrophage 
activation have been extensively studied and gene transcription microarrays have 
been used by several independent research groups as a tool for investigating 
genome-wide macrophage-activation biology. This has resulted in a relatively 
Identify suitable 
microarray data sets 
Obtain data 
Process and analyse 
individual studies 
Map gene probes 
between studies 
Apply meta-analysis 
-  What is the biological hypothesis studies should have in 
common? 
-  What is the purpose of the meta-analysis? 
-  Define inclusion/exclusion criteria (organism, cell types, 
doses, time points, treatments) 
-  Are raw data available? 
-  Is it necessary to rely on already processed data? 
-  Are all hybridisations well described?  
-  Can they be matched to inclusion/exclusion criteria? 
-  Is gene annotation provided? 
-  Can technical replication be distinguished from biological 
replication? 
-  Can all probes from all microarray platforms be mapped 
to a common identifier? 
-  Or can they be aligned by sequence matching? 
-  How are multiple matches handled? 
-  Are there probe sequence variants as well as simple 
probe replication? 
-  Given the number, size and variation levels of data 
sets, which method is most appropriate? Is multiple-
testing adjustment required? How are missing values 
handled? 
-  Can all studies be processed identically? 
-  Is data quality sufficient for analysis? 
-  Which statistical inference test should be used? 
-  Do other estimates need calculating for purpose of meta-
analysis (effect sizes, differential expression)?   
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small number of studies based on similar biological hypotheses. A common 
characteristic of these individual microarray studies is their lack of statistical 
power to detect small expression changes (Yang and Speed 2002, Wei, Li et al. 
2004), that is, the number of arrayed sample replicates is not large enough (given 
array sensitivity and financial or logistical constraints) to allow detection of genes 
with small transcription level changes. In addition to the statistical issue, this also 
often motivates use of arbitrarily set requirement for 2-fold or higher differential 
gene expression to be considered biologically relevant. It has been previously 
shown (through mathematical modelling) that small coordinated changes in 
expression level can affect cholesterol biosynthesis (Watterson, Guerriero et al. 
2013), and that even genes with low transcription rates cause strong bursts of 
protein translation (Ozbudak, Thattai et al. 2002). The described experiment 
design limitations are pertinent to the hypothesis underlying this thesis, which 
posits that a) small changes in gene expression can be biologically meaningful and 
b) using statistical meta-analysis on the results of multiple similar microarray 
studies increases power to detect small but consistent gene expression changes 
induced by type II interferon signal transduction in macrophages. 
A meta-analysis in theory results in genes for which differential expression 
between treated and control samples is too small to be statistically detected among 
the biological and technical variation inherent in any individual microarray study, 
but for which differential expression is consistently small across multiple studies. 
Although such genes may also be found through other experiment techniques 
(associated with higher sensitivity or easier processing of larger number of 
replicates), in terms of genome-wide assays the implication of missing meta-
analysis approaches to this biological system is that numerous genes transcribed 
within or downstream of the type II interferon signalling cascade remain 
undiscovered.  
On this background rests the hypothesis that responses of macrophages to immune 
activation by IFN-γ include small quantitative changes that are masked by noise 
but represent meaningful transcriptional systems in pathways against infection. 
The existing body of work on type II interferon signalling is comprehensive and 
particularly work based on high-throughput biological experiment platforms has 
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already identified thousands of interferon-stimulated or potentially interferon-
stimulated genes. Similarly, statistical meta-analyses of microarray data have 
shown some promise in contributing new candidate genes that in single microarray 
studies remain undiscovered because their subtle transcriptional changes are 
hidden within the biological variation and noise of individual microarray studies. 
However, to date no meta-analyses have been performed on type II signalling in 
macrophages, it is not clear which type of meta-analysis is best suited to this (or 
similarly limited) type of data, and it is unclear if any meta-analysis can provide 
meaningful biological results that add to the current knowledge on type II 
signalling. It is also an implicit purpose of this thesis to establish if acquired 
biological domain knowledge can alleviate the disconnect –present even in close 
collaborations-- between analyst and interpreter that disrupts the cycle of testing 
hypotheses and generating new hypotheses for further research. 
 
Research objectives. The principal research question posed by the central 
hypothesis of this thesis involves four individual research objectives and 
questions. Firstly, can statistical meta-analysis provide meaningful biological 
results when applied to a heterogeneous (in terms of experiment design, not 
subject matter) and restricted set of small microarray studies? Secondly, can 
existing meta-analysis models be improved? Thirdly, can the imputation of 
missing gene expression values due to merging of different microarray platforms 
increase the scope of meta-analyses? Lastly, can the existing body of knowledge 
with regard to IFN-γ-mediated JAK-STAT signalling in macrophages be expanded 
based on meta-analysis results? 
 
Methodology. In order to address the research questions outlined above, the 
following approach is taken. From an initial set of thirty identified microarray 
studies with relation to the biological system addressed in this thesis and found 
through local or public resources, six (only four of which are suitable for all meta-
analysis models) microarray studies are selected based on key criteria, where these 
studies use mouse models, Affymetrix microarrays, and IFN-γ treatment of 
macrophages irrespective of dose or time point. Individual studies are analysed 
 49 
before applying six different meta-analysis models to combine results across 
studies. Meta-analysis performance is first assessed quantitatively against existing 
knowledge. Possibilities for imputing (replacing, estimating) large numbers of 
missing values are investigated. Aggregated meta-analysis results are 
characterised in context of known macrophage immune signalling and new gene 
transcription hypotheses for the down-stream effects of IFN-γ-mediated JAK-
STAT signalling developed and compared to an independent gene expression 
network analysis of a microarray time-course study. 
 
Contributions to research. Within the applied methodology, this research makes a 
several novel contributions to the field. Meta-analysis benefits have previously not 
been investigated for IFN-γ-signalling in macrophages, or with a specific focus on 
their usefulness for limited collections of small studies outside standard data sets 
or simulated data sets. Improvements of the underlying meta-analysis models are 
here first proposed and tested. The influence of large-scale imputation of missing 
values is here tested for the first time. Existing knowledge of IFN-γ-mediated 
immune response genes is expanded through a high-confidence list of gene 
transcripts identified by meta-analysis, with speculation on their involvement in 
signalling crosstalk with type I signalling, sterol biosynthesis, and circadian 
rhythm. Finally, a gene association network analysis in substantiation of meta-
analysis results shows the importance and biological implications of anti-
correlated network structures.  
 
Limitations. Every step in the workflow necessary to perform a microarray meta-
analysis is associated with limitations that may affect the outcome of a meta-
analysis in terms of quantitative results or interpretation. Meta-analysis is here 
tested within the framework of a small and well-defined biological question 
(although even this does not lead to homogeneous data sets), the selected studies 
are constrained to one microarray technology platform, and merging of genes 
across studies assumes that the same gene is represented in all studies although 
different probe sequences are used. The statistical analysis of individual studies 
and statistical meta-analysis of combined results does not exclude the possibility 
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that other model choices could provide a more powerful analysis, models used for 
this thesis were chosen in 2005/2006 and do not take full account of developments 
since then. The quantitative assessment of results as well as the biological 
interpretation make use of a limited number and possibly imperfect other reference 
sources, and interpretation bias is possible with regard to biological understanding 
of macrophage immune responses. It must also be noted that by definition, meta-
analysis of multiple microarray studies can provide many true but not fully 
verifiable (without experimental characterisation of gene function) results, because 
it enables the detection of small gene expression changes that individual studies 
lack sensitivity for and which may therefore not previously be described in any 
relation to macrophages or immune responses to type II interferon activation. 
 
Prior research. The effect of IFN-γ in macrophage activation has been repeatedly 
investigated through use of microarrays, with this research identifying around 30 
studies on this precise or a closely related subject. However, this resource has not 
previously been used for meta-analysis, leaving a possibility that many genes with 
small but relevant transcriptional changes are as yet unidentified in this context. 
Previous attempts have been made to aggregate knowledge in this domain (such as 
the Interferome database) but this aggregation does not make use of formal 
statistical frameworks and may underutilise the power of combining study results). 
The three principal meta-analysis types used in this thesis were introduced as 
options for microarray meta-analyses in 2002, 2003 and 2006 (see section 1.4). 
These had a focus on different biological systems and did not involve model 
comparisons, although a comparison was later performed in 2008. Research into 
microarray meta-analyses has ostensibly peaked around 2008 but the numbers of 
applied microarray meta-analyses are still rising, indicating that interest in this 
subject will remain until next-generation sequencing (or other technology) has 
fully replaced the use of microarrays, but even in this scenario leaving large 




Thesis chapters. Subsequent to this introduction, chapter 2 introduces all data and 
methodologies used, with the exception of meta-analyses (covered in chapter 3). 
This includes the identification, retrieval and description of suitable microarray 
studies, the alignment of gene probes across multiple studies, processing and 
analysis of individual microarray studies, and biological and bioinformatical 
resources used. Chapter 3 introduces meta-analysis in context of microarrays, 
details the six meta-analysis models used, describes their application to the 
selected microarray studies and assesses the results quantitatively and in context of 
other data sources. Chapter 4 investigates missing value imputation strategies in an 
attempt to replace very large numbers of missing gene expression values that arise 
when merging microarray platforms with differing genome coverage. Chapter 5 
aggregates representative microarray meta-analysis results and uses independent 
biological data resources and in-silico tools to characterise the results and 
speculate on new down-stream gene transcription hypotheses related to IFN-γ-
activated macrophages. Chapter 6 applies a gene co-expression network analysis 
to an independent microarray time-course study that measures temporal gene 
expression changes of IFN-γ-treated macrophages, murine cytomegalovirus 
(mCMV) infected macrophages and combined treatment/infection. This is done in 
order to provide genome-wide expression patterns and modules of coordinated 
gene expression that can be related to the case-control type outcomes of statistical 
meta-analysis from chapter 5. Chapter 7 is a final discussion of overarching issues 











Materials and Methods 
 
All methods detailed here are listed chronologically in their order of application 
and cover the identification of suitable microarray studies, merging into a meta-
analysis data set, initial data processing, statistical analysis of each study, and the 
generation of reference lists of known biology to compare meta-analysis results to. 
These methods do not include meta-analysis or evaluation of meta-analysis, these 
are described in detail in chapter 3 as they are the focus of the investigation for 
this thesis. 
 
2.1 Microarray studies and data sets 
 
2.1.1 Microarray data sources 
 
For identification of microarray gene transcription studies relating to interferon 
treatment of biological samples, four resources were used: 
1. ArrayExpress    (http://www.ebi.ac.uk/arrayexpress/) 
2. GEO        (Gene Expression Omnibus, http://www.ncbi.nlm.nih.gov/geo/) 
3. GPX MEA       (Macrophage Expression Atlas, http://gpxmea.gti.ed.ac.uk/) 
4. Journal manuscripts (PubMed, http://www.ncbi.nlm.nih.gov/pubmed/) 
 
ArrayExpress and GEO are maintained as public data repositories by the European 
Bioinformatics Institute and the National Centre for Biotechnology Information, 
respectively. Both are MIAME (Brazma, Hingamp et al. 2001) compliant in terms 
of the type and amount of experiment design information gathered during the data 
acquisition process. Many journals publishing studies that include microarray data 
require or encourage the use of these two international resources to submit all 
expression data including detailed information on experiment design and 
laboratory protocols. These repositories were searched for key terms and the 
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results manually narrowed down to match the study parameters for this thesis, as 
described in section 2.1.2.  
GPX MEA11 is a microarray data repository with a specific focus on macrophages  
challenged with pro-inflammatory, anti-inflammatory, benign or pathogen insults. 
The data sets contained within this resource were compiled by staff of the Centre 
for Genomic Technology and Informatics (now Division of Pathway Medicine) at 
Edinburgh University and it contains microarray data sets generated by the centre 
itself or manually curated from academic collaborations or published articles that 
match the repository criteria. 
Other data sources were identified through literature searches via PubMed, using 
all of the search terms (in turn, not simultaneously) “interferon” or “Ifn”,  
“microarray”, “macrophages” and the authors contacted directly with a request to 
obtain their microarray data. 
 
2.1.2 Identification of relevant microarray studies 
 
Studies were obtained from above sources in three stages. In stage one, generic 
searches for simple keywords were carried out on the sources (GPX-MEA 
excluded, as these were already known). A second stage removed redundant 
information and studies for which the search terms matched but were misleading. 
In stage three, studies with similar biological hypotheses and experiment design 
are identified as suitable for statistical meta-analysis. 
 
Stage one. Resources described in 2.1.1 were searched for all microarray studies 
relating to search terms “interferon” or “ifn”. Search terms for “macrophage” were 
not included in the database searches because of the possibility of missing studies 
where only specific macrophage cell lines are mentioned or where only shorthand 
forms (e.g. MØ) are used. The biological hypothesis underlying this thesis (that it 
is possible to use meta-analysis of multiple similar microarray studies to identify 
                                                
11 Disclaimer: the author of this thesis contributed advice and work on data 
processing and statistical analysis and advice on data base design issues to this 
resource. 
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gene expression changes not otherwise noted) requires identification of studies 
fitting a small range of criteria, and any automatic imposition of strong or 
ambiguous filtering criteria would be detrimental to this purpose. The above 
searches therefore retrieve all studies making mention of the quoted search terms 
irrespective of the context it is mentioned in. The consequence of relaxing search 
criteria is a large number of false positive study hits and a small number of 
suitable studies, requiring subjective but informed decision-making in a 
subsequent step. All searches were carried out in May 2008 and will therefore 
miss any relevant studies that have become available after this time12. Searching 
for “interferon” on GEO resulted in 215 original user-submitted microarray data 
sets, while ArrayExpress identified 85 (with 38 of those not already found within 
GEO. When searching for “ifn”, GEO identified 127, ArrayExpress identified 42 
(with 23 of those not already found within GEO).  
 
Stage two. The total of 403 studies identified in stage one include multiple 
references to the same study and the majority are unsuited for consideration in a 
meta-analysis within the proscribed subject (macrophage activation), because they 
are studies for which the key search terms occur but are not directly related to 
study design. The total also contains studies using cell types that are not 
macrophage or dendritic cells. After removing all of the above (fibroblast studies 
were not excluded at this stage as it is an important modelling system), and adding 
four (known to be relevant to IFN-γ treatment in macrophages) studies from GPX-
MEA and one study obtained through contacting the authors of a relevant paper 
with microarray results not yet submitted to a public repository, this stage results 
in a compilation of 30 studies that measure the effect of an interferon treatment on 
biological samples, at this time still irrespective of which organism this was done 
for, the exact treatment used, the microarray platform used for hybridisations, or 
type of biological sample (macrophages, other dendritic cells, fibroblasts) used. A 
                                                
12 Available in supplementary material, folder “List and description of searches for 
microarray data sets”, files “MicroarrayRetrieverSearch…” 
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full list of these studies can be found in the supplementary material13, this includes 
study identifiers and tabulated study experiment factors. 
 
Stage three. For meta-analysis on a set of biological studies, the study hypotheses 
need to be similar. In this case, the biological hypothesis underlying the purpose of 
meta-analysis relates to the effect of IFN-γ (irrespective of dose and time points) 
on murine bone marrow derived macrophages. This limited hypothesis is also 
subject to assumptions that gene expression responses to stimulus would likely be 
different for different organisms, treatments or sample types. Therefore, this stage 




 1. Study contains at least one group of samples that are bone marrow 
 derived macrophages, treated with IFN-γ  (any dose, any time point). 
Bone marrow derived macrophages are here selected over Raw264.7 
macrophage cell line or other cell types (e.g. fibroblasts) as they are the 
prevalent mouse model and system for studying infection and immune response 
pathways within the Division of Pathway Medicine, allowing straightforward 
use of existing experiment data for validation purposes. Treatment options are 
limited to IFN-γ as this activates a different signalling pathway from other 
interferons (sections 1.1 and 6.1) and would not be expected to have identical 
outcomes to those. Although some cross-talk between type II and type I 
interferon signalling is assumed, this would be better identified by comparing 
separate meta-analysis. It is unclear how effective particular doses or treatment 
regimes of IFN-γ are at activating macrophages, prompting the inclusion of 
any dose and treatment time point used in a particular study’s experiment design 
(with the assumption that they study has been designed within biologically 
viable parameters). The central thesis hypothesis therefore pertains to common 
activation pathways of IFN-γ irrespective of dose and treatment regime.   
 
                                                
13 Available in supplementary material, folder “List and description of searches for 
microarray data sets”, file “InterferonMacrophageMicroarrayDatasets.xls” 
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 2. Study contains at least one group of samples of the same type as for 
 criterion 1, but without any treatment intervention. 
For RNA expression studies, the fold change between treated samples and 
reference samples (with all factors except the treatment being identical) is 
required for determining relative biological effects. Reference or control 
samples are not always treatment-negative and some studies may for example 
compare IFN-γ  with IFN-β , where this is valid but a different study 
hypothesis. To study the relative effects of IFN-γ  mouse macrophage 
activation compared to the absence of IFN-γ signal, it is necessary to identify 
studies that contain the same type of treatment-negative controls as part of their 
experiment design. 
 
 3.  All samples in groups described by criterions 1 and 2 are derived 
 from wild-type mice. 
In order to pursue different biological hypotheses, biologists often use mouse 
models that do not express particular genes (“knock-out” mice), that have 
reduced expression for particular genes (“knock-down” mice) or that have 
additional genes inserted (“knock-in” mice, transgenic mice) for expression. 
These changes are more specifically directed than those for mice bred (inbreeds 
or hybrids) towards particular and stable phenotypes (like C57Bl/6 or Balb/c), 
and although they can often be characterised phenotypically, it is less clear 
exactly how these changes may interact with a particular signalling pathway. 
Given the wide variety of such gene-engineered mice and unknown effects on 
IFN-γ signalling in macrophages, this inclusion criterion therefore limits studies 
to those using wild-type mice, albeit from different mouse strains. 
 
Exclusion criteria: 
 1. Studies not using an Affymetrix gene transcription chip platform 
This exclusion criterion is based on the added complexity in mapping and 
interpreting gene probes between fundamentally different RNA expression 
platforms. Amongst many other types, these encompass photolithographic 
nucleotide in-situ assembly with Affymetrix arrays, random bead assembly with 
Illumina bead arrays, two-channel hybridisations or single-channel 
hybridisations, and different gene probe designs (e.g. length, evidence-base, 
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algorithm). While the biological question at the core of this thesis could be 
better asked by including information from further (otherwise suitable) studies, 
combining data across multiple microarray platforms is in itself sufficiently 
complex to warrant separate bioinformatical research. 
 
 2. Studies where the only IFN-γ  treatment condition is a combined or 
 co-treatment 
In macrophages, IFN-γ treatment is considered the priming signal and LPS 
(lipopolysaccharide) the additional trigger for full activation. Both the priming 
and triggering of macrophages is biologically highly relevant, but for this thesis 
the central question relates to the former, as this can build on and be validated 
by experiment data existing within the Division of Pathway Medicine. As 
priming and triggering result in a different state for the macrophage, a meta-
analysis combining both primed and primed plus triggered macrophages could 
be carried out but would require rephrasing of the overall hypothesis. Other co-
treatments exist, an example of which would be 1alpha,25-
DihydroxyvitaminD3. This has been implicated in mediating 
immunosuppressive responses (counteracting IFN-γ), and as such this and other 
macrophage treatments relate to entirely different biological questions and are 
therefore here excluded from consideration. 
 
Applying the criteria above to the set of 30 studies results in 6 eligible studies, 
described in summary and individual detail below. Study numbers 1 to 6 are used 




Table 2.1 Overview of all microarray studies used in thesis 












1 MGU74av2 Mouse 
(C57B/6) 
3 3 10 u/ml for 24 
hours 
2 MGU74av2 Mouse 
(Balb/c) 
3 2 100 u/ml for 6 
hours or 48 hours 
3 MGU74av2 Mouse 
(Balb/c) 
2 2 100 u/ml for 6 
hours 
4 MGU74av2 Mouse 
(C57B/6) 
2 1 10000 u/ml for 6 
hours 
5 Mouse430A_2 Mouse 
(C57B/6) 
1 1 500 u/ml for 24-48 
hours 
6 Mouse430A_2 Mouse 
(C57B/6 
and Balb/c) 
7 7 50 u/ml overnight 
 
Table 2.2 Description of study 1 
Study ID 1 
Study subject Effect of interferon and/or murine cytomegalovirus infection on 
macrophage gene expression 
Publication (Kropp, Robertson et al. 2011) 
Data source GPX-MEA: GPX-000029.1 
Organism Mouse (C57B/6 background) 
Cells Macrophages differentiated from bone marrow cells of the femora and 
tibia of 10-12 week old mice, cultured in medium for 8 days (with 
interventions as listed below) 
Treatment Recombinant murine IFN-γ at a concentration of 10 u/ml. Control 
samples were in culture for 8 days, IFN-γ treatment was applied to 
culture on day 7 for 24 hours. 
Array platform Affymetrix MGU74av2 (contains ~6000 functionally characterised 
genes and ~6000 expressed sequence tags) 
Sample sizes 3 control samples, 3 IFN-γ treated samples. Biologically independent 
replicates, i.e. individual mice. 
Data reference See Excel spreadsheet for TFID 23 or GPX identifier 
Notes There is uncertainty in the timing of treatment, based on the database, 
the cited paper and DPM scientists, meaning the treatment may have 
occurred on day 7 ± 1, and there may be total duration of IFN-γ 
treatment of 24 hours or 48 hours. This data set should be publicly 






Table 2.3 Description of study 2 
Study ID 2 
Study subject IFN-γ induced gene expression in bone marrow derived macrophages 
following mock, UV treated MCMV and MCMV infection 
Publication (Popkin, Watson et al. 2003) 
Data source GPX-MEA: GPX-000034.1 
Organism Mouse (probably Balb/c background) 
Cells Bone-marrow derived macrophages, differentiated for 7 days in culture 
prior to treatment 
Treatment 100 u/ml IFN-γ, one sample for 6 hours, one sample for 48 hours 
Array platform Affymetrix MGU74av2 (contains ~6000 functionally characterised 
genes and ~6000 expressed sequence tags) 
Sample sizes 3 control samples, 2 IFN-γ treated samples. Biologically independent 
replicates, i.e. individual mice. Controls match time points of treated 
samples. 
Data reference See Excel spreadsheet for TFID 24 
Notes Same publication source and author as study #3, but a different data 
set. Mouse background is not mentioned in this paper, but in the 
protocol of cited journal paper (reference 10). Detail on culturing 
BMDM is also not given in this paper, and the cited sources for detail 
do not actually contain exact details. 
 
 
Table 2.4 Description of study 3 
Study ID 3 
Study subject IFN-γ induced gene expression in CIITA -/-, IRF1-/- and control B6 
bone marrow derived macrophages 
Publication (Popkin, Watson et al. 2003) 
Data source GPX-MEA: GPX-000035.1 
Organism Mouse (probably Balb/c background) 
Cells Bone-marrow derived macrophages, differentiated for 7 days in culture 
prior to treatment 
Treatment 100 u/ml IFN-γ for 6 hours 
Array platform Affymetrix MGU74av2 (contains ~6000 functionally characterised 
genes and ~6000 expressed sequence tags) 
Sample sizes 2 control samples, 2 IFN-γ treated samples. Biologically independent 
replicates, i.e. individual mice. 
Data reference See Excel spreadsheet for TFID 25 
Notes Mouse background is not mentioned in this paper, but in the protocol of 
cited journal paper (reference 10). Detail on culturing BMDM is also not 
given in this paper, and the cited sources for detail do not actually 





Table 2.5 Description of study 4 
Study ID 4 
Study subject Contribution of Interferon-b to the Murine Macrophage Response to the 
Toll-like Receptor 4 Agonist, Lipopolysaccharide 
Publication (Thomas, Galligan et al. 2006) 
Data source Email correspondence with Stephanie Vogel 
Organism Mouse (C57Bl/6J background) 
Cells Macrophages differentiated from bone marrow cells of the femora and 
tibia (mouse age not specified), cultured in medium for 6 days. 
Treatment IFN-γ (10,000 u/ml) from a “commercial source”, 6 hour duration of 
treatment. 
Array platform Affymetrix MGU74av2 (contains ~6000 functionally characterised 
genes and ~6000 expressed sequence tags) 
Sample sizes 2 control samples, 1 IFN-γ treated sample. Biologically independent 
replicates, i.e. individual mice. 
Data reference See Excel spreadsheet for TFID 30 
Notes The publication cited above only provides subsets of data and the data 
used here have not been submitted to an online repository and are not 
addressed in that publication because a final decision was made by the 
authors to focus the manuscript on interferon beta treatments only.  
 
 
Table 2.6 Description of study 5 
Study ID 5 
Study subject Investigation of molecular mechanisms of macrophage activation 
through IFN-γ and 1-alpha,25(OH)2D3 in wild-type and Vdr (Vitamin D 
receptor) knock-out mice 
Publication (Helming, Bose et al. 2005) 
Data source ArrayExpress: E-GEOD-2421 
Organism Mouse (C57BL/6 background) 
Cells Macrophages differentiated from bone marrow cells of the femora and 
tibia of 8-14 week old mice, cultured in medium for 7 days 
Treatment Recombinant murine IFN-γ, diluted in phosphate-buffered saline (PBS) 
to a final concentration of 500 u/ml. Macrophages were cultured in 
medium in the presence or absence of IFN-gamma for 24-48 hours 
Array platform Affymetrix Mouse430A_2 (based on Affymetrix documentation, 
contains ~14000 well-characterised mouse genes) 
Sample sizes 1 control sample, 1 IFN-γ treated sample. Both from individual mice. 




Table 2.7 Description of study 6 
Study ID 6 
Study subject Effect of macrophage infection with Yersinia enterocolitica with respect 
to different strains and host resistance 
Publication (van Erp, Dach et al. 2006) 
Data source ArrayExpress: E-GEOD-2973 
Organism Mouse (C57B/6 and Balb/c background) 
Cells Macrophages differentiated from bone marrow cells of the femora tibia, 
cultured in medium for 8 days 
Treatment IFN-γ (presumably recombinant murine, but this is not detailed) at a 
concentration of 50 u/ml, macrophages treated overnight. 
Array platform Affymetrix Mouse430A_2 (based on Affymetrix documentation, 
contains ~14000 well-characterised mouse genes) 
Sample sizes 7 control samples (4 Balb/c, 3 C57Bl/6 mice), 7 (4 Balb/c, 3 C57Bl/6 
mice) IFN-γ treated samples. Biologically independent replicates, i.e. 
individual mice.  
Data reference See Excel spreadsheet for TFID 13 or ArrayExpress identifier 
Notes Online repository contains only processed data, unprocessed 
Affymetrix CEL files were requested and obtained by email 
 
 
2.1.3 Combining microarray data sets 
 
Microarray platforms are subject to different design in terms of location of probes 
on arrays, which genes are contained as a probe or probes on an array, how many 
probes represent a single gene and how many times a given gene is represented. In 
order to perform a meta-analysis of several studies, it is necessary to ensure that 
the identity of measured genes is the same for all microarray platforms used. It is 
possible to (at some risk) simply match data sets on official gene symbols, or to 
match them on any available unique ID (e.g. EntrezGene). However, as all 
microarray studies used in this meta-analysis use one of two different Affymetrix 
chips, it is possible to use an Affymetrix-provided algorithm to match gene probes 
across arrays based on the amount of overlap in their actual nucleotide sequence. 
 
After normalisation and summarising of probe sets to gene level, Affymetrix chip 
MOE430A2 contains 22690 gene probes. Chip MGU74AV2 contains 12488 gene 
probes. Since Affymetrix identifiers changed between these two chip types, a 
matching based on Affymetrix probe identifiers results in only 43 matches, 
necessitating the method introduced above and detailed below. 
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Affymetrix provide product comparison spreadsheets14 based on the alignment of 
target gene sequences in two different platforms. In this case, the chosen 
comparison file15 contains 14230 “good match” gene probes that are contained on 
both array platforms, where “good match” is defined as the two sequences from 
different chip platforms matching all of the following criteria: their sequence 
overlap is > 90%, the minimum sequence length of the shorter of the two 
representative16 sequences is greater than 100 bases (that is, more than 100 bases 
can overlap between these representative sequences, this number does not relate to 
the actual array-bound sequences chosen from these representative sequences), 
and the number of Perfect Match probes in either sequence aligning with the other 
sequence is greater than 1.    
Affymetrix microarray platforms often use more than one chip to represent a full 
genome, usually referred to as “A” chip and “B” chip. The studies used for meta-
analysis in this thesis make use of only the “A” chips, which means the total of 
14230 matched gene probes includes those on “B” chips. Consequently, once 
these are removed, a total of 9812 gene probes remain for meta-analysis based on 
the two “A” chips used in all studies. 
 
2.2 Software tools and resources 
 
Microarray data were processed and analysed using R (R Development Core Team 
2009), available from http://www.r-project.org. The R Versions used for the 
implementation of the body of work relevant to this thesis were 2.8.x and 2.9.x (x 
denoting subversions). All R scripts relating to this thesis are provided as 
electronic supplementary material. Apart from simple utility functions or functions 
already provided with R, several packages from the Bioconductor (Gentleman, 
Carey et al. 2004) repository were also used. These are listed in the following 
table: 
                                                
14 http://www.affymetrix.com/support/technical/comparison_spreadsheets.affx?pnl=1_2#1_2 
15 mgu74av2_vs_mouse430_good_match.zip 
16 The ‘representative sequence’ is the sequence used at the time of chip design to represent the 
transcript that the probe set on the Affymetrix chip measures. Individual probe sequences (and the 
probe sets they constitute) on the array are shorter and selected from a ~600 base region at the 3’ 
end of the representative sequence. 
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affy 1.20.2 Loading and processing of Affymetrix microarray (CEL) files (Gautier, Cope et al. 2004) 
geneplotter 1.20.0 Graphics functions (Gentleman) 
arrayQualityMetrics 1.81 Quality control metrics and graphs (Kauffmann, Gentleman et al. 2009) 
gplots 2.6.0 Advanced graphs, specifically heat map variations (Martin 2011) 
marray 1.20.0 Colour palettes (Wang, Nygaard et al. 2002) 
RankProd 2.14.0 Rank Product analysis (Breitling, Armengaud et al. 2004) 
GeneMeta 1.14.0 Effect size d (Lusa) 
Epi 1.0.8 ROC statistics (sensitivity and specificity of results) (Carstensen 2012) 
preprocessCore 1.4.0 Quantile normalisation (only used in chapter 4, imputation) (Bolstad) 
impute 1.14.0 Missing value imputation functions (linear regression, KNN) 
pcaMethods 1.18.0 Missing value imputation (BPCA) (Stacklies, Redestig et al. 2007) 




For bioinformatical interpretation, statistically significant results were saved as 
lists and imported into Ingenuity Pathway Analyzer (IPA) where they were 
assessed for relevance to particular gene ontology function and transcription 
pathways/networks. Individual genes of interest were also assessed against a 
number of other resources containing either consensus or computationally 





Table 2.9 List of bioinformatics resources  





www.ingenuity.com Gene enrichment analysis for 
networks, pathways, gene 
ontology 
NCBI http://www.ncbi.nlm.nih.gov/ 
(Maglott, Ostell et al. 2011) 
Gene annotation and literature 
searches 
NEXTBIO www.nextbio.com (Kupershmidt, 
Su et al. 2010) 
Known association of individual 
genes with other studies, 
diseases, pharmacology, 
experiments 
BioGraph www.biograph.be (Liekens, De 
Knijf et al. 2011) 
Known relation of individual genes 
with other genes in established 
networks/pathways  
GeneCards www.genecards.org (Safran, 
Dalah et al. 2010) 
Compiled annotation on individual 
genes 
WikiGenes www.wikigenes.org (Hoffmann 
2008) 
Compiled annotation on individual 
genes 
iHOP www.ihop-net.org (Hoffmann and 
Valencia 2004) 




Gene expression profile browser 
for studies conducted within DPM, 
or relevant to DPM’s research. 
yEd www.yworks.com Graph editor for drawing 
pathways or general flowcharts 
Cytoscape www.cytoscape.org (Cline, Smoot 
et al. 2007) 
Drawing and analysis of network 
graphs 
Interferome www.interferome.org 
(Samarajiwa, Forster et al. 2009) 
Online database of interferon 
stimulated genes 
STRING string-db.org (Franceschini, 
Szklarczyk et al. 2013) 
Protein-protein interaction 
networks 
oPOSSUM opossum.cisreg.ca (Sui, Fulton et 
al. 2007) 
 







2.2.1 Imputation of missing values 
 
Imputation of missing values in context of meta-analysis employs several R 
functions, which are employed within a more complicated wrapper in order to 
apply them to resampled data sets and across multiple microarray studies. As such, 
the code is too long to reproduce in print, but the complete R code for imputation 
of missing values and their assessment is provided in electronic form with this 
thesis (“ImputationMissingValues_HF.R”).  
The imputation algorithms are described in more detail in chapter 4, this section 
lists the methods and the corresponding R code relevant for its implementation.  
 
K-Nearest-Neighbor or KNN (Troyanskaya, Cantor et al. 2001) uses R function 
impute.knn(…,k=30, rowmax=0.9) in package impute v1.14 as provided. For 
array-wise imputation, the input data matrix is rotated through 90 degrees (and 
arguments k set to 5 and colmax set to 0.8), so that similar samples rather than 
similar genes are used to impute missing samples. 
 
Bayesian Principal Components Algorithm or BPCA (Oba, Sato et al. 2003) uses 
R function pca(…,method=”bpca”, nPcs=6) in package pcaMethods v1.18.0 as 
provided. 
 
Imputation by linear regression uses a generic lm() R function for linear models in 
the basic stats package, using non-missing gene expression values from all other 
variables (in this case, those variables are samples or arrays) as explanatory 
variables. An alternative version is also employed where the explanatory variables 
are only those samples from the same biological treatment group (control or 
interferon gamma treated) as the missing sample. 
 
Imputation by ranked sets uses Euclidean distance between genes to identify genes 
similar to the one with missing values in another study. The 50 genes closest in 
their expression level profile are then identified by forming the rank product, 
which is 1/n times the product of the ranks of n Euclidean distances, where n is the 
number of studies the gene in question is not missing in. For each of these 50 
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genes in each of the studies (in which the gene is not missing in), inverse 
normalised weights  ( (1/distance) / sum(1/distance) ) are obtained based on the 
Euclidean distance, then averaged for each gene across these studies. Finally, a 
weighted mean (using average weights above) is computed from these 50 genes in 




2.3 Microarray target sample and array processing 
 
The steps described in this section are not immediately relevant to replicating the 
efforts contained within this thesis, as they precede the processing and analysis of 
numerical data. However, the standard laboratory procedures for using Affymetrix 
arrays are outlined here for better understanding of their place within the full 
laboratory-to-results workflow. These steps are described in detail in the official 
Affymetrix manual 17  and a schematic overview 18  is presented in figure 1.2 
(chapter 1). They include all processes from amplification of the initially extracted 
total RNA sample to biotin-labelled cRNA ready to be hybridised to a microarray. 
 
After hybridisation is complete, microarrays are scanned in an Affymetrix 
GeneChip instrument, where a confocal laser scans each microarray and obtains an 
image where each individual probe’s expression level is represented by fluorescent 
intensity. Using Affymetrix software (GCOS or GeneChip Operating Software 
prior to 2008, AGCC or Affymetrix GeneChip Operating Software from 2008), an 
image quantification algorithm converts the images (DAT files) to numerical 
signal intensity levels (CEL files).  
 
                                                
17 Eukaryotic Sample and Array Processing 
(http://media.affymetrix.com/support/downloads/manuals/expression_s2_manual.pdf) 
18 Figure 6, Dalma-Weiszhausz, D. D., J. Warrington, E. Y. Tanimoto and G. Miyada 
(2006). "The affymetrix GeneChip (R) platform: An overview." DNA Microarrays Part A: 
Array Platforms and Wet-Bench Protocols 410: 3-28. 
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2.4 Data quality control 
 
Data quality of each array in each study is inspected through graphs and metrics 
generated by Bioconductor package arrayQualityMetrics (Kauffmann, Gentleman 
et al. 2009). This involves the performance of specific control probes on the array, 
the per-array data distribution, and similarity across arrays and numerical 
representation of the array surface. Individual arrays are excluded from further 
processing and analysis if a majority of the aggregated evidence indicates low 
quality. For each study, a quality control report (“Qmreport.html”) is included in 
the supplementary material19. A selection of these graphs is shown in figure 2.1 
below and quality control assessments are described in more detail in the 
following sections. A complete description of the output the arrayQualityMetrics 
package produces is available as a tutorial20 from EMBL-EBI (Gabriella Rustici, 
Audrey Kauffmann 2009).  
 
  
                                                
19 Included as electronic files in folder “Study Quality Control Reports” 
20 http://www.sbforum.org/cmsimages/presentations/BioC_QM%20Tutorial.pdf 
(included here under Creative Commons Attribution-Share Alike 3.0 license:  
 http://creativecommons.org/licenses/by-sa/3.0/) 
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Figure 2.1 Array quality control graphs  
 
Shown are data distribution box-and-whisker plots for all the gene probes on an array (A) 
prior to data processing, with X-axis indicating an array and Y-axis representing log2 scale 
signal intensity.   Array groupings due to biological factors or unintended batch effects are 
identified through a heatmap representing distance between all data points of any two 
arrays (B). This distance is computed as the mean absolute difference between all 
unprocessed gene probe signal intensities and then represented by a colour (0 = blue = 
identical array expression levels). A clustering algorithm arranges (dendrograms) arrays in 
this heatmap by those distance estimates. A summary report (C) provides information 
about expected and observed Affymetrix control probe signal intensities, array 
background and array scaling factors. Red plotting symbols indicate abnormal values and 
a problem with the array.  The RNA degradation plot (D) estimates each array’s RNA 
quality by averaging signal at a given probe position (from 5’ to 3’ end) across all probes 
on the array, and concern is raised if any arrays are very dissimilar to others. 
 
 
Control probes. This method serves as a proxy measurement to determine RNA 
quality issues on an array. Affymetrix chips contain sets of control probes that are 
designed to provide information about the integrity of hybridised RNA. The chip 




and 5’ end of the transcripts. The 3’/5’ ratio of their measured intensity values is 
expected to remain below 3, although this threshold is arbitrary for any given 
organism or sample type, and the ratio is also expected to be smaller for the 
shorter transcript (GAPDH). This ratio is therefore mainly used to identify 
individual deviating arrays in a study21.  
Per-array data distribution. This method is based on the assumption that a 
biological intervention (in this case, various treatments applied to macrophages) 
should affect only a small proportion (less than 5-10%) of the gene probes on an 
array. Therefore, data distributions should be almost identical for all samples. For 
each microarray sample in a given study, the data distribution of (log-transformed) 
signal intensity values across all gene probes is assessed through probability 
density plots and box-and-whisker plots. If probability density plots and box-and-
whisker plots show individual samples of deviating frequency distribution, then 
this is an indication for quality issues. Shifted but otherwise identical distributions 
are not included in this statement, as this may be due to systematic factors equally 
affecting all gene probes, and this can be addressed through data normalisation as 
explained below. 
RNA degradation. Also known as RNA digestion plot, this assessment does not 
make use of selected control probes to estimate quality of RNA on the array, 
instead it uses all probes on the array. This is made possible by the way 
Affymetrix chips measure gene expression, i.e. for each gene there are a number 
of probes (11 for many Affymetrix chips) representing it, each covering a different 
part of the sequence of the target gene. For each of the 11 probes covering a 
distinct target sequence region between the 5’ and 3’ ends, average signal intensity 
is calculated across all target genes and plotted (shifted and scaled to allow a direct 
comparison between arrays). The resulting RNA profiles are expected to start 
lowest at the 5’ end (where degradation begins) and rise for 3’ end probes. In the 
absence of definitions for quality thresholds, main purpose of these graphs is to 
compare slopes for all arrays and identify individual outlier arrays, which will 
have more extreme slopes than other arrays. 
                                                
21 Source: Affymetrix 
(http://www.affymetrix.com/support/help/faqs/ge_assays/faq_17.jsp) 
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Multi-array metrics. Based on the assumption that only a minority of genes (out of 
the entire genome represented on the array) should be affected by the biological 
intervention made, there should be a good overall consistency of signal intensity 
across all samples. In contrast to per-array data distributions, the methods listed 
here retain gene identity information across samples. Between-array consistency is 
assessed by a) a heat map representing all pairwise sample distances (or 
conversely, correlation), b) MA-plots showing the log-scaled intensity levels (X-
axis, referred to as “A”) and log-scaled differential expression (Y-axis, referred to 
as “M”) between each individual array and a virtual array representing an average 
across all arrays, and c) probe-level estimates for each probe (individual sequence 
deposited on array, not at gene level) across all arrays in form of NUSE (per-gene 
standard error in relation to median standard error across all arrays) and RLE (per-
gene expression level in relation to median expression level across all arrays).   
Physical chip problems. This method aims at identifying large scratches or chip 
regions where large numbers of probes have failed to work for reasons associated 
with the physical chip structure or the hybridisation/washing procedures. Each 
array has the rank (indicated by colour) of all individual probes’ signal intensity 
plotted by its array coordinate location, visualising the numerical signal levels 
(which may differ from the original scanned images in that those do not aggregate 
pixel information). 
 
2.5 Microarray data processing 
 
Background correction, probe set summation and between-array normalisation 
follow the Affymetrix-specific methodology referred to as RMA or Robust 
Multichip Average (Irizarry, Hobbs et al. 2003). Arrays are not independently 
processed, but in context of all arrays in a study, which requires that no arrays be 
discarded from a study prior to meta-analysis as discussed in this thesis. Within 
the algorithm, three separate stages are performed in sequence, as detailed below. 
 
Background correction is based on the assumption that signal intensity measured 
for Affymetrix “Perfect Match” or PM (probes representing a gene of interest) 
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probes is comprised of two independent components, one being real binding 
events during hybridisation (following an exponential distribution when 
considering all probes on an array) and the other being non-specific binding or 
cross hybridisation and optical noise (following a normal distribution and 
truncated at 0). This means the expected true expression value – given the 
observed signal intensity – can be obtained by adjusting or rather solving for the 
observed signal intensity with the mean and variance parameters (normal 
distribution) and the rate parameter (exponential distribution), all estimated from 
probes on array. It should be noted that RMA background correction ignores 
mismatch (MM) probes that are included on Affymetrix arrays as a hybridisation 
control for each given PM probe. Other Affymetrix data processing algorithms 
may use these to subtract from their corresponding PM probes. Irizarry et al have 
found this to introduce noise, and instead follow the above strategy. Specifically, 
per-array observed PM raw signal scale intensity S is modelled as S=X+Y.  X in 
this case is the probe hybridisation signal and follows an exponential distribution 
with its parameter α. Y is the background noise component and follows a normal 
distribution with its parameters µ and σ2. The data transformation using these two 
distributions then is solved as: 
E(X|S) = a + b[φ(a/b) – φ((s-a)/b)] / [Φ(a/b) – Φ((s-a)/b)-1],  
 where a = s – µ - σ2α ; b = σ ;  φ = normal density; Φ = cumulative density. 
 
 
Normalisation of data across samples is performed with background-corrected 
data still on the linear scale and at the level of individual (Perfect Match) probes. 
All normalisation methodologies are targeted at making whole-array data 
distributions comparable across multiple arrays by accounting for systematic 
effects on signal intensity levels, i.e. any factors that are expected to affect every 
probe on an array to the same degree. This may for example include hybridisation 
efficiencies, laser scanner settings, or biological sample processing. The approach 
is inappropriate if the biological condition on some arrays is expected to affect 
more than 5-10% of the probes on an array. Normalisation within the RMA 
framework forces whole-array data distributions to be identical for all arrays. 
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When applied, the algorithm sorts all probes (not aggregated to gene level) on 
each array by measured signal intensity. Each arrays’ lowest quantile (probe with 
lowest signal value) is set to be the average of all lowest quantiles across all 
arrays. This is repeated for every quantile (probe). When all probes’ intensity 
values are so adjusted, the full data set of all arrays is returned to its original probe 
ordering.     
 
Probe summarisation is the process of combining the signal of all probes on an 
array representing a given target gene. Given different expected affinities of 
probes, a simple average across a probe-set in one array is rejected in favour of a 
robust median polish taking account of a probe-sets signal intensities in all arrays. 
Within the RMA algorithm, all perfect match probe intensities are first log2-
transformed, allowing any error to have constant variance (because signal error is 
expected to be proportional to measured intensity on the original scale). Tukey’s 
median polish procedure is applied to the log2-transformed data, with each probe-
set represented as a matrix of rows and columns, where the rows are arrays and the 
columns are individual probes of a probe-set. Row and column medians are 
iteratively subtracted from row and column values until convergence (all row and 
column medians = 0) determines a set of final residual values. Subtracting these 
residuals from the original matrix for a given probe set allows per-array estimation 
(arithmetic mean of those fitted values per row) of the expression level of the 
given gene in a given array. 
 
Following RMA, probe signal intensity values are now background-corrected, 
quantile-normalised, log2 transformed and summarised measures of the expression 
level of a given gene in a given sample.     
 
2.6 Statistical analysis of individual microarray studies 
 
For each gene in each study, the null hypothesis of “no differential expression 
between IFN-γ treated samples and control samples” is tested. While the presence 
of biological samples not relevant to the meta-analysis was necessary for initial 
 73 
data processing, these are no longer required and removed from further analysis, 
resulting in the per-group sample sizes shown in the study summary tables in 
section 2.1.2. For regular analyses of individual studies, a single statistical model 
is usually employed, but the use of three different meta-analysis models requires 
multiple statistical tests corresponding to each meta-analysis model.  All statistical 
tests described here take as input only the microarray samples matching the two 
biological conditions relevant to this thesis: untreated controls and IFN-γ treated 
samples. For all tests, the input data are pre-processed and normalised, including 
transformation of expression values to log2 scale because gene expression values 
are assumed to follow a log-normal distribution (Quackenbush 2002). For the non-
parametric Rank Product test, data transformation is inconsequential. 
 
Rank Product test (Breitling, Armengaud et al. 2004). This test is the single-study 
analysis equivalent of the Rank Product meta-analysis. However, the results of this 
test (p-values) are also used as alternative input for Fisher’s meta-analysis method 
as described in chapter 3. Using the RankProd package for R, statistically 
significant differentially expressed genes are identified based on calculating each 
gene’s rank product statistic, which is the product of all possible pairwise-sample 
ranked differential expression values K (difference on logged data) between the 
control and the IFN-γ condition, to the power of 1/K.  Statistical significance is 
assigned by measuring how extreme the statistic is when compared to a Null 
distribution of possible Rank Product statistics based on permuting the original 
data set gene-wise B times (in this case, B=100) and computing the Rank Product 
statistic each time. The approach is repeated once more, with ranking of 
differential expression reversed (i.e. identifying down-regulation with respect to 
control condition). This test uses ranking across all genes measured in a sample 
instead of testing each gene in isolation, and therefore includes more information 
than other statistical tests. The end result is a list of genes with a statistical 
significance p determining how consistently high (or low, in the reverse case) each 
gene is ranked in terms of expression ratios between control group samples and 




Welch’s t test (Welch 1947). This test calculates the per-study significance of the 
difference in mean (log2-transformed) expression between control and IFN-γ 
samples, the per-study p-values so obtained are used as input for Fisher’s meta-
analysis method. Welch’s t test is almost identical to a standard Student’s t test 
and estimates the statistical significance of the difference in the means (per gene 
probe, in this case) between two groups of observed expression values, given their 
variance. As opposed to the Student’s t test, it replaces an estimate for pooled 
group variance with individual estimates for per-group variance, therefore 
allowing each group in the comparison to have a different variance. Genes are 
tested one at a time and the end result is a list of genes with statistical significance 
assigned to their mean difference in expression between control and IFN-γ group. 
The specific R function used for this is ttest(). 
 
Effect size z score. This is the per-study test statistic equivalent to the combined 
effect size used for meta-analysis. Apart from not combining the effect size 
estimates across studies (as is done in a meta-analysis), the equations used here are 
identical to those discussed in detail in chapter 3 (equations cited here as 
appropriate). Effect size d (eq. 3.10) is very similar to a standard Student’s t 
statistic, but instead of standardising the difference in group means to the pooled 
standard error, it standardises the difference in group means to the pooled standard 
deviation (the denominator), i.e. it does not explicitly account for sample size and 
is therefore biased.  However, subsequent to calculating the biased effect size 
statistic, a sample size bias correction (eq. 3.11) is applied and the variance of this 
unbiased effect size estimator estimated (eq. 3.12).  A z statistic is then 
constructed by standardising the per-study unbiased effect size to the per-study 
standard deviation of the effect size (eq. 3.19, but for individual study estimates, 
not combined estimates across studies). This z statistic follows a standard normal 
distribution and its statistical significance can therefore be obtained from the 
standard normal reference distribution table, in this case specifically using the 
pnorm() function in R with the mean and standard deviation parameters set to 0 
and 1, respectively and in accordance with a standard normal distribution. 
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2.7 IFN-γ pathway reference lists 
 
For chapter 3, and in order to quantify relevance of meta-analysis results against 
known IFN-γ and immune response gene transcription pathways, current 
consensus information is obtained from 2 alternative sources. The first is NCBI 
Gene database queries, with four different sets of search criteria and limited to 
Mus musculus. These are referred throughout as gold standard or reference lists A 
to D in this thesis. These are not curated for scientific trustworthiness and simply 
identify all genes ostensibly connected with type I or type II interferon pathways. 
In contrast to this, the second type of list is manually curated and referred to as the 
DPM gold standard or reference list. All lists are included in the supplementary 
material22, with the DPM list also included as Appendix A12. 
The lists described in this section are used for a quantitative assessment of meta-
analysis results and are not primarily based on microarray gene expression data. 
This differs from the approach taken in the biological assessment of meta-analysis 
results, which uses microarray-derived reference sources (section 2.8) 
2.7.1 NCBI gene reference lists 
 
In a two-stage process, the NCBI [Gene] database was first queried with relevant 
search parameters to identify gene transcripts and corresponding EntrezGene IDs, 
and the retrieved results then matched against the Affymetrix gene probes 
contained on the two chip platforms used for meta-analysis in this thesis.  
 
Stage 1. The query results used in this thesis were obtained on 14 Jan 2009, 
annotation updates subsequent to this date are therefore not reflected in those lists. 
All queries were run through NCBI’s Gene portal23 (Maglott, Ostell et al. 2011) 
and the results are summarised in table 2.10. The four queries submitted to NCBI 
                                                




are not independent and investigation of overlap through Venn diagrams identified 
considerable overlap between all lists. 
 
Stage 2. Using the EntrezGene identifiers obtained in the previous stage, further 
identifiers and annotation were added by retrieving Ensembl24 (Flicek, Ahmed et 
al. 2013) data for Mus musculus from Biomart25 (Kasprzyk 2011), with explicit 
reference to the two Affymetrix microarray platforms Moe430a and Mgu74av2. 
This was implemented through package biomaRt within R. Specifically, the 
biomaRt package was used to access the dataset “mmusculus_gene_ensembl”, 
version NCBI37.  This stage reduces the number of gene transcripts in each list 
because it discards those not present on a given microarray platform.  
 
Table 2.10 Query-based reference list of known biological pathways 
Reference 
list 






A “ifng” OR “interferon  
gamma” 
532 190 
B “immune response”[GO] 944 244 
C “immune response” 1218 343 
D “interferon” 1219 271 
Queries were submitted to the NCBI[Gene] database. Searches were limited to one 
organism (Mus musculus). Searches for lists A,C,D were done on database fields 
containing gene symbol and gene description, list B was limited to the database field 
(indicated as [GO] in this table) containing gene ontology categories. Letter case has no 
influence on the search. The number of retrieved gene transcripts is the total of all NCBI 
gene records where the specified search terms were found in the specified database fields. 
In contrast, the number of genes matching meta-analysis microarrays is the subset of all 
retrieved gene transcripts that are contained in the combined (number of genes = 9812) 
microarray data sets used for meta-analysis. 
 
2.7.2 Division of Pathway Medicine gene reference list 
 
This list is based on extensive manual curation of literature and databases, 
undertaken by several DPM MSc students and their supervisors over several years 
with the aim of compiling a consensus signalling pathway map relating to 





macrophages (Raza, McDerment et al. 2010). Although the target signalling 
pathway is intended to be based on human macrophages, information is compiled 
from human and mouse, and using other cellular systems. Relevant data were 
curated from PubMed, Google Scholar, STRING, BIND, KEGG, Reactome, 
Ingenuity and consist of protein/gene identifiers, interaction types and other 
annotation. This information was organised in interaction lists and a pathway 
database, assembled into a signalling pathway map and refined through expert 
opinion and comparison with experimental data. The outcome comprises many 
macrophage signalling pathways, but for the purposes of this thesis the list is 
limited to the IFN-γ related signalling pathway only. In January 2009, this list 
subset contained 67 genes that are a) known to be related to the IFN-γ 
transcriptional network and b) contained on both microarray platforms used for 
this thesis. 
 





Interferome (Samarajiwa, Forster et al. 2009) –database available at 
www.interferome.org- is manually curated from publicly available microarray data 
sets (36 to date) to consolidate type I, type II or type III interferon regulated genes. 
The interferome study set is heterogeneous with regard to organism, cell/tissue 
types and type/subtype of interferon. 
 
Gene symbols present in meta-analysis results were converted to ENSEMBL IDs 
using Biomart26. While the database contains ~2000 genes identified as interferon 
stimulated, it is limited to accept 100 genes at a time for any input list, and meta-
analysis results were therefore submitted in batches of the required size. For each 
gene, the returned information indicates if it has previously been identified as 
interferon-stimulated (type I, II, III, or any combination thereof). 




2.8.2 Microarray time course study (MITCH12) 
 
This microarray study consists of 3 biological conditions, murine bone-marrow 
derived macrophages (BMDM), grown in culture for 7 days, then primed with 
low-dose Ifn-γ and activated by Ifn-γ, infected with murine cytomegalovirus and 
both Ifn-γ activated and virus infected. Transcription levels for all murine genes 
(Agilent arrays) in each condition are measured over 25 half-hourly time points, 
starting at 0h and ending at 12h. BMDM are extracted from the original set of 
mice, pooled and then plated out into 75 individual experiments, with each 
undergoing one of the three specified treatments and an RNA sample obtained at 
one of the 25 specified time points. Biological inter-subject variation does 
therefore not contribute to overall variation in this study and the only observable 
gene transcription differences should be due to the treatment or time of 
measurement. For purposes of statistical analysis, replicates (BMDMs treated with 
interferon gamma in more than one experiment per time point and condition) 
would be preferable in order to assess the experiment noise contributed by 
effectiveness or duration of treatment, but the final study design sacrificed this in 
exchange for extended longitudinal observation. Each array is a co-hybridisation 
of the test sample and a universal reference, where the reference is pooled material 
from all macrophage cultures across the entire time-course. 
Macrophage cultures were established from the bone marrow of ten to twelve 
week old male Balb/c mice (Charles River Laboratories, Kent, U.K.). Briefly, 
bone marrow progenitors were flushed from femurs and plated at 8 x 105 cells in 6 
well tissue culture dishes (Costar, Corning Inc., NY, USA).  The cells were 
cultured in DMEM/F12 medium supplemented with 10% fetal calf serum (FCS), 
pen/strep, glutamine and 10% L929 conditioned medium as a source of M-CSF. 
BMDM were infected with the different viruses at a MOI of 1, Ifn-γ treatment 
consisted of 10 u/ml (Boelinger Manhaim Corp). RNA was extracted from each 
sample using Trizol RNA extraction protocol.  Mock samples were pooled and 
labelled with Cy3 while the lyzed or IFN-γ treated samples were labelled with Cy5 
using a modification of the Agilent Fluorescent protocol, using half of the standard 
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Cy3/Cy5 labelled dUTP concentration. The Cy3 labelled pooled control was 
hybridized with each of the 75 Cy5 labelled samples according to the Agilent Low 
RNA Input protocol. The dual hybridizations were carried out on Mouse Agilent 
V2 array (G4121A, 20868 annotated probes), and were scanned on an Agilent 
Technologies scanner. Agilent feature extraction software (V.A7.5.1) was used to 
extract numeric data for further analysis. 
 




Background noise was corrected for by subtracting background signal from 
foreground signal, any resulting expression values less than 1 were set to 1.  Data 
were then transformed to log2 scale. Normalisation between all arrays was 
performed on the basis of an identified subset of control probes (positive control 
probe set), separately for test and reference samples. The normalised data set was 
then filtered to remove “flat” expression profiles, based on performing a ROC 
analysis on each microarray, using known positive and known negative control 
probes for identification of a threshold value (an expression level that provides 
>=80% sensitivity in distinguishing negative from positive control probes). These 
threshold values are averaged across all 75 arrays (3 time courses with 25 samples 
each) in the study, resulting in an overall threshold value. In order for a gene probe 
to remain in the analysis data set, it was required to have an expression level 
greater than or equal to the overall threshold in 5 or more consecutive time points 
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for a given time course. The final data set size for analysis (14299 gene probes) 
consists of all gene probes that match this criterion in at least one of the time 
courses. 
 
2.8.3 Transcription factor binding site enrichment (oPOSSUM 3.0) 
 
This tool is available at opossum.cisreg.ca (Sui, Fulton et al. 2007). 
Searches for Gamma-Activated-Sites (GAS motif) were carried out for two 
purposes. One was to create a reference list of genes in the mouse genome that 
contain a GAS motif and are therefore a relevant comparison to microarray meta-
analysis of Ifn-γ activated macrophages.  A second purpose was to establish which 
transcription factor binding sites the meta-analysis result lists were enriched for. 
 
In order to use oPOSSUM, gene symbols contained in meta-analysis results were 
first converted to Ensembl IDs, using the Biomart ID Converter tool available at 
www.biomart.org. Ensembl IDs are then submitted to oPOSSUM, also specifying 
the following parameter choices. 
Background: all genes (29347) in oPOSSUM database 
JASPAR CORE profiles: specific vertebrate profile, select STAT1 





Meta-analysis of the effect of IFN-γ on 




In this chapter three different and established statistical models and three model 
variations for meta-analysis are applied to a collection of six27 microarray gene 
expression studies that test the effect of IFN-γ stimulation in murine macrophages. 
The three meta-analysis models comprise Fisher’s sum of logs, effect size model 
and rank product meta-analysis. Subsequently, meta-analysis results are assessed 
with reference to quantitative metrics both in isolation and with reference to 
biological expectations. A more detailed and bioinformatic assessment of the 
biological meaning underlying these results is the focus of chapter 5. Altered 
variants of the basic meta-analysis models are devised in some cases and also 
assessed.  
 
The overall goal is to combine the statistical hypotheses tested in individual 
studies in order to obtain a combined statistical estimate across those studies. The 
primary questions for this chapter are as follows: 
1. In a setting with multiple very small studies, does meta-analysis provide 
additional results when compared to individual studies? 
2. In a setting with multiple very small studies, are there performance differences 
between the meta-analysis methods here? 
3. Can performance-improving alterations to the meta-analysis approaches be 
identified? 
4. In a setting with multiple very small studies, do meta-analysis results show 
biological relevance? 
                                                
27 Six studies where the meta-analysis model (Rank Product meta-analysis) allows the inclusion of 
studies with a single sample in one group, only four studies are methodologically eligible for the 
other two models. 
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Although not separately pointed out in every instance of a meta-analysis model or 
data estimate in this chapter, it is clear that statistical robustness (for both 
parametric and non-parametric models) will be impacted by the availability of 
only 4 (6 in some cases) studies, where the sample size of individual studies is also 
very low. While there are certainly microarray studies with tens to thousands of 
hybridised samples, these are relatively rare (an estimated 6%, see below). 
Although meta-analyses are of course being done on these and provide 
biologically useful results, it is unclear how they perform with the much more 
frequent smaller and individually underpowered sets of studies. An estimated 33% 
of experiments have less than 6 hybridisations, where this may include anything 
from 1 to 6 biological conditions. Reference numbers for this are based on a 
broadly selected set of all RNA array-based studies on mus musculus, with 
𝓍 = 11 (MAD=7.4) assays per experiment (total experiments = 6355 at 21 Jun 
201228,), across all biological conditions/groups it contains. To provide some 
admittedly very broadly defined estimates for ostensibly large and small studies, 
only 6% of all experiments consist of more than 50 hybridised samples, 33% 
consist of 6 samples or less. The number and size of studies here fits into this 
scenario and is comparable to or higher than that used e.g. by Breitling or Choi in 
their respective meta-analysis approaches. 
 
The steps prior to assessment are summarised in a flowchart, figure 3.1. 
 
                                                
28 source: http://www.ebi.ac.uk/arrayexpress/browse.html 
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Figure 3.1.1 Study selection, analysis and meta-analysis workflow 
 
Not shown in this overview are studies #4 and #5, as they are too small to contribute to 
parametric methodology since means or variances cannot be computed. However, studies 
#4 and #5 are included as additional inputs for Rank Product meta-analysis as this best 
represent the actual problem investigated. R scripts corresponding to this figure are 
included as electronic supplementary files for particular steps: Quality control, 
background correction, normalisation and probe summation can be found in 
“TFIDXX_Processing.R”. Mapping genes between array platforms is carried out in 
“Script5a_CreateMetaset.R”. Analysis and meta-analysis of individual studies by a given 
method is contained in “Script6_MetaSet_XX.R”. Additional summary graphs (across 
meta-analysis models) are added in “Script7_GraphingResults.R”. 
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3.1.1 Study selection 
 
Based on the collection of microarray studies described in chapter 2, the data sets 
chosen represent the narrow field of studies with overlapping experiment design 
parameters. Their area of investigation matches biological hypotheses that the 
Division of Pathway Medicine is both familiar with and has data for, which 
supports validation and interpretation of results. Inclusion criteria for the six 
studies used were murine bone marrow derived macrophages, IFN-γ treatment, a 
control condition and Affymetrix-branded microarrays. As described in detail in 
chapter 2, this still leaves a broad range of differences between the studies, i.e. 
interferon dose and timing, mouse model, laboratory protocols, probe-sequence. 
While this means a compromise in the biological questions that can be answered 
from any meta-analysis, it is representative of the general variation of microarray 
study designs and laboratory protocols across research laboratories. In this case the 
choice of inclusion criteria is a reflection of the requirement to make a meta-
analysis useful under pragmatically limited conditions, as well as an explicit 
biological focus on IFN-γ induced changes in murine macrophages irrespective of 
dose or time frame.   
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2 MGU74av2 Mouse 
(Balb/c) 
3 2 100 u/ml for 6 
hours or 48 
hours 
(Popkin, 
Watson et al. 
2003) 
3 MGU74av2 Mouse 
(Balb/c) 
2 2 100 u/ml for 6 
hours 
(Popkin, 
Watson et al. 
2003) 
4 MGU74av2 Mouse 
(C57B/6) 
2 1 10000 u/ml 
for 6 hours 
(Thomas, 






1 1 500 u/ml for 
24-48 hours 
(Helming, 








7 7 50 u/ml 
overnight 
(van Erp, 




3.1.2 Data pre-processing 
 
There are filtering and data processing steps that apply to some or all of the studies 
used as input for the three meta-analysis models. All data sets underwent the same 
basic quality control checks, processing and statistical analysis (see chapter 2, 
section 2.5) in order to ensure all data exist on equal scales and are of suitable 
quality. All six data sets were reduced to those 9812 gene probes that are in 
common to the different microarray chip platforms. Due to minimal sample size, 
two of the six studies are only eligible for the non-parametric Rank Product meta-
analysis, reducing other methods to using data from four studies. Depending on 
the biological reliability of those two studies, the additional two studies may 
introduce bias towards or improve results from the RP method. However, with the 
emphasis on this thesis on the real-world application of meta-analysis, exclusion 
of two studies would support the evaluation of that objective less than it would 
support the comparison between statistical methods on a sample-for-sample basis. 
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3.2 Meta-analysis models 
 
The meta-analysis models are chosen with a view to cover the combining of p-
values, combining of ranks, and combining of effect sizes. These are Fisher’s 
combined probability model (FP), Rank Product model (RP) and Effect Size 
model (ES), respectively. In addition to these main approaches, variants and 
potential improvements are also tested. In order to interpret results and 
visualisations, it is important to note that any microarray analysis differs from 
‘traditional’ analyses in the sheer number of variables (often interchangeably 
referred to as genes, probes or features) to test, and conversely, the very limited 
numbers of observations (interchangeably referred to as samples or arrays) for 
each variable. For each gene, an independent meta-analysis is carried out. The 
implications of this are raised in the discussion section of this chapter. 
 
Where samples sizes (n) are mentioned, in the studies used for meta-analysis here, 
these refer to the number of biologically independent samples (in this case, 
individual mice).  
 
3.2.1 Fisher’s combined probability model 
 
Also referred to as Fisher’s sum of logs method, this model (Fisher 1932) predates 
the introduction of the term “meta-analysis” by Gene Glass (Glass 1976). It relies 
on the idea that any number of independent statistical tests on the same research 
and (null) hypothesis can simply be combined, resulting in a new statistic that 
follows a chi-squared distribution with degrees of freedom equal to two times the 
number of studies. This model belongs to a family of models concerned with 
combining p-values from individual studies. Other representatives of this model 
family all combine p-values, but use normal or binomial distributions for p-values, 
add weighting or set minimum significance thresholds for individual studies 
(Stouffer 1949, Wilkinson 1951, Sidak 1967, Edgington 1972, Simes 1986, 
Zaykin, Zhivotovsky et al. 2002). Other models use the same principles, but 
combine per-study test statistics rather than their significance (Ghosh 2003), and 
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this comes very close to the effect size model described later in this chapter. It is 
possible that Fisher’s method is more susceptible to bias from individual studies 
(publication bias, reporting of one-sided tests), but the other models listed above 
also make assumptions that in themselves cannot be confirmed, e.g. the presence 
of a large p-value in only one study representing bias rather than variation or 
experiment factors. Fisher’s basic assumption of probabilities ranging from 0 to 1 
holds true in this thesis, with probabilities calculated and known fully, i.e., not 
drawn from research papers or other external sources that likely do not report 
statistical significance above the 5% threshold. Fisher’s is the most generic of the 
3 models used here, the methodology allows for the combination of p-values from 
any source, e.g. it would be possible to combine a statistical test performed on 
protein abundance with a statistical test performed on gene transcription level, 
although this option is not explored here. An issue that is explored here is the 
dependence of Fisher’s meta-analysis on the nature of the statistical hypothesis 
tests performed in the individual studies, e.g. parametric tests performed on non-
normally distributed data would transfer a non-robust result into the meta-analysis. 
Given the specific studies used here, how do meta-analysis results compare when 
the individual studies have been analysed with a parametric or a non-parametric 
model? 
 
For studies i…K and per-study result of statistical hypothesis testing pi , Fisher’s 
combination of probabilities is defined as: 
 
 
𝜒!"! = −2 ln 𝑝!
!
!!!
 (Eq. 3.1) 
Eq.  3.1  Fisher's  combination  of  probabilities  
 
Term df defines the degrees of freedom and equal 2K. In words, the negative 
scaling of a sum of log transformed probabilities by a factor of two results in a chi-
squared distributed variable for which a p-value can be looked up in a chi-squared 
probabilities table with df=2K. 
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3.2.2 Rank-Product meta-analysis 
 
Rank Product (RP) methodology was originally proposed as a robust method for 
identifying differentially expressed genes in individual studies (Breitling, 
Armengaud et al. 2004) but was later expanded to application as a meta-analysis 
methodology (Hong, Breitling et al. 2006, Hong and Breitling 2008). The rank 
product approach changes the focus from isolated gene-by-gene testing of 
hypotheses centred on differences is mean expression to a focus on biological 
expression fold-changes and taking into account the relative ranking of genes to 
one another. It has been shown (Yuen, Wurmbach et al. 2002) that the ranking of 
gene expression fold changes can be inherently more stable across multiple studies 
than fold changes themselves. RP has the simple aim of identifying genes that are 
consistently top-ranked (in their differential expression between experiment 
groups) across replicated samples from two or more biological conditions. This 
metric is improved on by assigning a statistical probability to the rank product 
statistic, which is based on comparing the observed rank product statistic to a 
permutation-based null distribution of rank product statistics. The methodology 
was originally intended to provide a level of robustness in the analysis of small 
individual studies, but was quickly and easily extended to work across a number of 
studies. Unlike Fisher’s combination of probabilities, no hypothesis tests are 
applied in any of the individual studies, their contribution to the meta-analysis is 
the rank product estimate of each gene. And because there is no standardisation to 
the variance, it is possible (even if it may not be advisable) to include studies with 
just a single sample in a treatment or control group. 
 
The notation for the implementation of this algorithm is different from that used 
by Breitling or Hong, for the simple reason that the authors provide sparse or 
changing notation in the original and related papers. 
 
Following the removal of systematic measurement error from all individual studies 
through background correction and normalisation steps (see section 2.5 in chapter 
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2), there are S studies. Each study is a separate expression data matrix with G 
genes in rows and T+C samples in columns, where T and C denote the total 
number of IFN-γ and control samples in a single study, respectively. 
 
The first step is to calculate, for each study, all possible pair-wise gene expression 
ratios (or differences on log scale) between (not within) control and IFN-γ 
samples. This ratio or quotient Q for gene g in study i for a pairing k of samples 
can be represented as the outer product between the two groups in each study 
(using the inverse of one group to achieve division). 
 
 
 𝑄!"# = 𝑇!"⨂  𝐶!"!! ! (Eq. 3.2) 
Eq.  3.2  Expression  ratio  Q  between  sample  pairs  
Tgi and Cgi denote, for a given gene, expression values from all IFN-γ samples in 
study i and all control samples in study i, respectively. The total number of 
sample-pairings between IFN-γ and control samples for a study is Ki, which is 
TiCi. After calculation of these expression ratios, the new data matrix for each 
study now contains G rows and Ki columns. As they can now be considered as a 
single data matrix for the purposes of a meta-analysis, the total number of 
expression ratios and therefore columns is 𝐾!"! = 𝐾!!!!!  
 
Next, expression ratios are converted to ranks (largest ratio is 1), 
 
 
 𝑟!"# = 𝑟𝑎𝑛𝑘(𝑄!"#) (Eq. 3.3) 
Eq.  3.3  Rank  of  expression  ratios  
 
followed by obtaining the rank product RP for each gene g across all sample-
pairings k in all studies i. It should be noted that the study index is no longer 
required and subsumed by the index for sample-pairings across all samples (Ktot). 
The below rank product equation is also equivalent to the geometric mean of the 









 (Eq. 3.4) 
Eq.  3.4  Rank  Product    
 
Subsequent to obtaining the observed RP statistic, a random experiment with 
identical numbers of samples and genes is created by randomly permuting all gene 
expression values within each array relative to gene identity. This is repeated B 
times, each permutation set followed by equations 3.2 to 3.4. Each permutation 




∗(!) (Eq. 3.5) 
Eq.  3.5  Rank  Product  permutations    
 
Over B permutations this constitutes the reference null distribution 𝑅𝑃!∗ of RP 
values that are observed by chance. The exact statistical significance for a gene is 
the number of permutation estimates that are smaller than or equal to the observed 





Ι(!!!! 𝑅𝑃!"∗ ≤ 𝑅𝑃!)
𝐵  
(Eq. 3.6) 




Finally, the procedure (equations 3.3 – 3.6) is repeated with rankings reversed, 
meaning there are separate runs for identifying up and down regulated genes. 
 
Although the authors briefly discuss per-study weighting in the contribution to 
meta-analysis estimates by other models, this discussion on weighting is not 
extended to the RP method. Equation 3.4 corroborates that the RP model is 
implicitly weighting each study’s contribution to the meta-analysis, because the 
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number of sample-pairings within it (Ki) grows with the square of study sample 
size, assuming sample sizes in each treatment group are equal (or more 
generalised, it grows with product TC). As each doubling of sample size increases 
a study’s Ki and therefore the contribution to the meta-analysis rank product 4-
fold, this is a strong implicit weighting factor. A modification of this strategy is 
therefore proposed and assessed here. A generalised weighting scheme based on 
study size can be expressed as follows, with rank values still going into an overall 










 (Eq. 3.7) 
Eq.  3.7  Per-­‐study  weights  for  Rank  Product  
 
Term wk is a vector of weights with length Ktot, with each element k in a study i 
weighted in relation to the number of sample pairings Ki in that study. 
Two different weighting schemes are considered here, in addition to the standard 
method. If n is the per-group sample size of a study and study groups are balanced, 
then for the standard method individual study weight is n2. In the first new 
weighting scheme, here referred to as proportional weighting, individual study 
weight is 2n. In the second weighting scheme, here referred to as equal weighting, 
each study’s weight is 1. Formally, the two new weighting schemes are as follows: 
 
 





  (Eq. 3.8) 
Eq.  3.8  Proportional  study  weighting    
 





  (Eq. 3.9)  
Eq.  3.9  Equal  study  weighting    
 
With the exception of sample size per group n=1 or n=2, the relationship between 
the normal weighting wnorm, equal weighting wequal and proportional weighting 
wprop is: wnorm > wprop > wequal. 
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Once the weighted rank products are calculated, comparison against a newly 
constructed null distribution of permutation-based weighted rank product values 
yields new probability values, as described for the non-weighted rank products. 
 
With respect to computing p-values for rank product values (eq 3.5 and 3.6) 
through a permutation-generated null distribution, recent work on this subject 
(Eisinga, Breitling et al. 2013) suggests another method. The authors suggest that 
the above permutation strategy performs well for genes with large rank product 
values (resulting in less significant p-values), but is either less accurate in the 
generation of low p-values or only accurate for unfeasibly long computation times. 
The introduced method calculates the probability of a given gene’s observed rank 
product by relating it to the total number of rank value combinations that could 
attain the same rank product value in a data set with a given number of genes and 
sample replicates. The exact p-value for this gene is then the probability of the 
observed rank product being equal to or less than the observed rank product.   
 
 
3.2.3 Effect size model 
 
The effect size model (Choi, Yu et al. 2003) draws on a standardised difference in 
means between two biological conditions in a study in order to identify a meta-
analysis effect size across all studies. It differs from Fisher’s and Breitling’s meta-
analysis model mainly in its inherent use of within-study and between-study 
variability in the meta-analysis estimate, which is of course related to the size of a 
study. Effect size and its variance are calculated for each gene in each study, with 
the inverse of its variance used as a weight in combining the estimates for a gene 
across all studies, giving greater weight to larger studies or generally to studies 
with less random variation. Another feature of this methodology is the ability to 
test for between-study variance (Cochran 1954) and if required compute estimates 
for between-study variance (Dersimonian and Laird 1986). This allows a decision 
on the type of model that is used to combine effect sizes across studies, where the 
choice is between fixed effect model (FEM) and random effects model (REM).  
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For the REM, the assumption is that the studies in a meta-analysis are a random 
sample of a theoretically infinite number of studies with different true effect sizes 
(e.g. subject to multiple study population differences, known or unknown), all 
centring on an average true effect size. In this scenario, one does not assume all 
studies to be identical even in their theoretical outcome. For the studies in this 
thesis, one may for example not expect different mouse strains or interferon 
gamma doses to lead to exactly the same level of gene expression. As such, one 
would in the meta-analysis not only have to account for the variance within a 
study (depending on statistical sample size), but also for the variance between 
studies that is caused by the above-mentioned factors. When needing to determine 
an overall average effect size across all studies in a meta-analysis, under REM this 
average needs inverse weighting based on an estimated value for between-study 
variance (e.g. DerSimonian & Laird, as detailed in eq. 3.16) as well as the default 
weighting (addressing per-study random sampling error) by the inverse of within-
study variance.  
 
For the FEM, the assumption is that every study in the meta-analysis measures the 
same true effect size and all studies would therefore theoretically (with large 
sample sizes) return the same result. This scenario is really only plausible if all 
samples in all studies are drawn from the same population. If this assumption of a 
fixed effect were true for the studies used in this thesis, either only one mouse 
strain (or other identical experiment factor) would be considered, or one would 
assume that gene transcription levels are completely independent of the mouse 
strain (or other experiment factor) used. The between-study variance is then 
assumed to be 0 and the overall average effect size only requires inverse weighting 
by the within-study variance. 
 
An overview of the full effect size (ES) model is provided in figure 3.1.2 below 





Figure 3.1.2 Effect Size model overview  
 
This figure outlines the order of computations for the Effect Size meta-analysis model. 
“Eq.” numbers refer to the equation numbers given in this chapter, FEM and REM refer to 
Fixed Effect Model and Random Effects Model, respectively. QQ refers to a quantile vs 
quantile plot, here specifically the quantiles of Cochrane’s Q statistic vs the quantiles of 






Among many possible options, the chosen estimator for effect size for a given 







   (Eq. 3.10) 
 
Eq.  3.10  Cohen's  d  (effect  size)    
 
Terms T and C refer to the treatment (IFN-γ) and control group, and Si is the 
pooled standard deviation across both groups. Effect size d is obtained for each 
gene in each study. It should be noted that this estimator is similar to a t-statistic, 
but the difference in means is not standardised to the standard error but to the 
pooled standard deviation, thus sample size is not taken into account. Effect size d 
is then corrected (by scaling the biased effect size in relation to N) to an unbiased 
effect size estimate d’ as introduced by Hedges and Olkin (Hedges 1985), where N 




𝑑′! = 𝑑 1−
3
4 𝑛!! + 𝑛!! − 2 − 1
   (Eq. 3.11) 
 
Eq.  3.11  Unbiased  Cohen's  d    
 
A variance estimate for this unbiased effect size is obtained next, with 𝑛! and 𝑛!  













2 𝑛!! + 𝑛!!
 (Eq. 3.12) 
 
Eq.  3.12  Variance  of  unbiased  Cohen's  d    
 
Having established effect size and effect size variance for each gene in each study, 
it is now necessary to determine the type of statistical model required to combine 
estimates across studies, based on variation in study outcomes between studies. 
This heterogeneity can be estimated on the observed data, and although it has low 
statistical power with small numbers of studies in a meta-analysis (Gavaghan, 
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Moore et al. 2000), Cochran’s Q statistic (Cochran 1954) is used for this purpose. 




𝑄 = 𝑤! 𝑑′! − 𝜇 !
!
!!!
 (Eq. 3.13) 
 
Eq.  3.13  Cochran's  Q    
 
Term S is the total number of studies. While 𝑑′ has been obtained before this 






!  (Eq. 3.14) 
 






 (Eq. 3.15) 
 
Eq.  3.15  Overall  treatment  effect    
 
Summarising the above steps, Cochran’s Q is the squared difference between the 
estimated overall treatment effect and the estimated effect in individual studies, 
where individual studies are weighted by their inverse variance. The Q statistic 
follows a 𝜒!distribution with S-1 degrees of freedom, and while it is trivial for 
single-variable meta-analyses to obtain a p-value of statistical significance based 
on this distribution, for multi-variable microarray-based meta-analyses this 
process is adapted somewhat, by comparing the quantiles of empirically obtained 
Q statistics of all genes against the quantiles of a theoretical 𝜒!distribution with S-
1 degrees of freedom. A quantile-quantile plot (QQ) is suitable to show if the 
empirical values are more extreme than expected, major deviations from the 
diagonal suggest that studies are heterogeneous and a fixed effect model (FEM) is 
inappropriate for combining effect sizes across studies, and a random effects 
model (REM) should be used instead.  
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If the statistical test result does not reject the assumption of study homogeneity, 
effect sizes are combined across studies under the FEM model, with between-
study variance set to 0. However, if studies are shown to be heterogeneous, then 
effect size estimates across studies are combined under the REM model and an 
estimate for between-study variance is required. A weighted estimator for this 




𝜏!"! = 𝑚𝑎𝑥 0,
𝑄 − 𝑆 − 1
𝑤!!!!! − 𝑤!!!!!! / 𝑤!!!!!
 (Eq. 3.16) 
Eq.  3.16  DerSimonian-­‐Laird  heterogeneity  estimator  
 
Term S is the total number of studies and 𝑤! is the inverse variance 1 𝜎! for each 
study i.  
With individual study effect sizes calculated, a decision on REM or FEM made 
through a QQ plot of Cochran’s Q statistics, and an estimate for between-study 
variability of true effect size obtained, it is now possible to combine effect sizes 
for each gene across all studies. The combination provides estimates for the 
average treatment effect (in this case IFN-γ) and the variance of the average 
treatment effect. The average treatment effect size can now be calculated by 
weighting the per-study unbiased effect sizes with the inverse of the within-study 





(𝑠!! +   𝜏!"! )!!  𝑑′!!!!!
(𝑠!! +   𝜏!"! )!!!!!!
 (Eq. 3.17) 
Eq.  3.17  Weighted  overall  effect  size    
 
The associated variance of the average effect size is: 
 
 
 𝑉𝑎𝑟 𝜇 𝜏! =
1
(𝑠!! +   𝜏!"! )!!!!!!
 (Eq. 3.18) 
Eq.  3.18  Variance  of  overall  effect  size    
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If FEM were the model under which effect size estimates were to be combined 
across studies, then between-study effect size variance 𝜏!"! would be 0 and 
therefore not have any influence on the outcome. For the four studies considered 
here, the QQ-plot (appendix A3) of observed versus expected Cochran’s Q 
quantiles shows strong rejection of the null hypothesis of study homogeneity, 
requiring use of a REM model for combining effect size across studies, as 
described above. But in either case, standardising the average treatment effect size 







 (Eq. 3.19) 
 
Eq.  3.19  z-­‐score  for  overall  effect  size    
 
Statistical significance values p can be derived from z by relating it to a standard 
normal distribution table, under the usual normality assumptions. Alternatively, a 
null distribution of z values can be constructed through permutation and repeat 
estimation of z on the original data, in cases where normality cannot be not shown 
or assumed. 
 
3.3 Assessment methods for meta-analysis results 
 
For meta-analyses performed on a single variable or very few variables, it is 
usually straightforward to assess the results in that one can simply list all relevant 
output (e.g. study contribution coefficients, statistical significance, confidence 
intervals) and plot results of individual studies and the meta-analysis in a standard 
forest plot as shown in the example, figure 3.2. 
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Figure 3.2 Example of a standard forest plot 
 
 (Brien, Ronksley et al. 2011). Brien et al, British Medical Journal 2011; 342. Fig 2; used 
under Creative Commons Attribution Non-commercial License. 
The first column of each of these two panels lists the individual studies included in a 
meta-analysis, the second column graphically displays the analysis outcome of each study, 
using the same outcome measure (in this case, mean difference between two study 
groups) as that combined for a meta-analysis. The centres of squares indicate the mean 
difference between the treatment groups in a study, with horizontal lines indicating its 
95% confidence limits. The area of the square is proportional to the study’s weight in the 
meta-analysis. The diamond indicates the meta-analysis result across all individual 
studies, with the lateral edges of the diamond denoting the 95% confidence limits for this 
estimate. 
 
While this is a good representation, it does not accommodate microarray studies 
where thousands of variables (i.e. genes, probes, features) are analysed and one 
graph per gene would be required to represent this information. Analogous to heat 
maps representing microarray gene expression, relative expression or fold 
changes, it would be possible to represent per-study and overall effect sizes or 
equivalent statistics in a form of heat maps (or heat maps after hierarchical 
clustering on variables) where that effect size is mapped to a colour and shown for 
all genes across all individual studies and the meta-study. But also analogous to 
heat maps from basic microarray data, such an overview is difficult to assess 
quantitatively or meaningfully. 
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For this thesis, four principal methodologies have been used (and partially 
expanded on) to summarise these results. They provide numerical results but for 
simplicity and ease of categorisation are here named after their primary graphical 
output: Pyramid plots, IDD plots, ROC curves and CAT plots. 
 
3.3.1 Pyramid plots and discovery counts 
 
At the simplest level of result evaluation, note is taken of the number of 
“discoveries” made in individual studies and the number made through meta-
analysis. The term discovery is at this stage not associated with any biological 
meaning, it is only intended to be a conceptual and short phrase to replace 
“number of statistically significant genes”, where statistical significance is set at 
an alpha of 1%. Counts of discoveries are displayed in horizontal bar plots that 
distinguish between discoveries in up- or down regulation with reference to the 
control condition. As these bar plots come with some level of expectation that a 
meta-analysis identifies most individual-study discoveries as well as meta-
analysis-only discoveries, the corresponding largest bar of counts would be at the 
bottom of the graph like the base of a pyramid. This type of graph is proposed 
within the framework of this thesis and not previously used elsewhere, a basic 
example is therefore shown in figure 3.3. 
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Figure 3.3 Example pyramid plot
 
Each horizontal bar represents the total count (indicated on X axis) of statistically 
significant genes in a given study or in the meta-analysis of the combined study results. 
The bar section to the left of vertical zero reflects down regulated genes (with respect to 
control condition), the bar section to the right reflects up regulated genes. If the studies are 
approximately sorted by number of samples (study size), the expectation would be that 
smaller study sizes (at the top) have less power to identify significant changes and will 
therefore be narrower. Similarly, a meta-analysis might be expected to increase the power 
to detect significant genes beyond that of any individual study and is therefore represented 
at the base of this ‘pyramid’. Deviations from this pyramid structure may indicate issues 
or features of studies or analysis methods. 
 
 
The visualisation of discoveries per study or through meta-analysis is informative 
about the relationship between study size and discoveries as well as the 
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relationship between individual studies and the meta-analysis in question, and it 
does address the need to summarise information across thousands of genes. 
However, simple counts do not provide any information on the magnitude of 
effect sizes or levels of significance, they do not map the outcome for individual 
genes in single-study analysis to the meta-analysis outcome for the same genes, 
and they do not allow a precise comparison between different meta-analysis 
methods. These points are addressed by the IDR method in the following section.  
 
3.3.2 Integration-driven Discovery Rates (IDR) 
 
A moderately more formal method of assessing meta-analysis benefits is derived 
from Integration-Driven Discovery (IDD) and Integration-driven Discovery Rates 
(IDR) as introduced by Choi (Choi, Yu et al. 2003) and with microarray meta-
analyses in mind. As the name suggests, this is aimed at quantifying the benefit of 
meta-analysis by focusing on discoveries that do not occur in single studies but 
only in their combined analysis. The original method is adapted to work within the 
framework of this thesis, as the original was not intended for comparisons of 
different meta-analysis models. For this purpose, it is the negative log of 
significance p (one-sided) of the respective average treatment effect statistic that is 
plotted against the IDR, rather than a z score. This allows comparison between 
meta-analysis models on the same scale, with the negative log transformation 
aiding in visualisation of the otherwise compressed scale of p-values. Equations 
have been adjusted accordingly. 
 
In detail, IDD is a count of the number of statistically significant genes (or 
“discoveries”) in the meta-analysis that are not statistically significant in any of 
the individual studies, i.e. meta-analysis-only discoveries. The IDR is that count 
divided by the total number of discoveries in individual studies and the meta-
analysis (total discoveries), i.e. the proportion of total discoveries accounted for by 
meta-analysis alone, with this in theory ranging from 0 to 1. For each individual 





𝐼𝐷𝐷! ∶= 𝑝!"#$ < 𝑝!!  𝑎𝑛𝑑   𝐼 𝑝! < 𝑝!! = 0
!
!!!
 (Eq. 3.20) 
Eq.  3.20  Integration-­‐Driven  Discovery  gene  status  (IDDg)  
 
Where pmeta is the statistical p-value resulting from the meta-analysis of gene g, pi 
is the statistical p-value resulting from an analysis of study i, and pth is a given 
threshold for statistical significance. 




𝐼𝐷𝐷 =    𝐼𝐷𝐷!
!
!!!
 (Eq. 3.21) 
Eq.  3.21  Integratio-­‐Driven  Discovery  (IDD)  
 
, IDR is the number of meta-analysis-only discoveries in relation to the total 





𝑝!"#$ < 𝑝!!  𝑜𝑟   𝐼 𝑝! < 𝑝!! > 0!!!!!!!!
 (Eq. 3.22) 
Eq.  3.22  Integration-­‐driven  Discovery  Rate  (IDR)  
 
Note that the contents of the Iverson bracket in equation 3.22 are not that from 
3.20 but aggregate the total number of genes that are statistically significant in an 
individual analysis or the meta-analysis. The metrics obtained through this method 
are shown on IDR plots, which show the rate of meta-analysis-only discoveries 
(standardised to total number of discoveries as described above) for different 
thresholds of statistical significance.  
IDR plots provide an immediate impression of the comparative performance of 
meta-analysis models, where a larger IDR indicates that the method is better in 
combining study results. However, the use of proportions can hide underlying 
absolute counts, and this graph therefore does not replace simple counts as shown 
in the pyramid plots. IDR may also be affected through the quality of analysis in 
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individual studies, e.g. if the Rank Product statistic is more robust at identifying 
statistically significant genes in small individual studies, the proportion of meta-
analysis-only discoveries (IDR) is reduced. Both the pyramid plot and the IDR 
plot also rely on the assumption that every discovery is a good and biologically 
sound discovery. This assumption cannot be supported in light of false positive 
rates associated with simultaneous testing on multiple variables, and even a 
correction for this (by applying a Bonferroni or another p-value adjusting 
algorithm) does not assure biologically valid discoveries. This issue is addressed 
in the following section. 
 
3.3.3 Receiver-Operating-Characteristics (ROC)  
 
ROC is a generic technique for comparing observed to expected/known/true 
results, for example in evaluating new clinical diagnostics, evaluating algorithmic 
classifiers or evaluating algorithms applied to simulated data. By calculating how 
many outcome measurements of a new diagnostic or algorithm correctly match 
known true positive and known true negative outcomes, for any given level of that 
measurement, data for a curve combining true positive and false positive rates can 
be obtained. Calculating the area under this curve (AUC) provides a single 
summary estimate of how well the observed results match the expected results, 
with AUC=0.5 representing matching no better than random and AUC=1 
representing a perfect method. In terms of assessing meta-analysis results, ROC is 
here used to compare observed discoveries to biologically expected results in form 
of reference lists of genes known to be transcribed when IFN-γ is present in 
murine bone marrow derived macrophages. The diagnostic input here is the vector 
of negative log transformed p-values (to avoid flipping of ROC curves) without 
distinguishing between up- and down-regulation. Any definition of “biologically 
expected” is likely to be far from comprehensive, because biological systems are 
complex and not readily reduced to a snapshot that would hold true for a given set 
of experiment conditions. This is also true in the specific case here, using “gold 
standard” reference lists consisting of accumulated snapshots of IFN-γ related 
genes. This is explained in detail in chapter 2, but briefly, there are two types of 
reference lists used here, one based on IFN-γ related genes retrieved from the 
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EntrezGene database, and one manually curated over several years at DPM. These 
lists will have omissions or inclusions depending on the sources they are derived 
from. As described in detail in chapter 2, in addition to the snapshot issue, another 
problems is that any such reference list by definition contains positive findings 
only, i.e. there is no definitive list of genes that are not involved in the IFN-γ 
pathway (other than simply assuming this is the whole genome minus reference 
list). Even within these limitations, a proportion of true biology captured and 
compared against would have advantages over no biology at all, at a minimum it is 
to be expected that any given analysis should recover at least a proportion of the 
already known underlying biology. In order to avoid circular reasoning in the 
biological interpretation of results, it is also important that reference lists be 
independent from the data used in the meta-analysis, and this is the case here. 
There are a number of disadvantages to the ROC evaluation. One is the 
uncertainty about the comprehensiveness of the gold standard reference lists, 
another is the assumption that a new method can only achieve performance as 
good as but not better than the gold standard. A third is that ROC in this case 
cannot distinguish between up-regulated genes (with respect to a control 
condition) and down regulated genes, because the gold standard lists do not 
contain this information. It is possible to compare up/down separately against the 
gold standard, but this would shift the emphasis on the regulation direction, not 
improve ROC itself. Lastly, while the threshold of declaring a discovery 
(statistically significant gene) is important in obtaining the continuous estimates 
for ROC curves, this provides no overview over the number of observed most 
significant genes compared to gold standard lists. The first three issues are 
problems inherent to the methodology, the last issue is addressed through the use 
of CAT plots. 
 
3.3.4 Correspondence-at-Top (CAT) 
 
This list-comparison statistic has been proposed for microarray-based meta-
analyses (Irizarry, Warren et al. 2005). I visualises the proportion of meta-analysis 
discoveries that overlap with a reference list of known results. It differs from the 
other methods used here in a number of ways. Firstly, it has a focus on 
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“rediscovery” of known facts. As such, it is not limited to meta-analysis-only 
discoveries and counts meta-analysis discoveries irrespective of their significance 
status in individual studies. Secondly, the original authors present CAT plots in the 
context of what amounts to the leave-one-out principle (albeit without using more 
than a single permutation), where two studies undergo meta-analysis and a third 
study serves as reference. This raises questions, because it is basically a trade-off 
between an increased-power meta-analysis with less evaluation and a decreased-
power meta-analysis with more evaluation. For this thesis, the method is adapted 
in that it does not compare meta-analysis results to a third study, but to the 
biological ‘truth’ through using the same biological reference lists as for the ROC 
analyses. The adaptation is subject to a small penalty in form of result granularity, 
because the biological reference lists are shorter than the full genome. Also, the 
displayed proportions are reduced to a selected threshold of statistical significance 
of p≤ 0.01, which can shorten plotted lines but provides useful comparative 




Results are outlined in terms of the assessment methods described in 3.3. Lists of 
statistically significant genes have not been shortened through correction for 
multiple testing, accepting the presence of false positives amongst results.  
 
3.4.1 Discovery count results 
 
In terms of simple counts of discoveries through meta-analysis (where they need 
not be unique to meta-analysis), there are several outcomes worth highlighting 
(figure 3.4). 
 
Effect of study size. Statistical analysis of individual studies is strongly affected by 
study size (Figure 3.4, all panels), with the two smaller studies resulting in far 
fewer discoveries by any given statistical model. For the smaller studies, non-
parametric methods (Figure 3.4, panels A-right, B) result in more discoveries than 
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parametric methods. Conversely, for the two larger studies parametric methods 
result in more discoveries than non-parametric methods (Figure 3.4, panels A-left, 
C). The prevalence of small microarray studies has long since led to many 
proposed analysis standards for small studies, favouring models that are either 
non-parametric (rank or list based) or moderate gene variance by borrowing 
information from other genes (Breitling, Armengaud et al. 2004, Smyth 2005, 
Jeanmougin, de Reynies et al. 2010). The small-study advantage of the non-
parametric analysis may be due to the chosen one here being list based, while a 
simple rank based statistic (e.g. Wilcoxon Rank Sum test) would result in very 
granular p-values for such small sample sizes.  
 
Effect size model. Comparing over all meta-analysis models, it is clear that the 
effect size model (ES) stands apart in terms of meta-analysis discoveries (it has far 
fewer) and in terms of discoveries unique to individual studies (far higher; black 
highlighted areas in figure 3.4 panel C). While this cannot be taken as a statement 
on the quality of these results, it highlights a potential weakness of the effect size 
metric in obtaining reproducible results across independent studies of differing 
size. This lowers the total number of meta-analysis discoveries including genes 
already identified in individual studies, but it does not greatly affect the number of 
meta-analysis-only discoveries (signified by the black regions in the meta-analysis 
counts), this subset is broadly comparable to other models.  
 
Parametric vs. nonparametric generation of p-values for FP method. In line with 
above findings, when FP is used with parametric p-values, small studies result in 
fewer results than the nonparametric method, and vice versa. While the meta-
analysis discoveries are almost identical (total count and unique count) for up 
regulation results, the non-parametric method results in fewer down regulation 
discoveries, with the largest study (for which the parametric model is better suited) 
likely driving those results, thus favouring the parametric model. 
 
Effect of weighting on RP model. The model as proposed by the original authors is 
inherently weighted by the square of study group sample size (equation 3.4), this 
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will allow the largest study to have a very large effect on the meta-analysis 
outcome. While there is nothing to say that this is not a good weighting scheme 
(with larger studies expected to have lower variance), in case of unbalanced study 
sizes it outweighs the contribution of smaller studies and this is here considered 
against two alternative weighting schemes, one is proportional to study sample 
size and therefore moderates the effect of large studies more than the original, the 
other removes the influence of study size, with each study influencing the meta-
analysis outcome equally. Up regulation discoveries are not affected by the 
proportional weighting, while down regulation discoveries are increased. Up 
regulation discoveries are strongly reduced by equal weighting, while down 
regulation discoveries remain similar to the original method. For both proportional 
and equal weighting, the number of discoveries made through meta-analysis only 




Figure 3.4 Discoveries in individual studies and meta-analyses 
 
   
 
For each individual study analysis and the combined meta-analysis (Y-axis), the X-axis 
shows counts (out of total ngenes=9812) of genes with significantly higher expression in 
Ifn-γ than in controls (up regulated, shown left of vertical centre) and vice versa (down 
regulated, shown right of vertical centre). X-axes in all panels are on the same scale, 
with plotting limits at count=1000 at either end from the central 0 count, and tick 
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marks at intervals of 100. Black shaded areas within the horizontal bars indicate the 
number of statistically significant genes that were unique to that analysis. 
 
 
Summary of quantitative assessment. Based on pure counts of discoveries, the 
suggestion at this stage is that, for the combination of small are large studies used 
here, the oldest and simplest model for combining study results (FP) appears to 
perform best, followed by the proportional-weighting version of the RP model. 
The worst performing meta-analysis method is the effect-size based model. The 
latter is not surprising given the small study sizes and statistical power issues 
associated with this. It is somewhat more of a surprise that the FP model based on 
parametric analysis results in the largest number of discoveries, ahead of the FP 
model with non-parametric study input and RP meta-analysis models, although the 
proportionally weighted RP method introduced here performs well. This is a 
reversal of findings by the original authors of RP (Hong and Breitling 2008) who 
do not recommend Fisher’s method and observe RP to have the edge over both FP 
and an effect size model. Given that the same methods are used here (ignoring the 
new weighting schemes for now), this would suggest that meta-analysis results for 
small collections of small studies are very dependent on the composition, size and 
biological context of those studies. More studies are used here, and the single 
reasonably sized (in microarray study terms) study may be better suited to the 
simple parametric test and therefore drive meta-analysis results. 
 
3.4.2 IDR results 
 
In a level of complexity beyond simple per-method discovery counts, results 
uniquely obtainable through meta-analysis alone need to be identified. Before a 
detailed look at the meta-analysis proportion through IDR plots, a simple summary 
graph (figure 3.5) provides information on the difference between a meta-analysis 
and the analysis of an individual study in terms of number of discoveries. This 
differs from the results shown in section 3.4.1 (which do not identify overlap in 
gene sets) and the IDR plots in section 3.4.3 (which assesses results for changing 
values of p and reflects per-gene information across all individual study analyses). 
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Figure 3.5 Overlap between individual studies and meta-analysis results 
 
For each model of meta-analysis, overlapping proportion of discoveries (gene discoveries 
made at p≤ 0.01 in both single study and meta-analysis) is shown for the individual 
studies, analyzed by the method corresponding to that meta-analysis. The numbered 
columns refer to the study number. Red bars denote discoveries in down regulation, blue 
in up regulation with reference to control condition. A value of 100% is defined as the 
total number of statistically significant genes for a given meta-analysis model, and the 





Individual study performance compared to meta-analysis. From figure 3.5 it is 
clear that meta-analysis in every case is more than simply recall of single-study 
results, with even the largest study (#6) in the standard RP model identifying less 
than 80% of discoveries made in the corresponding meta-analysis. Non-parametric 




































while parametric methods have marked performance differences between the same 
studies. 
 
The next step is to identify the number of genes identified in statistical meta-
analysis that were not identified in any of the individual studies. Because the 
quantitative assessment in 3.4.1 indicates differences in discovery-numbers for up- 
and down-regulated genes, IDR plots are also broken down into those categories 
in figure 3.6 below. Crucially, this figure differs from figure 3.5 in that it 
aggregates information per gene across all individual studies rather than just 
stating how many genes are found to be statistically significant in a particular 
study. 
 
Figure 3.6 IDR plots for meta-analysis-only discoveries 
 
The X-axis represents a given threshold of statistical significance transformed to negative 
log scale for visualization purposes. The two vertical lines are visual guides at p≤0.05 and 
p≤0.01, respectively. Given a particular threshold on X, Y-axis shows the proportion of 
genes identified as significant in meta-analysis-only with respect to total number of 
discoveries (total = 1 = meta-analysis-only discoveries plus single-study discoveries in 
any of the individual studies). 
 
 
Best model for up regulated gene set. For a commonly used statistical threshold of 
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to the number of genes already identified as discoveries in individual studies, with 
only the two new weighting schemes for RP at the top end of this estimate, and the 
FP model using non-parametric tests as the worst performer. It must be noted that 
this could also mean the analysis of the individual studies is far better than that of 
other methods, this is outlined in the discussion below. At a more stringent 
statistical threshold of p≤0.01 and consequently including fewer false positive 
discoveries, it is clear that the proportional weighting version of the RP meta-
analysis performs much better (IDR~10.5%) than the original RP model or any 
other model, with ES coming in last (IDR~5%). This pattern gets more 
pronounced if the statistical stringency for significant differential expression is 
increased further, as would be the case when adjusting p-values for multiple 
testing. The noticeable peak of increased proportions shown for the equal-
weighting version of RP is in the region of not usually used p-value thresholds, 
meaning a discovery as defined here would be exceedingly easy to make and 
contain a large proportion of false positive results. This does not explain why it is 
different from the other methods in this abnormality, but this could be related to 
the weighting scheme increasing the weight of smaller (‘bad’) studies and 
decreasing the weight of larger (‘better’) studies, leading to a larger number of 
missed (at least at such a low threshold of statistical significance of p≤ ~0.2), 
discoveries in individual studies and therefore driving up the rate of meta-analysis-
only discoveries. Given that the IDR drops again, this would point to the presence 
of a set of genes with somewhat variable expression properties in at least one of 
the studies. 
 
Best model for down regulated gene set. Within the constraints set by microarray 
technology, IFN-γ appears to be associated with a larger number of down 
regulated than up regulated genes, which is seen in the generally higher proportion 
of meta-analysis-only discoveries. The pattern also seems to suggest that it is only 
in the set of down regulated genes that differences between meta-analysis models 
are much more distinct even for lower thresholds of statistical significance. At the 
modest statistical threshold of 5%, it is the equally weighted (IDR~11.5%) and 
proportionally weighted (IDR~8%) RP versions that show the largest meta-
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analysis benefit, with all other models below an IDR of 5% and the non-
parametric version of FP showing the least benefit. At the more stringent statistical 
1% threshold, the proportionally weighted RP provides an IDR of ~13.5% and 
then continues to outperform other models at all higher statistical stringencies. 
Comparatively, the ES model provides the least benefit at higher statistical 
stringency.  
 
Individual study results not rediscovered through meta-analysis. The reverse 
scenario of genes identified in any individual study but not through meta-analysis 
is also briefly investigated. They broadly answer the question, which of the 4 
studies produce results that are not reproduced in a given meta-analysis. The 
corresponding graphs (appendices A6-10) are similar in construction, in that they 
show the proportion of genes identified in a single study that were not identified in 
the meta-analysis, across thresholds for p (in this case not transformed). Although 
there are many features in these graphs (e.g. differences in up and down regulated 
gene sets), the one that may best summarise this outcome is the comparatively 
high proportion of genes identified in the largest study (study #6) using the ES and 
FP models, particularly up regulated genes (blue). This would suggest that these 
meta-analyses are unable to re-discover a larger number of genes that were 
successfully identified in the largest study, presumably because the analyses of the 
three smaller studies outweigh the contribution of the largest study to the overall 
effect size and combined probabilities. Conversely, the RP meta-analyses – 
particularly the proportionally weighted and standard method – all appear to 
recapture a larger proportion of genes that were identified as statistically 
significant in any single study. A conclusion of this may be that the robustness of 
the RP methodology in a scenario with multiple smaller studies outweighs the 
parametric advantage of a single larger study contributing to the combined effect 
sizes or probabilities. In other words, where RP is concerned, more small studies 
may be better for the meta-analysis than single large studies. Where ES and FP are 





3.4.3 ROC results 
 
Following the quantitative benefits of meta-analysis as described by discovery 
counts and IDR, it is now necessary to begin comparing results with reference to 
known biology, at least in broad terms. Detailed biological results are discussed in 
chapter 5. As an aside, comparison of a manually curated IFN-γ reference list and 
computer/database derived reference lists clearly shows that – although better than 
random with AUC > 0.5 – the latter do not contain the same quality of information 
as the former (appendices A4 and A5). This either signifies that the information 
contained in all-purpose-databases is far too weak to be of any use as a reference 
for any specialised experiment, or maybe more likely it signifies that a much more 
detailed database query structure than attempted here is required to produce a valid 
reference set for a specialised experiment, enriched for only those genes that are 
related to the specific biological hypothesis tested in the selected microarray 
studies. This description in practice matches the manually curated DPM gene list, 
motivating its use instead of the inferior lists generated through computational 
searches of the NCBI database. 
Given the meticulous and deliberate construction of this list (section 2.7.2 in 
chapter 2) by several Division of Pathway Medicine MSc students over several 
years, this list is here considered as the “gold standard” to compare any new 
findings to, although this interpretation may be subjective to DPM. ROC results 
for all meta-analyses are directly compared in figure 3.7. 
 
With all possible values of the negative log transformed statistical significance p 
sequentially serving as a threshold for determining a meta-analysis discovery, 
sensitivity and specificity are calculated with respect to the ‘known’ truth of 
discoveries in form of the DPM reference list of genes known to be involved in 
IFN-γ pathway in murine macrophages. All pairs of specificity (or rather 1-
specificity, which is the false positive rate) and sensitivity (which is the true 
positive rate) are plotted, resulting in the ROC curves. The area under the curve is 
calculated as a representative outcome statistic of the curve, where a value of 0.5 
represents the diagonal (sensitivity and false positive rate are equal for all possible 
significance thresholds, i.e. the overlap between meta-analysis results and 
 116 
reference list is random) and a value of 1 represents a curve apex at the top-left 
coordinate (full sensitivity and specificity for all possible significance thresholds). 
 
 
Figure 3.7 ROC curves for meta-analysis compared to DPM reference 
 
The curves in this ROC plot show sensitivity and false positive rate for all possible meta-
analysis significance levels for which the meta-analysis outcome (significant or not 
significant) is compared to ‘known’ truth (contained in DPM reference list or not 
contained in it). For each meta-analysis method, the area under the curve is also shown as 
a summary statistic, where a value of 1 would indicate 100% sensitivity and 0% false 
positive rate for any given decision threshold of statistical significance 
 
 
Meta-analysis performance comparison based on ROC. From this analysis it is 
clear that all meta-analysis findings broadly recover the known IFN-γ pathway. 
Perfect classification (100% sensitive, 100% specific) can of course not be 
expected from any method, given the gold standard list uncertainties described 
earlier. It is also clear from this analysis, that if the aim is to keep the rate of false 
positive findings low at below 10-20%, it would be more appropriate to choose 
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one of the RP meta-analysis models or the non-parametric testing for the FP 
model, as they are approaching around 80% sensitivity at that level. The 
sensitivity of the ES and the parametric FP model are 10-20 percent points lower 
for the same false positive levels. Apart from the comprehensiveness of the DPM 
gold standard list, another issue to be kept in mind in this ROC interpretation is the 
definition of false positive results, this is detailed in the discussion section of this 
chapter. 
 
Individual study performance based on ROC. Since all statistical outcomes can be 
obtained for each study, it is also possible to assess their biological context 
through ROC curves, providing some insight as to how much value a meta-
analysis adds over individual studies, particularly larger ones. Figure 3.8 repeats 
the meta-analysis ROC curves, but also includes for each approach the ROC 
outcome for individual studies. 
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Figure 3.8 ROC curves for study results compared to DPM reference 
 
The curves in this ROC plot show sensitivity and false positive rate for individual study 
results and meta-analysis results. The analysis outcome (significant or not significant) is 
compared to ‘known’ truth (contained in DPM reference list or not contained in it). For 
each analysis method, the area under the curve is also shown as a summary statistic, 
where a value of 1 would indicate 100% sensitivity and 0% false positive rate for any 
given decision threshold of statistical significance. Grey lines (dotted and solid) refer to 
analysis results for single studies, the largest of these is a solid line, and the smaller 
studies intentionally all share the same dotted line pattern in order to increase visual 
contrast to meta-analysis results.  
 
 
This assessment indicates that in terms of AUC the largest study (study #6) is in 
every case marginally worse than the corresponding meta-analysis, apart from the 
parametric FP where it is considerably worse. This is also true when limiting 
results to lower false positive rates only. On the whole this would therefore 
suggest that meta-analysis provides a marginal improvement over the statistical 
analysis of a single larger study, leading to two possible conclusions. One, meta-
analysis may be superfluous in scenarios where a large study on the chosen subject 
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meta-analysis in scenarios where larger studies are indeed available may not lie in 
the identification of large numbers of previously unknown contributing genes, but 
only in the identification of a small number of previously unknown contributing 
genes. This is not entirely unexpected, because it is unlikely that after decades of 
research into IFN-γ there would be any reason to expect the discovery of a large 
number of new genes in the biological pathways identified to date. And it can 
certainly be assumed that genes with low but consistent expression changes are of 




3.4.4 CAT results 
 
Correspondence-At-Top assessment as used in this thesis is somewhat similar to 
ROC in that it uses the same biological reference list, but it highlights the number of 
ordered significant results that overlap with the reference list. Figure 3.9 compares 
this metric between the meta-analysis models. 
 
 
Figure 3.9 Correspondence-At-Top using DPM reference
 
For a given number of the top n most significant genes (ordered) in a meta-analysis (X-
axis), the proportion of genes in that set overlapping with the DPM reference gene list is 
shown (Y-axis). Each list is curtailed at significance level of p≤ 0.01, determining the 
length of a line. 
 
 
Meta-analyses reflect biological knowledge. Curves peaking towards the left 
indicate that the most significant genes are also the ones that have the best overlap 
with the DPM reference list. This is a welcome confirmation that meta-analyses in 
general reflect biological knowledge, although the ES model may be an exception 
to this, at least for the given of studies. 
Correspondence-At-Top: Comparison of meta-analysis models 
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Gene set sizes. Optimum number (peaks) of top significant results is between 50 
and 150 for most models. Beyond this, overlap with “known truth” decreases. An 
exception to this is the ES model, where this peaks at just under 500 or in plain 
terms, it is worse than other methods but for that reason does not deteriorate 
further. 
 
Meta-analysis model performance. An unknown point from section 3.4.1 was the 
association of the ES model with the lowest number of meta-analysis discoveries, 
as that low number may still have had the best overlap with biological knowledge. 
Based on the CAT assessment for the ES model, this is not the case and the low 
number of statistically significant meta-analysis genes is also the worst reflection 
of known biology. It only approaches the biological validation level of other 
models once their result lists are extended to the top 1000 genes and have 
therefore accumulated more false positives. While both variations of the FP model 
show good performance where the top 100 most significant genes are considered, 
the parametric version quickly accumulates false positive results and is reduced to 
ES level performance. As for best performance with relation to biology, the non-
parametric FP model and the equal weighing RP model are associated with the 
highest overlap rates and slowest inclusion of false positive results, followed by 
the proportionally weighted and standard RP models.  
 
Individual study performance based on CAT. Similar to the ROC analysis, this 
method also allows a closer look at the performance of individual studies’ analyses 
in relation to meta-analysis (Figure 3.10). 
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Figure 3.10 CAT for per-study results using DPM reference 
 
For a given number of the top n most significant genes (ordered) in a meta-analysis (X-
axis), the proportion of genes in that set overlapping with the DPM reference gene list is 
shown (Y-axis). Each list is curtailed at significance level of p≤ 0.01, determining the 
length of a line. 
 
 
Based on this, the top ~100 most significant genes identified in individual studies 
(including smaller ones) appear to be a better match to existing biological 
knowledge than their corresponding meta-analyses. A more extreme case is the ES 
model, where all individual studies perform better than the meta-analysis when 
considering up to the top 300 genes. For all models, it is worth pointing out that it 
is not the largest study that best matches known biology, suggesting that some 
studies may have a more ‘typical’ study design in terms of interferon doses, time 
points or other protocols better matching the known interferon/macrophage 
biology as curated by DPM staff and students. This advantage of individual 
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studies does not extend to the inclusion of larger numbers of significant genes, it is 
here that their false positive count increases and therefore reduces overlap with the 
biological reference list. Meta-analyses are of course intended to increase the 
statistical power of analysis, and the reduced rate of false positive results among 
the top few hundred genes (beyond the initial top 100 as described above) when 
compared to individual studies seems to bear this out. As with ROC analysis, for 
the largest study the overlap with known biology is very close to that of the meta-
analysis (RP models and nonparametric FP model), highlighting the need to 
identify a small set of genes for which the meta-analysis gain in statistical power is 





Wider implications of these quantitative results and the biological investigation 
from chapter 5 and 6 are discussed in the final thesis chapter. 
 
As outlined in chapter 1, the basic models of meta-analysis used here are not novel 
in themselves and the comparison between them is no longer novel since the 
publication of a paper (Hong and Breitling 2008) based on the same foundation 
works (Rhodes, Barrette et al. 2002, Choi, Yu et al. 2003, Breitling, Armengaud et 
al. 2004) as this thesis, with the added advantage that one of the meta-analysis 
models was their own. There is therefore a definitive need to highlight the areas in 
which this thesis differs, these being a) notional improvements to the actual meta-
analysis models, b) inclusion of more studies (other papers use effectively two 
small studies, with a third used only as reference), c) a different biological system, 
c) result and validation against biological domain knowledge rather than 
simulation or reference studies, and d) an investigation of missing values and 
assessment of methods dealing with them. 
 
Main outcomes. From discrepancies between simple counts of meta-analysis 
discoveries and evaluations taking into account gene identity or biological context, 
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it has to be concluded that the former are not a good indicator of performance. For 
example, the parametric FP model is associated with the highest number of meta-
analysis discoveries (figure 3.4), but clearly also results in a larger proportion 
(better only than the ES model) of false positive results than other models (figures 
3.7 and 3.9). It seems sensible to attach more weight to carefully curated 
information (DPM reference list) than to blind counts, the majority of 
interpretation is therefore based on results beyond counts. 
From some results (figure 3.4) it would appear that a single study is sufficient to 
make the majority of discoveries that a meta-analysis is capable of. However, 
additional findings from CAT analysis show this to be only evident for the most 
highly significant genes (figure 3.10). The more the significance criterion is 
relaxed the more meta-analysis outperforms individual studies (while still staying 
within common statistical significance thresholds). The other issue of course is 
that even if a single study almost matches the outcome of a meta-analysis, the 
biological value lies in identification of the small number of added genes, with 
large sets of new biological findings not expected. This is particularly clear from 
figure 3.5, which identifies individual study’s overlap with meta-analysis results 
and measures this at less than 80% at best. 
Based on all available evidence so far, it is the RP models and the simple FP 
model (non-parametric variant) that perform best in a direct comparison of meta-
analysis models. With reference to biology, the improvement over the largest 
single study alone is marginal (figure 3.8), but potentially still translates into 
dozens of new discoveries among hundreds of known ones. By other indicators 
(figure 3.10) and if using more stringent statistical thresholds (i.e. allowing fewer 
false positives), RP meta-analysis, or rather the two introduced weighting variants 
for RP, is more clearly adding value to identifying ‘novel’ genes. It may be the 
discrepancy between these two outcomes that in the end identifies new biology, 
because those novel findings or a percentage thereof would clearly not yet be 
present in the gold standard list and therefore not yet taken into account in the 
above marginal findings with reference to known biology. In the presence of 
outlier-sized studies in the meta-analysis, the alternative proportional weighting 
scheme for the RP model is of particular interest, as it by some measures (figure 
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3.6) shows promise, although with reference to biology this is more marginal and 
only when allowing for small false positive rates (figure 3.7). The better non-
parametric meta-analysis outcomes can conceivably be attributed to their inherent 
robustness where the study sample size is low and unbalanced, variance high, gene 
expression not necessarily normally or log-normally distributed and the number of 
studies small and heterogeneous. For the RP model only, a small factor in the 
better results may be the inclusion of two more studies, although the contribution 
in terms of estimates is small, as explained later in this section. However, where 
evidence supports this for this set of circumstances and the particular models used, 
this should not automatically be generalised to scenarios where there is a larger 
number of small studies, a small number of large studies, a more homogenous mix 
of studies, or a more confined range of study inclusion criteria. Similarly, other 
non-parametric tests may be worse and other parametric tests may be better than 
those used here, with particular emphasis on those using information from 
multiple genes to moderate a parametric statistic, as they have shown their worth 
in general microarray analysis, e.g. empirical Bayes moderated t statistic (Smyth 
2004). 
 
The above main findings exist in context of a large number of issues that can 
affect them, these are discussed in the following paragraphs. 
 
Single-study analysis methods. When interpreting single-study findings against 
meta-analysis findings, the comparisons are here made like for like, i.e. RP meta-
analysis is compared to RP study analysis. Although there are widely used 
statistical tests – particularly the empirical Bayes moderated t test - for individual 
microarray studies, there is no single ‘best’ test when considering the different 
sample sizes here. In order to avoid comparisons of all individual tests methods to 
all meta-analysis models, like for like as explained above seems most appropriate. 
This may lead to some single-study vs. meta-analysis comparisons being subject to 
low-quality single-study tests, although this is mainly an issue for the effect size 
model, where the effect size statistic per study is inferior even to a Student’s t test 
in that it does not pool gene standard error between conditions. 
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Alternative meta-analysis models. The models applied here are a conscious 
selection based on articles published early in the history of microarray meta-
analyses. In the years since, the interest in microarray meta-analysis as a subject 
has increased, peaked, and decreased again, at least judging by annual citation 
counts with relevant terms (see chapter 1, figure 1.3). Despite this, a recent 
comprehensive review (Tseng, Ghosh et al. 2012) still refers to the three methods 
chosen here as main comparators. Other methods are being developed and may 
show benefits, e.g. Bayesian statistic-moderating techniques using multiple genes 
to model priors (Marot and Mayer 2009), but show no clear dominance of use.  
  
 Data integration techniques. Apart from meta-analyses in the statistical sense, a 
number of interesting methodologies have been devised that could also be used to 
obtain combined results across studies (outlined in chapter one). These often focus 
on the stability of biological motifs or the consistent co-expression of genes across 
multiple studies, some allow the integration of data from multiple domains, e.g. 
transcriptomics and proteomics. These are worthwhile pursuing in the same way 
that pattern analysis for microarray data is worthwhile pursuing in conjunction 
with statistical hypothesis testing, with the main difference being the same: Single-
gene hypothesis in contrast to gene-gene relationships.  
 
Study matching and gene identity. By limiting studies to Affymetrix-branded 
microarrays and using an Affymetrix algorithm that uses actual sequence 
similarity to combine data across their proprietary chip platforms, the problem of 
how to match genes between studies is avoided for this thesis, and the assumption 
can be made that the same gene is measured in all studies used here. However, this 
is of more concern if there is a heterogeneous mix of microarray platforms. The 
two problems posed are that a) it is unclear if probes meant to represent the same 
gene on different arrays are really measuring the same biological entity and b) that 
different measuring scales may need to be combined across studies if one is based 
on absolute levels of transcription and one on levels of transcription in relation to 
some control condition. This problem used to pose greater practical difficulties 
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and required more time solving in years past, but recently R/Bioconductor 
packages like MADGene have become available that automate this procedure 
somewhat (Baron, Bihouee et al. 2011). 
 
Definition of false positives when using biological knowledge. When interpreting 
the overlap of meta-analysis results with a biological reference list, false positive 
results are related to two factors. One is the level of correctness and 
comprehensiveness of the biological gold standard list(s). This is addressed at 
length in chapter 2. The other factor is the meta-analysis itself, which aims to 
identify genes with small expression level differences on top of easier to identify 
genes with large expression levels. Genes with stronger transcriptional response 
will have a better chance of being identified in individual and smaller studies and 
can therefore be expected (with higher likelihood, at least) to contain true and 
known positives. Genes with weak but consistent transcriptional response are 
more likely to be unknown and not contained in the reference lists and therefore 
incorrectly counted as false positive results. This has to be considered in the 
interpretation, but the problem is of less importance if accepting that a) the number 
of genes that is uniquely identified by meta-analysis is small compared to what is 
already known and b) that some of these meta-analysis-only discoveries will 
already have been identified in studies outside this meta-analysis and therefore are 
part of the reference list(s).  
  
Experiment factors. The discussion of the influence of study group sample size on 
meta-analysis is not fully tractable in scenarios where only a small number of 
studies are used for meta-analysis. In meta-analyses, using large numbers of 
studies brings into play the law of large numbers, with an expectation that 
estimates for the main outcome will settle around some average. With few studies 
in a meta-analysis, experiment factors like IFN-γ dose, treatment timing, mouse 
background may very well lead to meta-analysis contributions that are not solely 
down to study size and may not be close to an average effect of IFN-γ. For the 
assessments here, the only way to interpret meta-analysis results is to maintain the 
original biological hypothesis at very broad levels. 
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Mouse strains. The meta-analyses use studies based on both C57BL/6 mice and 
Balb/c mice. Both C57BL/6 and Balb/c are inbred strains with different properties 
at phenotype level, with the former susceptible to several diseases like 
atherosclerosis, type II diabetes or general obesity, and the latter susceptible  to 
various tumours and as a source of monoclonal antibodies. C57BL/6 mice are 
assumed to be less susceptible to microbial infection than Balb/c mice(Bohn, 
Heesemann et al. 1994, Heinzel, Rerko et al. 1998, Leakey, Ulett et al. 1998). It 
has been suggested that the macrophage response to IFN-γ activation may differ 
between these two mouse strains (with some caveats regarding macrophage type 
and particular mouse strain phenotypes). Based on those studies (Oswald, Afroun 
et al. 1992, Dileepan, Page et al. 1995, Mills, Kincaid et al. 2000), C57BL/6 mice 
may be more efficient in IFN-γ induced nitric oxide (NO) production and 
activation through IFN-γ may activate different and opposing signalling pathways, 
in C57BL/6 this would be the control of intracellular pathogens (iNOS pathway) 
and in Balb/c this would be wound repair (arginine pathway leading to production 
of ornithine). It has been acknowledged that it is the IFN-γ induced production of 
NO that confers resistance to microbial infections to C57BL/6 mice (Santos, 
Andrade et al. 2006). IFN-γ inducible NO production has also been linked to JAK-
STAT and ERK signalling pathways (Blanchette, Jaramillo et al. 2003). In 
summary, it is very conceivable that microarray samples or studies based on either 
Balb/c or C57BL/6 mice will have several specific differences in gene 
transcription in response to IFN-γ stimulation. While this would be valuable to 
pursue in the presence of a larger available set of studies with either mouse strain, 
for this thesis the meta-analysis hypothesis has to centre on the IFN-γ inducible 
effects that are common to these two strains, and may also be a secondary problem 
to that of very different IFN-γ doses and treatment durations. 
 
Study size and number expectations. The results section uses the terms ‘larger’ and 
‘smaller’ studies in context of the microarray studies used. It should be clear that 
while a comparison of seven IFN-γ treated samples with seven control samples is 
a reasonable (if not good) size for a microarray study, it is of course to be 
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considered a very small sample size in context of clinical trials or population 
studies. Although estimates for average number of studies in meta-analyses are 
difficult to find, it is expected that the number of studies available for meta-
analysis here is also on the small side. Additionally, this meta-analysis is very 
unbalanced, with one study of reasonable sample size and 3 (or 5, see below) 
studies of questionable size for most statistics or metrics. For many areas of 
biological investigation, these are the facts on the ground, and make a test of 
pragmatic use important despite the statistical shortcomings. The RP model may 
benefit from the inclusion of the two smallest studies in the meta-analysis, which 
are too small to even obtain the necessary mean and variance estimates for 
parametric methods. However, out of a total of Ktot=71 ranked differential 
expression combinations, the two extra studies only contribute 3 of those. A jack-
knife procedure would be a possibility for investigating the effect of individual 
studies, i.e. leaving one study at a time out of meta-analysis. Although the 
usefulness would be limited due to the small number of studies, it would 
conceivably clarify broad study size effects. 
  
Multiple testing. This occurs in any statistical analysis that applies statistical 
inference testing to more than one variable at a time or to multiple pairwise sample 
group comparisons. It has the effect of increasing the chance of obtaining false 
positive results amongst all these tests, because the probability of making a false 
positive call (significance level or alpha) is set at a given acceptable value for a 
single variable (gene, in this case) or comparison and not applicable to more than 
one test. Simultaneous statistical hypothesis testing on multiple variables has been 
well understood and described for general statistical inference (Hsu 1996) and the 
issue has been introduced in the early days of microarray technology (Dudoit, 
Yang et al. 2002, Storey and Tibshirani 2003), although problems remain 
regarding the algorithm used for adjustment and the assumption of statistical 
independence between genes. Without applying any type of correction, large gene 
lists will contain many discoveries that are purely down to chance or rather error.  
If avoiding false positive results is a priority and gene-hypothesis p-values are 
intended for publication, multiple-testing corrected p-values need to be used, but 
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even then the assumed independence between variables (again, genes in this case) 
remains problematic, in that a particular gene target may be represented by more 
than one probe sequence on the array, or two genes may entirely depend on one 
another or are similarity affected by a third variable in their transcriptional 
activity. In any of these cases, the expression levels of these genes cannot be 
considered independent of one another. However, for machine learning 
approaches, network graphs or other bioinformatics approaches it can be 
beneficial to initially allow a higher proportion of false positive results that are 
subsequently removed through domain knowledge or filtering steps. This is 
because two genes may be similar in transcription activity even if they fall on 
different sides of a selected statistical criterion. The statistical methods here only 
use a reasonably stringent threshold (p≤0.01) for determining what constitutes a 
discovery and will therefore contain more false positive results than necessary. 
This is helpful for the biological validation in chapter 5 and it avoids having to 
take into account performance of very different multiple-testing correction 
algorithms such as Bonferroni or Benjamini & Hochberg. It should be noted that 
comparisons between RP and the other two models are complicated by the fact 
that the former uses a permutation Null distribution to obtain statistical 
significance, whereas the other two models use reference distributions (chi-
squared for FP, standard normal for ES). In theory, the RP methods reported 
estimated percentage of false positive predictions is equivalent to using a False 
Discovery Rate p-value adjustment on p-values derived from reference 
distributions, or alternatively the distribution properties of ES and FP statistics 
could be ignored and a Null distribution generated instead. 
 
Alternative statistical inference. Combining per-study estimates of statistical 
significance across all studies is also subject to the method used to obtain the per-
study estimates. This is here particularly evident for the FP model using 
parametric (Welch t test) and non-parametric (Rank Product test) input, where the 
former is amongst the worst performers and the latter amongst the best. There are 
many other possible choices that are not addressed here. There are various updates 
and alternatives to the effect size estimator d in the ES model, any many other 
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possible parametric or non-parametric tests as input for the FP model. This does 
not apply to the RP model, it is based on fold-change between groups and as such 
does not get assigned a per-study significance-estimate, although the overall 
geometric mean of ranked ratios could conceivably be replaced by other point 
estimates. In addition to the statistical test, it would also be possible to make 
further suggestions for the meta-analysis models themselves, e.g. apart from 
different weighting schemes for the RP model, the inherent effect size model 
weighting could also be modified, or a more explicit (p-values themselves are 
already affected by study size) weighting scheme introduced for the FP model. 
Since the number of possible avenues of investigation would quickly multiply the 
necessary assessment output, only a subset of options and variations can be 
considered here. 
 
Model assumptions. A large and expected part of the difference in results between 
the meta-analysis models is related to their underlying assumptions in order to 
correctly test hypotheses. Independently of which statistical test is used, FP 
assumes study homogeneity and is sensitive to individual biased studies in that a 
single large p-value can outweigh several small p-values. There are modifications 
like restricting per-study statistical p-values to a given threshold (e.g. 0.05), a 
procedure that is similar in principle to trimmed means (Zaykin, Zhivotovsky et al. 
2002). However, this in itself makes the assumption that large p-values are a 
product of bias (e.g. publication bias, one-sided testing), which is difficult to 
assess and may not be true. The ES model does not assume study homogeneity, 
but can account for heterogeneity if there is evidence for it. It otherwise shares 
weaknesses with other parametric methods, in that the effect size statistic assumes 
normality and homoscedasticity of experiment groups in all studies. It also relies 
on estimates for group means and variance being available for each study, which is 
a potential problem when relying on published results rather than having access to 
the full study data. The RP model is not subject to many assumptions about 
underlying distributions, which makes it robust, but the absence of assumptions 
about the distribution of the tested parameter in a population also means that 
results cannot necessarily be extrapolated to population-level. For microarray 
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studies, log-normality of gene expression is commonly assumed, but it has already 
been shown (Breitling, Armengaud et al. 2004, Smyth 2005) that in context of 
small studies, some non-parametric methods or the shrinkage of gene expression 
standard errors towards a combined value (from multiple genes) improve results 
over parametric options. If this holds true in meta-analyses of microarrays, then 
RP and non-parametric FP (and models not applied here) are better options 
independent of distribution assumptions being correct or not.  
 
Simulated data. It could be argued that simulation would provide more 
comparative information between meta-analysis performance, but it is not 
attempted here because trade-off between time spent and high-value results is 
likely to be affected by the required number of parameters and parameter values. 
While some of the reference articles cited do include simulation runs, the 
parameter range is by necessity limited and ultimately not referencing biology. For 
the purposes of this thesis, a full simulation would need to take into account 
combinations of number of studies, size of studies, quality of studies, test type, 
missing values, and biological effects of different treatment regimes on variance 
and differential expression. Given that a resource for a direct biological 
assessment of results was available, this is the preferred choice here.  
 
Missing values. By removing gene measurements that are incomplete across all 
samples and studies, the issue is avoided entirely in this meta-analysis. This affects 
hundreds to thousands of gene probes and is therefore potentially detrimental to 
results. The issue is complex this type of missing data has not been fully addressed 
before and is therefore the subject of chapter 4. 
 
Addressing the main questions posed at the outset of this chapter, the assessment 
and notional changes of meta-analyses yield sufficient results to answer them in 
numerical and broadly biological context, with the interpretation of true value in 
biological terms reserved for chapter 5. The answers to those four questions are 
provided first before extending the discussion to more detailed issues. 
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Does meta-analysis provide additional results when compared to individual 
studies? By any form of assessment, meta-analyses add value beyond individual 
study analysis even with small numbers of studies, small sample sizes and a range 
of experiment factor values. The largest study in itself provides a large number of 
findings present in the meta-analysis and will largely drive any meta-analysis, but 
additional meta-analysis results are returned. 
 
Are there performance differences between the three meta-analysis methods? 
There are fairly large differences, the theoretically powerful effect size model is 
the worst performer, showing very little robustness to small study numbers and 
small study sizes. The rank product method or Fisher’s combination of 
probabilities have very clear performance advantages, but it is important to chose 
the most suitable variant. 
  
Can suitable meta-analysis alteration be identified? For the rank product model, 
the suggested proportional weighting scheme appears to perform at least as good 
and in some circumstances better than the standard model and should be 
considered for more thorough investigation and publication. When choosing 
Fisher’s model, meta-analysis results clearly benefit in quality (if not in quantity) 
if input data sets are analysed under non-parametric assumptions or more 
specifically, using rank product analysis for individual studies. This cannot 
necessarily be generalised to other non-parametric tests.  
 
Do meta-analysis results show biological relevance? All results show notable 
overlap with DPM’s manually curated gold standard list of genes associated with 
IFN-γ in murine macrophages. Meta-analysis is on par or marginally better than 
analysis of a single ‘good’ study where the most highly significant genes (of 
individual studies) are concerned, but meta-analysis performs better than any 
single study where genes of more moderate levels of significance (in individual 
studies) are concerned. The highest biological relevance is achieved by RP models 





Imputation of missing values in microarray 
meta-analyses 
 
This chapter tests the possibility of replacing (imputing) special cases of missing 
values for gene expression data in meta-analysis data sets. Six imputation methods 
are applied to sets of artificially introduced missing values. 
 
The applied meta-analyses in chapter 3 were performed on 9812 genes, ignoring 
more than 3000 genes that are not present on all microarray platforms.  This raises 
the question if there is any benefit of imputing replacement values for these genes 
rather than accepting their loss in meta-analysis. 
 
Imputation of missing expression data values in microarray studies is not a new 
subject. Many algorithms exist that aim to replace a missing expression level 
measurement for a gene in a given microarray sample with an estimated 
expression level, where this estimation is based on data obtained from non-missing 
data of other genes or the same gene in other samples. However, this type of 
imputation has not been attempted for a special case of missing values in 
microarray meta-analysis, where merging data from different microarray platforms 
can result in a multitude of missing data that are not rooted in data acquisition 
problems or physical chip problems, but in the chip design of different microarray 
platforms.  
 
The investigation and proposed solutions are based on semi-synthetic data, making 
use of the same source data as used for the meta-analyses run in chapter 3 and 
described in detail in chapter 2. Imputation algorithm performance is tested on the 
basis of artificial and repeated introduction of missing values amongst the full set 
of known gene expression values, allowing a final comparison of imputed 
(estimated) gene expression with known (observed, original) gene expression. 
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4.1 Introduction to microarray missing value imputation 
 
In meta-analyses, the necessity to combine data from multiple studies at the level 
of statistical results or other per-study metrics requires a data mapping step in 
which probe transcripts from one type of microarray are mapped to transcripts on 
another type of microarray, assuming not all studies use the same microarray 
platform. This can easily lead to hundreds of probe transcripts that exist on some 
microarray platforms, but not on others, and it can be assumed this set of 
transcripts is made up of both newly identified genes that were not incorporated 
into older chip designs, sequences that were included due to some sequence 
selection algorithm but may or may not have a real biological function, and some 
microarrays having a particular biological focus. Although this seems to suggest 
that unmapped probes cannot automatically be regarded as irrelevant, for the sake 
of simplicity or a focus on statistical methodology rather than biological results 
these transcripts are often explicitly excluded from meta-analysis data sets as not 
having complete observations (Rhodes, Barrette et al. 2002, Hong, Breitling et al. 
2006, Thomassen, Tan et al. 2009) or the problem is avoided altogether by only 
considering studies that have been performed with the same microarray platform 
(Sims, Smethurst et al. 2008, Gyorffy and Schafer 2009). 
General mechanisms for 'missingness' of data were first formally discussed by 
Donald Rubin in 1976 (Rubin 1976) and subsequent publications, defining 
missing-completely-at-random MCAR, missing-at-random MAR, and not-
missing-at-random NMAR, all of which relate to the probability of a value 
missing being dependent on observed or unobserved data. In context of 
microarrays, most researchers implicitly or explicitly assume MAR or MCAR, 
where the probability for the value missing is not dependent on the value itself. 
This assumption is not necessarily correct in cases where background noise is 
higher than signal, or where values are removed by the user because they fall into 
an arbitrary low expression range, i.e. the probability of the observation being 
missing is increased because its expression value is low. In terms of investigating 
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gene observations missing in a meta-analysis through platform design, the reason 
for given gene transcripts not being present on particular microarray platforms 
may differ from gene to gene or be driven by external factors such as array 
manufacturing cost or updates to the knowledge on known gene sequences. 
Imputation here is therefore on the basis of these genes being missing at random or 
completely at random.  
In terms of missing values in microarray studies (not meta-analyses), the most 
commonly investigated types of missing values include scratches or dust on the 
array surface interfering with the laser scanning process, faulty probe deposition 
mechanics or spot morphology. This usually results in a small percentage (often 
assumed to be around 5%) of observations for a gene in a study missing, and 
presents a problem for those researchers using multivariate analysis approaches 
like Principal Components Analysis and Support Vector Machines, or generally 
algorithms requiring complete data matrices to work robustly or to work at all. 
Consequently, it was this research community that first introduced methodologies 
to recover or impute missing values within a microarray study, beginning with 
Troyanskaya proposing a K-Nearest-Neighbour gene-similarity approach 
(Troyanskaya, Cantor et al. 2001). This was sporadically followed by newly 
introduced algorithms like a Bayesian Principal Components imputation model 
(Oba, Sato et al. 2003) or least squares based imputation (Bo, Dysvik et al. 2004, 
Kim, Golub et al. 2005), and more recent attempts to focus the imputation on 
genes with function similarities as determined by GO gene ontology database 
(Xiang, Dai et al. 2008) or taking a higher-level approach in which the imputation 
method applied is dependent on data characteristics (Brock, Shaffer et al. 2008). It 
should be noted that most of these algorithms include simple reference approaches 
in form of replacing missing values with a constant or a sample mean, and these 
are invariably shown to be inferior. 
These methods apply to microarray studies in general, but similar research has not 
been conducted for the imputation of missing values in microarray meta-analyses. 
Although the above concepts can of course be extended for meta-analyses by 
applying an imputation algorithm to each study in turn, this does not encompass a 
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situation with all observations missing for a gene in all samples of a microarray 
data set. The difference between these concepts is outlined in figure 4.1.  
 
Figure 4.1 Missing gene expression values in microarray studies 
 
Panel (A) represents a gene expression data matrix (genes in rows, biological samples in 
columns; C and T are control and treatment samples, respectively) obtained from a single 
microarray data set, panel (B) represents three aligned/mapped gene expression data 
matrices as used for meta-analysis of microarray studies, where alignment is based on the 
identity of a gene. Horizontal solid red lines indicate missing data. The difference between 
panels (A) and (B) lies in the nature of their missing values, with (A) missing some gene 
expression values due to localised array quality issue and individual studies in (B) 
potentially also suffering from this issue, but with the addition of genes for which there 
are no observations at all in a single study because its microarray chip type does not 




By extension of the above single-study approaches to imputing missing data, it 
should be possible to identify genes relevant to imputation of a missing gene in a 
study by borrowing information from other independent studies. In effect, this 
means treating a set of independent studies as a unified data matrix or single large 
study. This is conceptual rather than factual, as studies are difficult to combine at 
data level (otherwise meta-analyses would hardly be necessary) and they remain 
independent. Applying single-study imputation methodology in a multi-study 
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context is currently unexplored, as is the loss of information that is brought on by 
excluding genes from a meta-analysis because they are missing in a subset of 
studies, or the reduction in the power of a meta-analysis to detect overall effects 
across fewer studies that a gene is measured in. 
The question posed here is therefore if a missing gene’s expression values can be 
imputed for an entire study wholesale, given that there is available but 
independent data for this gene in other studies, and that use could be made of 
gene-to-gene similarities to identify suitable other variables (genes) to use for 
imputation. The ability of performing such an imputation also needs to be 
investigated for benefits compared to leaving these values missing in a meta-
analysis.  
The studies used in this thesis comprise two Affymetrix chips (two each), 
MGU_74Av2 and MOE_430a. The two platforms contain 22690 and 12488 gene 
transcripts, respectively. An Affymetrix-designed mapping algorithm29 identifies 
an intersection set of 9812 as “good matches”. If one uses the smaller microarray 
platform probes as reference, this means out of the potentially available 348000 
data points (~12000 genes x 29 samples), 58000 could be considered missing 
values (~2000 x 29 samples), which is a missing value frequency of around 17%. 
Where a broader range of microarray platforms is used and the number of studies 
is larger, it may still be possible to obtain reasonable overall effect sizes for each 
gene by simply accepting missing values. As exemplified by this thesis itself and 
the reference works cited, this availability of larger numbers of studies is not a 
given and meta-analysis results are therefore limited in their genome coverage. 
The motivation underlying the investigations in this chapter therefore lies in 
testing if there is an advantage in using statistical models and rules to estimate 
large volumes of missing data rather than accepting the loss of hundreds to 
thousands of observable variables (genes) from the meta-analysis results. 
 
R scripts generated for the analyses in this chapter are contained in the electronic 
supplementary material (“HF” for high frequency of missing values): 
ImputationMissingValues.R,  ImputationMissingValues_HF.R 




4.2 Imputation algorithms 
 
In order to address the question of replacing missing data with estimated data in a 
realistic context (with numbers of studies and study sizes small), the same data 
sets as used for meta-analysis in this thesis are used again, with a selection of 
existing or alternative imputation methods, and evaluation on a small number of 
outcome criteria. Assessing imputation requires comparison of imputed values to 
known values, which means these data cannot be used in full but are used as the 
basis for a limited simulation where status missing/non-missing is set rather than 
observed, that is, missing values are artificially introduced. 
 
For all imputation methods, the initial design matrix is identical to that in their 
original use: 
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That is, gene expression matrix G with m genes and n samples for the original 
application of these methods represent a single microarray study, but for the 
application here the concept is expanded to including the samples of all studies. 
An additional study index is therefore not shown here and would only be used in 
some of the assessment methods (where each study’s values are set to missing in 
turn to assess the effect study size has on imputation). Similarly, an index for 
treatment status is not included here, as only one method below uses treatment 
group specific imputation (control samples predict control samples and treatment 
samples predict treatment samples). 
 
In the absence of a de facto standard for imputing missing values in a multi-study 





KNN (Troyanskaya, Cantor et al. 2001) imputation identifies genes with  
expression profiles (gene m across samples n) most similar (based on K nearest 
neighbours algorithm) to the gene with missing values, and the imputation value is 
the average (weighted by similarity) expression of those similar genes in the same 
sample. Importantly, this approach is ‘perpendicular’ to BPCA and linear 
regression as described below, in that KNN identifies similar genes to impute 
missing values, whereas the other methods identify similar samples to impute 
missing values. 
Algorithm description: 
- Identify gene with missing values, the target gene 
- Using non-missing data for this gene (i.e. other studies), calculate Euclidean 
distance between this gene and other genes 
- Identify K (user-specified) nearest genes to the target gene 
- Missing value for target gene is imputed as the average (weighted by 
distance) of the K nearest genes from the same sample 





BPCA (Oba, Sato et al. 2003). The Bayesian Principal Components algorithm has 
been shown to be one of the best performing imputation algorithms (Jornsten, 
Wang et al. 2005). It uses a principal component regression on samples with non-
missing values to predict a sample with missing values, that is, missing gene 
expression values are estimated based on their expression in (a linear combination 
of) similar samples rather than estimating missing values based on the expression 
of similar genes. Instead of using individual samples to predict a response variable 
(the sample with missing values), it first reduces the set of predictor variables to 
its major dimensions or principal axes (in decreasing order, linear combinations of 
samples that best represent variance between samples). Three advantages of this 
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methodology are a) the use of lower-dimensional space (samples rather than 
genes) to perform the estimation of missing values, b) the lack of requirement for 
any user provided model parameters and c) it emphasizes important principal 
components by shrinking less important ones towards zero. The model initial state 
begins with missing values imputed by gene expression means across samples, a 
variational Bayes then both estimates the models posterior parameter distribution 
and re-imputes the missing values, iteratively arriving at optimal model 
parameters using an Expectation-Maximization algorithm. 
 
 
4.2.3 Array-wise KNN 
 
Array-wise KNN is a simple use-adaptation of KNN, based on the question of how 
this approach works when using similarity of samples (across all genes) rather 
than similarity of genes (across all samples). In order to do so, one simply rotates 
the data matrix through 90 degrees before applying KNN imputation to see if the 
relationship between sample expression vectors instead of gene expression vectors 
can successfully be used to replace the missing values. Imputation is therefore 




4.2.4 Array-wise linear regression 
 
Array-wise linear regression is introduced as a simple alternative to BPCA. Like 
BPCA, it uses information from the same gene but other samples to impute 
missing values in a given sample. Instead of iterative parameter estimations and 
Bayesian probabilistic PCA it simply uses regression coefficients in the estimation 
of missing values. The linear model considers all genes in a given array as a 
response variable that can be predicted by the genes in all samples of all other 
studies. Using the coefficients obtained from this model, missing values for a 
given gene in a given array can then be imputed from non-missing instances of 
that gene in other studies, providing a weighted mean replacement. 
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  Algorithm description: 
- Identify an array (the target array) containing missing values. 
- Apply a linear model where the target array is the response variable and all 
arrays from all other studies are predictor variables. 
- Impute missing gene expression value in target array using the expression values 
of the same gene from all arrays in other studies, each multiplied with its 
prediction coefficient (intercept added subsequently). In other words, this is a 
weighted mean with the weight depending on the “predictive” strength of an array 
regarding the target “response” array. 
 
 
4.2.5 Array-wise linear regression by sample type 
 
This is identical to the linear regression above, but instead of using all arrays in 
other studies, it uses only predictor variables (arrays) that match the type of the 
response variable (array with missing values), where type is either treated or 
control samples. This is to investigate the balance between a more biologically 
targeted prediction and a reduction of statistical power because the number of 
available predictors is reduced. 
 
 
4.2.6 Ranked sets 
 
This scheme first identifies genes similar to a missing gene (based on other 
studies), then uses a weighted average of those genes to impute the missing gene’s 
value. While the distance metric and final imputation matches that of the KNN 
algorithm, the main difference lies in the selection of a gene set to use for 
imputation. Where in KNN these are the k nearest neighbours in terms of 
similarity of gene expression profiles to the target gene across all other studies, the 
ranked set selection here considers the similarity of genes to the target gene 
separately for each study. Subsequently, the per-study lists are combined based on 
the rank product statistic. This methodology is introduced because in theory it is 
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independent of the linear or non-linear relationship between studies (between-
study normalisation does therefore not matter). 
Algorithm description: 
- Identification of a gene with missing values in a study (target gene) 
- For this gene in each of the other three studies, obtain Euclidean distance to all 
other genes 
- In each study, rank all genes by similarity to target gene 
- For each gene, compute a summary statistic across three studies, indicating how 
consistent its ranked similarity is to the target gene. The statistic is the rank 
product (same method as described in chapter 3) of each gene across three studies. 
- Identify 50 genes with the highest consistency across studies in terms of their 
similarity to target gene 
- Those genes are the selected set 
- For each gene in the selected set of genes, compute a weighting factor for each 
study (normalised inverse Euclidean distance)  
- Average weighting factors for each selected gene across three studies 
- Impute value for missing target gene in a sample as the weighted mean of the 
selected most similar 50 genes in that sample.  
 
4.3 Evaluation methodology 
 
Gene selection and introduction of missing values. In order to assess the effect of a 
missing value imputation, the 'truth' needs to be known. Since this is not known 
for the actually missing gene data in these studies, semi-synthetic data are created 
from the original, this is here achieved by starting with a subset of genes (n=9812) 
that are in common to all four studies. To avoid random selection of only noise 
genes (which would not enable subsequent assessment of treatment effects), this is 
reduced to a gene set of 6564 genes that are biased towards containing a 
proportion of differentially expressed genes, through a requirement that each gene 
have at least 1 out of 29 samples with an expression value greater than log2(10). A 
single random selection of 600 genes is then drawn from this set, with the 
rationale that this (given that 100 of these 600 are artificially set to missing) 
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mirrors the missing value frequency (17%) for the data sets used in this thesis. 
This initiation of missing values on the same set of 600 genes is repeated 
(randomly, with replacement) 50 times, that is, 50 different sets of 100 genes are 
independently set to completely ‘missing’. This generates a total of 5000 
imputations per method, with this allowing to establish accuracy and stability 
across repeated sets with respect to the identity and possible different expression 
characteristics of any single set of selected genes. Genes are set to missing for 
each study in turn, and it is always the same set of 100 genes for each study. 
 
Imputation of missing values. For each resampling instance and gene, missing 
values are imputed by each of the algorithms methods listed above. Or in the 
comparative instance, left as missing. 
  
Evaluation of imputation quality. Two outcomes are assessed, the first is the 
accuracy with which an imputation method recalls original values, the second is an 
imputation method’s ability to recover biological and statistical differences 
between treatment and control groups. Accuracy is here estimated through the 
normalised root mean squared error (NRMSE, in this case normalisation is to the 
range of original values) comparing the original gene expression values (prior to 
their being set to “missing”) with imputed gene expression values. Biological and 
statistical relevance is represented by log2 scale differential expression between 
IFN-γ and control group averages, and by Fisher’s sum of logs meta-analysis 
(individual studies are analysed by Welsh’s t test), again comparing original 




Imputation accuracy depends on amount of non-missing data 
There are 29 biological samples (arrays) in the four microarray studies used for 
meta-analysis (with 6, 5, 4, 14 samples for studies 1,2,3,6, respectively). Looking 
at the imputation accuracy (z axis), it is clear from figure 4.2 that the largest 
normalised root-mean-squared error (NRMSE) is linked to the largest study (the 
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right-most 14 arrays in this graph). This is most likely to be evidence for the fact 
that if there are missing values for the largest study, then the imputation of those 
missing values suffers from a lack of other available data. That is, for each array in 
this study only 15 other arrays (from studies 1,2,3) are available for imputing a 
gene’s expression level. For the smallest study (study 3), each arrays’ missing 
values can be imputed based on 25 arrays in the other three studies, increasing 
imputation success.  This figure also highlights that in terms of error, all six 
imputation algorithms are broadly similar to one another, and that this error is 
reasonably stable across the application of those algorithms to 50 separate random 
sets of genes. 
 
Figure 4.2 Imputation accuracy for individual arrays 
 
Each graph shows the imputation error (measured by NRMSE) for comparing imputed 

























































































































Ranked gene set 
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belonging to four microarray studies. Arrays 1 to 6 belong to study 1, arrays 7 to 11 
belong to study 2, arrays 12 to 15 belong to study 3 and arrays 16 to 29 belong to study 6. 
Y-axis represents each of the 50 randomly sampled data sets (of 100 genes each) where 
the expression value was set to “missing”. All random sets were drawn from a set of 6564 
genes that is enriched for high expression measurements. Z-axis represents the 
normalized root-mean-squared error (NRMSE) of comparing the original expression 
values for 100 genes in that random set against their imputed expression values. 






Differential expression is not well recovered by imputation 
Here, imputed gene expression values are compared to the original expression 
values in terms of a biological measurement. Differential expression between 
control and treated samples is usually measured in terms of average fold change, 
in case of log2 scale data, this is for each gene the difference in the arithmetic 
mean of treated samples compared to the arithmetic mean of control samples. A 
zero represents no change, a positive value up regulation and a negative value 
down regulation. In figures 4.3 and 4.4, the best (linear regression on arrays) and 
worst (KNN) differential expression outcomes are visualised by plotting the 
original (known) fold change against the fold change based on imputed values. 
Other algorithms fall in between these two and are not shown, with BPCA 
performing similarly to regression and array-wise KNN and ranked set selection 
performing similarly to KNN. A perfectly recovered fold change measurement 
would fall on the centre diagonal. Two features are evident from these graphs. 
One, the amount of data available for estimating a replacement value plays a 
crucial role, as can be seen by the strong deviation of data points from the centre 
diagonal in studies 1 and 4, suggesting that for these larger studies there are not 
sufficient numbers of samples from other studies to obtain a good imputation 
estimate. Two, simple array-wise linear regression is associated with best recovery 
of the original fold change values, but even this method provides at best 
reasonable replacement estimates for genes in the two smaller studies (2 and 3). 
Overall, the accuracy of imputation is insufficient for biological assessments. A 
two fold (+ or – 1 on log2 scale) change is often seen as biologically relevant 
change in mRNA levels, and imputation difference alone comes close to this for 
many genes and may cancel out or exaggerate biological differences, particularly 
where imputation is performed on the larger studies 1 and 4 (with less data 
available from the remaining studies for the estimation process). This imputation 
insufficiency is particularly notable in the KNN and the gene set selection 
algorithm, where imputed values are only marginally different from zero (which is 
equivalent to noise as the majority of genes in a study will not be differentially 
expressed). In a real application, with original values not known, imputation 
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would therefore not clarify for any given gene if the observed fold change is real 
or due to lack of imputation quality.  
 
 
Figure 4.3 Recovery of differential expression values by array-wise linear regression 
imputation 
 
Each graph shows the effect (on biological fold change estimates) of imputing gene 
expression values that were artificially set to status “missing” in one of the four studies. 
X-axis represents the originally computed fold change between control and treated 
samples for 50 random sets of 100 genes (5000 data points). Y axis represents the same 
computation after artificially setting each set of 100 genes to status “missing” and 
imputing a replacement estimate for them based on data from other studies. Fold change 
values based on imputed values and matching original fold change values fall on the 
centre diagonal line, the upper and lower diagonal indicate where an imputation would be 
2 times higher or lower than the original fold change. A LOWESS line is fitted to all data 
points to indicate data trends. The colour scale maps standard bivariate normal density at 

















































































































































































































































































































Figure 4.4 Recovery of differential expression values by KNN imputation 
 
Each graph shows the effect (on biological fold change estimates) of imputing gene 
expression values that were artificially set to status “missing” in one of the four studies. 
X-axis represents the originally computed fold change between control and treated 
samples for 50 random sets of 100 genes (5000 data points). Y axis represents the same 
computation after artificially setting each set of 100 genes to status “missing” and 
imputing a replacement estimate for them based on data from other studies. Fold change 
values based on imputed values and matching original fold change values fall on the 
centre diagonal line, the upper and lower diagonal indicate where an imputation would be 
2 times higher or lower than the original fold change. A LOWESS line is fitted to all data 
points to indicate data trends. The colour scale maps standard bivariate normal density at 
each point and shows the estimated density value. 
 
Imputation underestimates biological fold changes 
Irrespective of good or bad performance (exemplified by figures 4.3 and 4.4), 
imputation consistently underestimates fold changes, that is, if the original known 
fold change is notably positive (up regulated genes) or negative (down regulated 
genes), the imputed value tends to be closer to 0 rather than a larger positive or 
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negative value. There are individual genes for which the opposite is true or where 
this effect is minimised in the best imputation and with sufficient amounts of data 
(figure 4.3, studies 2 and 3), but these are not in a majority. The effect is caused by 
imputation assigning similar estimates to missing values in control and treatment 
samples, meaning noise in form of a large number of low or non-expressed genes 
has a greater influence on the estimates than biologically active genes. This is not 
improved by two theoretically suitable modifications. The first modification 
(sample-type specific linear regression) is to explicitly estimate expression for 
missing values in treated samples through non-missing values in other treated 
samples, and conversely using control samples to predict control samples. The 
second modification (ranked set selection) uses a multi-step algorithm to curate a 
small set of genes with statistical similarity to those with missing values. 
However, in the simulation runs both modifications reduce (data not shown, but 
within the range established for best and worst imputation algorithm) rather than 
increase the quality of imputation in terms of differential expression 
measurements. For the modified linear regression model, it will certainly be the 
case that the imposed limitation of estimation only through the same sample type 
has a negative effect by reducing the number of samples available to the linear 
regression model, that is, the weighted-mean replacement estimate for a gene has 
less power. The outcome for the ranked set selection algorithm is almost identical 
to the KNN algorithm, which suggests that despite the very different algorithms, 
their application identifies and is limited by the same features in the data it is 
applied to. 
 
Imputation recovers statistically significant results 
Biological fold changes as described above are a measure of differences between 
groups that does not take into account within-group variation (other than the mean 
being affected in non-normally distributed gene expression values). From a 
statistical point of view, the question is if the imputed missing values recover the 
original within-group variance levels and are therefore able to identify statistically 
significant gene expression differences between control and treatment groups. The 
logical follow-up question is if this imputation performs better than simply 
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accepting missing values in the meta-analysis. This concerns the trade-off between 
reduced statistical power (with a reduced number of studies available for 
inclusion) and imputation error. With the original data, meta-analysis by Fisher’s 
sum of logs results in 583 out of 5000 genes (50 random sets of 100 genes each) 
significantly up regulated and 799 genes down regulated at p<=0.01. Taking this 
to be the standard, figure 4.5 shows the proportions of these genes that are still 
identified as significant when meta-analysis is applied with data missing, or with 
missing data imputed from non-missing data. Three notable results are illustrated. 
One, BPCA imputation comes closest to the original meta-analysis results, but 
remains similar to linear regression. Two, meta-analysis with missing values is 
generally inferior to meta-analysis using imputed values, although this is less 
pronounced for missing values in smaller studies (with more samples available for 
imputation). Three, all methodologies are dependent on the size of the study in 
which gene expression values are missing.  This is of course most notably for 
study 6 (which contains 14 out of 29 samples), reducing imputation effectiveness 




Figure 4.5 Comparison of meta-analysis on missing or imputed data to original 
meta-analysis (missing values frequency 17%) 
 
This graph identifies the proportion of genes that a Fisher’s sum of log meta-analysis on 
missing or imputed data can identify as statistically significant, where a proportion of 1 
means the method detects 100% of the same genes as the meta-analysis on the original 
data does. X-axis signifies the study for which data was artificially introduced as missing. 
Y-axis signifies the proportion of statistically significant genes that are in common with 
the results obtained on the original data (583 and 799 for up and down regulation, 
respectively). “Missing” refers to meta-analysis where missing values were not imputed 
but left missing. “BPCA”, “KNN”, “LinReg”, “LinReg ST” and “Ranked Sets” refer to 
meta-analysis performed using BPCA, KNN, linear regression, linear regression by 
sample type and ranked sets imputation, respectively. 
 
 
The above analysis is based on the frequency of missing values matching that 
inherent to the original microarray studies for this meta-analysis (17%). While not 
covering a full spectrum of missing value frequencies, another statistical 
assessment was run at a missing value frequency of 1.5% (100 genes out of 6564 
per array) in order to determine if the imputation quality is strongly dependent on 
this. Figure 4.6 suggests that there are only small differences in the number of 
successfully retained meta-analysis results between having 500 or 6464 non-













































































































































Figure 4.6 Comparison of meta-analysis on missing or imputed data to original 
meta-analysis (missing value frequency 1.5%) 
 
This graph identifies the proportion of genes that a Fisher’s sum of log meta-analysis on 
missing or imputed data can identify as statistically significant, where a proportion of 1 
means the method detects 100% of the same genes as the meta-analysis on the original 
data does. X-axis signifies the study for which data was artificially introduced as missing. 
Y-axis signifies the proportion of statistically significant genes that are in common with 
the results obtained on the original data (583 and 799 for up and down regulation, 
respectively). “Missing” refers to meta-analysis where missing values were not imputed 
but left missing. “BPCA”, “KNN”, “LinReg”, “LinReg ST” and “Ranked Sets” refer to 
meta-analysis performed using BPCA, KNN, linear regression, linear regression by 





Unlike missing value imputation in individual microarray studies, the imputation 
of values missing due to different probe coverage of multiple combined 
microarray data sets has not been investigated before. With some justification, this 
can be assumed to be because the generation of mRNA expression values for large 
numbers of genes that have not even been included on a microarray chip does 
seem to implicate fabrication of data. However, this has to be weighed against the 
major concern of losing thousands of genes in a meta-analysis because they are 














































































































































simple investigation as described in this chapter is therefore used to give this 
problem numerical consideration instead of accepting intrinsic assumptions. 
 
Developments in missing value imputation. Since the time the work in this chapter 
was carried out, other algorithms have been devised to impute missing values in 
microarray studies, and at least one convenient online tool (MissVIA30) has been 
developed to run many of these on a user-supplied data set. Of the algorithms 
described in this chapter, it includes KNN and BPCA. While this is highly 
convenient, it is aimed at imputation within single microarray studies 
characterised by a different and infrequent type of missing values. 
 
Normalisation. Referring to normalisation across all studies (only within-study 
normalisation has been carried out), it is assumed that data are not normalised 
(where this means mathematical matching of per-array gene expression 
distributions between all arrays) across studies. In case of BPCA, this is explicitly 
stated as preferable to normalisation, which the authors’ empirical evidence has 
shown to degrade imputation performance. For KNN, it is not stated if normalised 
or non-normalised data are preferable, but it is here assumed that different studies 
are only systematically and linearly different from one another. This means that if 
one study provides higher expression level readings than another, these higher 
levels are consistent for most genes and have less effect on measuring similarity of 
genes or samples than it would have on measuring statistical differences (where a 
5% higher expression level for all genes in an array would affect a statistical 
metric). This assumption would extend to arrays within a study, but is here not 
necessary because individual studies are normalised as they were for meta-analysis 
in chapter 3. 
 
Differential expression vs. statistical significance. Notably, if assessment of 
imputation is limited to differences between group mean expression levels, results 
would be limited and, in terms of differential expression, underestimated (figure 
4.3).  This applies to even the best methodologies (BPCA and array-wise linear 
                                                
30 http://cosbi.ee.ncku.edu.tw/~godkin/ 
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regression) and is indicative of biological fold change being an ill-defined 
criterion with no really meaningful threshold. With imputation causing a decrease 
(rarely an increase) of observed average fold changes, genes would easily be 
discarded as not biologically relevant, and it is only due to the better defined 
thresholds of statistical testing that an advantage of imputation over keeping 
missing values is established. After imputation, a gene may be associated with a 
less significant p-value, but for a large proportion of genes these p-values still are 
significant at the same allowance level for false positive results (figure 4.5). For 
fold changes, no such objective cut-off exists and an analyst would likely consider 
many different and arbitrary fold change thresholds in a trial-and-error approach to 
identify genes of interest. 
 
Frequency of missing values. Statistical results for data missing with high 
frequency (17%) are almost identical to results from data missing with low 
frequency (1.5%), as demonstrated in figures 4.5 and 4.6. These two global 
missing values frequencies do not cover more complicated patterns of missingness 
(such as data missing for more than one study, or additional data missing at 
random or not at random) and are therefore not entirely conclusive without further 
study. However, the current computation are similar to what imputation in single 
microarray studies achieves (Scheel, Aldrin et al. 2005), with imputation in their 
assessment losing around 6-15% of statistically significant results. 
 
Influence of study size. It is clear from figure 4.5 that imputation of missing values 
depends on study size. The more samples are available for estimation of a 
replacement value, the better the imputation. This means that if values for the 
largest study (study 6) are missing and being imputed, statistical power is limited 
by the lower number of available samples in the other three studies. However, 
even in this circumstance, imputation (particularly using BPCA and linear 
regression, which recover around 80% of the original results) is considerably more 
effective than performing meta-analysis with data for this study remaining missing 
(which recovers only 47% of original results). The study size effect is therefore 
clear, but not a counter indication to imputation.  
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Simulation and parameters. The promising and not entirely expected results in this 
chapter may warrant a more expansive assessment. This chapter assesses the value 
of imputation only within the real data as used for this thesis as a whole. If this 
pragmatic data selection had proved ineffective for imputation of missing values, 
alternative simulation models would not provide much confidence in their 
applicability. Given that imputation shows some advantages over keeping or 
ignoring missing values, a more wide-ranging simulation could determine more 
exact parameter boundaries. This will likely prove necessary for purposes of 
publication, because the imputation of complete observations for a gene in a 
microarray study is entirely different from established methods for infrequently 
and randomly missing data. A full simulation would in particular address the 
effect of a range of study sizes, study numbers, gene expression levels, missing 
value frequencies and missing values patterns. With a large parameter space to 
cover, the results of the current work would be useful – apart from motivating 
further investigation - in limiting the number of imputation approaches to BPCA 
and linear regression.  
 
Gene selection and resampling procedure. There are alternative implementations 
to assure stability of imputation estimates with respect to the number and 
expression properties of gene chosen as missing or non-missing. The current 
implementation involves repeated resampling of the artificial introduction of 
missing values to one fixed set of 600 genes, with each sample setting a different 
set of 100 genes to completely missing. It would also be possible to repeatedly 
sample gene sets of size 600 from the list of 6564 genes (biased for high 
expression), with a subsequent single introduction of 100 missing genes to each 
set. It would also be possible to do both in combination or to vary the number of 
non-missing genes while keeping the proportion of missing genes stable at 17%. 
The here favoured option is an attempt to sensibly limit the parameters of 
investigation to the crucial stage, that is, the artificial introduction of missing 
genes where the non-missing genes may consequently have different expression 
characteristics depending on the selection. 
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Imputation through BPCA and linear regression of samples. It is perhaps not 
surprising that linear regression on samples performs similarly well to BPCA 
imputation method, as both are based on similarity of samples. For microarrays, 
missing value imputation methods often make use of the correlation structure 
available in these high-dimensional data with few observations (samples) and 
large numbers of variables (genes). However, in context of missing values for all 
observations of a gene in a study, it appears to be not the gene correlation structure 
(as used by KNN and ranked sets) but the sample correlation structure that informs 
the best results. KNN is often assumed to perform less well than BPCA (Jornsten, 
Wang et al. 2005) unless there is a strong ‘local’ correlation structure in the data 
(strong gene-gene similarities). Based on the observation that linear regression is 
conceptually similar to BPCA and also performs similarly, the idea was tested that 
imputation could be further improved by only using samples of the same class 
(treated or control) for the linear regression model, that is, if a missing gene’s 
observation is in a treated sample, only treated samples are used to estimate the 
replacement value. This does not improve imputation quality here, presumably 
because any additional value gained is lost through lowering the sample numbers 
for estimation. 
 
Ranked set gene selection. The newly introduced ranked set selection algorithm 
shows few advantages over the KNN algorithm, itself shown not to be a good 
method in the context of this chapter. Given the similarity of outcomes, the newly 
introduced method evidently only takes a different algorithmic path to arrive at 
very similar imputation estimates to KNN. This may be due to relationships 
between studies being sufficiently linear to provide no noticeable advantage to the 
per-study approach used in the ranked set method when compared to the across-
all-studies approach used by KNN.  In terms of gene selection schemes, both of 
these two algorithms are inferior to BPCA and linear regression, which suggests 
that a) these studies do not have a strong gene correlation structure that would help 
gene-correlation based algorithms, and b) imputation improvements for the ranked 
set selection would have to be directed towards including biological information, 
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that is, genes not only similar in expression profiles in a study or meta-analysis, 
but also known to have functional association through other sources of 
information. 
 
Strength of evidence versus scope of proposed procedure. What is attempted in 
this chapter is fundamentally different from the usual imputation of missing gene 
expression values in microarray study. The proposal here is that all observations 
for a gene in a complete microarray study can be generated in their entirety, that 
is, a gene is “invented” from scratch where there has originally not been a gene. 
However, three factors make this scenario worthwhile exploring in microarray 
data. One, it is known which genes form part of the genome and therefore should 
be represented on a microarray platform; where an “invented” patient is fictional, 
an “invented” gene is at least known to exist. Two, the high-dimensionality of 
microarrays means there are a very large number of variables available with which 
to predict missing values. Three, a meta-analysis that omits (and excludes from 
analysis) genes missing on a particular array type is likely to miss out on a large 
number of reasonable biological results. While these factors motivate the 
investigation in this chapter, the obtained evidence in favour of imputation of 
complete genes cannot yet be considered sufficient to match the scope of the 
chapter. Next steps will likely require a full simulation of imputation parameters 
and a biological assessment of genes identified through meta-analysis of 
incomplete or imputed data.  
 
Conclusion. Surprisingly, the imputation of data for genes entirely missing from a 
microarray platform shows clear advantages over the alternatives of keeping 
missing values, or omitting genes from analysis altogether. Despite differential 
regulation being somewhat underestimated after imputation, the number of 
significant meta-analysis results matches that of the original data upwards of 80%. 
Any reduction in the actual p-value is less important than maintaining a constant 
type I error level, and better than no results at all. It is also clear that imputation 
strategies based on sample-correlation (BPCA, linear regression) outperform those 
based on gene-correlation (KNN, Ranked Sets). While this is promising, it cannot 
 159 
be taken as complete verification of imputing the type of missing data discussed in 
this chapter. Firstly, all results are based on semi-synthetic data derived from a 
single meta-analysis set of studies. Secondly, only a narrow parameter space is 
tested, leaving unclear how higher frequencies of missing values, availability of 
more studies or samples, or different gene-correlation or sample-correlation 
structures in microarray studies could affect these outcomes. 
To date, missing value imputation appears not to have been tested for anything 
other than individual microarray studies with randomly missing data values, and 
given the positive outcomes in this chapter, this supports publication in this space 









This chapter develops results obtained through meta-analysis of IFN-γ microarray 
studies into biological context, with the aim of exposing new biological insights. 
 
Interferons are classically separated into three types. Type I interferon signalling is 
characterised by interferon alpha or beta (or all with the exception of IFN-γ) 
proteins binding to the interferon alpha receptor on the cell membrane and 
activating the JAK-STAT pathway, resulting in STAT1/STAT2 heterodimers that 
can form a complex with IRF9 (then a heterodimer), translocate to the nucleus and 
activate genes containing ISRE (Interferon Stimulated Response Element) motifs 
in their promoter. Type II interferon signalling is typified by IFN-γ binding to an 
IFN-γ receptor and also activating the JAK-STAT pathway, but where this results 
in the formation of STAT1 homodimers that translocate to the nucleus and activate 
genes containing GAS (Gamma Activated Sites) motifs in their promoter. Type III 
interferon signalling is less well characterised, and is assumed to share its function 
with type I interferon, but with JAK-STAT activation through IL28 or IL29 (and 
other cytokines) binding to an interferon lambda receptor. Both type I and type II 
interferon play a role in the activation of macrophages, although type II is 
regarded as the classical factor in this. 
 
Current biological knowledge related to the IFN-γ signalling pathway can be 
separated into three semantic classes. One is the canonical view of the type II 
interferon activated JAK-STAT pathway as described above. The second class is 
then the set of interferon-stimulated genes (ISGs) transcribed by STAT1 and 
further downstream. This much larger set of genes is less well defined than the 
canonical pathway, but still contains what is considered as known in the cell 
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response to interferons in general. Notably, research suggests that this list has 
considerable overlap with genes activated through the type I interferon pathway. 
The third class contains genes for which there exists research or hypotheses that 
mean they may be part of the response of interferon but are pending further 
confirmation. These three classes are outlined and used for reference later in this 
chapter.  
 
Contextualising the meta-analysis results requires both definition of gene sets 
related to the above three classes, as well as a condensed definition of meta-
analysis test results. The full process described in this chapter can be outlined as 
follows. Results of the meta-analysis of multiple microarray studies investigating 
the effect of IFN-γ on murine macrophages are reduced to “meta-analysis-only 
discoveries”, those genes that are statistically significant (p<=0.01) in a meta-
analysis but not statistically significant in the analysis of any individual 
microarray study. It is important to note that this does not constitute the full 
measured type II response, because genes statistically identifiable as significant in 
any single microarray study are excluded. Next, result lists are reduced to a 
consensus list of all genes that are statistically significant in at least two out of 
three meta-analysis model families. 
Subsequently, these results are evaluated for their known inclusion in interferon 
responses through an independent database (Interferome.org) of known interferon-
stimulated genes (ISGs), experimental data provided by the Division of Pathway 
Medicine, simple gene annotation and information obtained from GeneCards31, 
and searches of literature through PubMed 32  (with search term “interferon” 
combined with official gene symbol).  
The biological context revealed in the overlap between meta-analysis results and 
existing research of the type II activated immune response is then assessed and 
novel findings presented.  
  




5.2 IFN-γ signal transduction 
 
The JAK-STAT pathway plays a critical role in initiating both the innate and 
adaptive immune responses upon infection.  
The classical activation of macrophages requires stimulation by an extracellular 
IFN-γ signal, which engages a cells’ JAK-STAT pathway with the specific 
outcome of phosphorylating STAT1 proteins, which in turn dimerise, translocate 
to the nucleus and activate the transcription of genes containing a GAS (STAT1 
homodimer binding site) motif in their promoter region. With no particular focus 
on the type of interferon involved, these genes and those affected indirectly are 
referred to as Interferon Stimulated Genes (ISGs). This paradigm is frequently 
represented as a pathway schematic with differences in the level of detail and 
biological specialisation. Figure 5.1 represents the simplest form of this pathway, 
with alternative schematics available from many sources (Vilcek 2003, Schroder, 
Hertzog et al. 2004, Platanias 2005, Horvath 2013). This canonical model is 
however a simplification that ignores other contributors and modifiers to the type 
II immune response: 
- Other genes or miRNAs positively or negatively regulating (via respective 
proteins) the JAK-STAT pathway, such as SOCS, PIAS (Greenhalgh and 
Hilton 2001) or miR-155 (Lu, Thai et al. 2009) targeting and potentially 
down regulating SOCS (at least in T-cells), or nitric oxide synthase 2 
(NOS2) associating with IFNGR1 in bacterial infection (Velez, Hulme et 
al. 2009). Other examples are Prn, Ptpn1, Cd45. 
- Complicated crosstalk with other signalling pathways like MAPK 
signalling or PI3K-AKT (Rane and Reddy 2000), particularly type I 
immune response and in newer research, with Ch25h in sterol metabolism 
(Blanc 2013).  
- Activation/suppression of gene transcription that is not due to STAT1 
alone (such as activation of Irf1 only through joint activity of STAT1 and 
TNFα-activated NFκb (Ramana, Gil et al. 2002). Other examples are Jun, 
Cebpb, Hmga1, Myc. 
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- Presence of a gamma-activated site in a gene may need to be 
complemented by both co-activators with STAT1, e.g. Brca1 (Ouchi, Lee 
et al. 2000) and other transcription factors like SP1 bound to other sites on 
that gene (Ramana, Gil et al. 2002). 
- In addition to interferon (or IFN-γ) related genes that are directly 
transcribed by STAT1, there are of course also genes (indeed, the majority 
of the interferon response) activated or suppressed further downstream and 
therefore only indirectly regulated by STAT1. 
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Figure 5.1 Canonical IFN-γ activated JAK-STAT signalling 
 
[Source: (Platanias 2005). Mechanisms of type-I- and type-II-interferon-mediated 
signalling. Leonidas C. Platanias.; licence for reuse obtained: 3140331400980) 
(additional dotted frame added for highlighting type II activated JAK-STAT pathway)] 
 
Extracellular IFN-γ binds to an IFN-γ receptor complex (IFNGR1 and IFNGR2) on the 
cell surface. This activates (through autophosphorylation) the receptor-associated kinases 
JAK1 and JAK2, which in turn regulate STAT1 phosphorylation, allowing 
homodimerisation of STAT1 proteins and translocation to the cell nucleus, where STAT1 
is able to bind to the promoter regions of genes containing a gamma activated site (GAS) 





5.3 Known interferon stimulated genes (ISGs) 
 
This thesis assesses the effect of IFN-γ treatment on gene transcription, it is 
therefore necessary to relate meta-analysis findings to those genes that are already 
known to be stimulated by interferons (specifically, type II). This serves two 
purposes, the first is simple confirmation that a reasonable proportion of results 
are biologically relevant rather than chance, and the second is to identify novel 
participants in the response. 
Many research groups have compiled existing experiment-derived knowledge in 
the form of ISG (interferon stimulated genes) lists or databases (Boehm, Klamp et 
al. 1997, Der, Zhou et al. 1998, de Veer, Holko et al. 2001), where de Veer et al 
have also provided an early example of database based on compiled microarray 
results 33 . A more recent and supposedly more complete resource is 
Interferome.org 34  (Samarajiwa, Forster et al. 2009). Interferome is manually 
curated from publicly available microarray data sets (36 to date) to consolidate 
type I, type II or type III interferon regulated genes. The interferome study set is 
heterogeneous with regard to organism, cell/tissue types and type/subtype of 
interferon, resulting in a broad source of information that in this case may be 
helpful in highlighting meta-analysis-only discoveries that otherwise show little 
activity in individual small specialised microarray studies. This is the main 
database used in this chapter for validating meta-analysis results. However, the 
following limitations apply: 1) Due to experiment outcomes being determined by 
parameters like cell type, time, intervention, environmental factors, laboratory 
protocols, organism and of course quality of experiment design, it is not specific to 
any of these parameters. 2) It is unfortunately currently not possible to download 
the interferome data set in its entirety or to submit more than 100 ENSEBML IDs 
at a time (this presumably is as intended, and direct inquiries to the authors on this 
                                                
33 Database available at: http://www.lerner.ccf.org/labs/williams/xchip-html.cgi 
34 http://www.interferome.org/ Samarajiwa, S. A., S. Forster, K. Auchettl and P. J. 
Hertzog (2009). "INTERFEROME: the database of interferon regulated genes." 
Nucleic Acids Research 37: D852-D857. 
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subject have not received a reply). 3) In contrast to the meta-analyses undertaken 
in this thesis, this resource is a simple catalogue of aggregated findings, 
conditional on genes being >= 1.5 fold up/down regulated, and not based on 
statistical models combining the underlying data. 
As the Interferome database does not use any of the microarray studies that were 
considered for the meta-analyses described in this thesis, it provides a reasonably 
unbiased independent validation source against which meta-analysis results can be 
examined for known interferon (and IFN-γ) related genes.  
 
5.4 Other evidence of ISGs 
 
While the Interferome database is used as the primary resource for defining 
current knowledge on interferon stimulated genes, two other sources were 
considered for further validation purposes, one based on in-house experimental 
data, one based on promoter predicted GAS binding sites. 
 
5.4.1 Experimental evidence for ISGs provided by DPM 
 
The Ghazal lab has a research emphasis on the interaction between host and virus 
infections observable in macrophages, and for this purpose a large microarray 
study (referred to as MITCH12 and described in detail in chapter 2) was carried 
out to measure changes in gene expression levels across twenty-five 30-minute 
intervals following addition of IFN-γ to murine bone marrow derived 
macrophages. This study has a single replicate (treatment of BMDM culture) per 
time point and is therefore not amongst the set of microarray studies used for 
meta-analyses conducted for this thesis, providing an independent and nuanced 
(compared to snapshots of IFN-γ treatments versus control samples) experimental 
validation resource. Although it lacks statistical power through the absence of 
replication at each time point, its relatively frequent sampling time points and the 
theoretical absence of biological inter-subject variation provide useful longitudinal 
information in form of trends. In this case an online database of all gene 
expression profiles (of fully processed data) for this study is available via 
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GEViSE35. The limitations of visually classifying expression profiles into up and 
down regulation are described later on in this chapter. 
  
5.4.2 Promoter predicted GAS binding site evidence for ISGs 
 
Since the IFN-γ activated JAK-STAT signalling pathway results in STAT1 
homodimers that bind to a GAS motif in the promoter regions of target genes, a 
succinct list of all genes with promoter predicted GAS binding sites was generated 
via oPOSSUM v3.036. These represent all theoretical targets directly transcribed 
by STAT1, with this of course not covering activation or inhibition of genes 
further downstream. The process and parameters are described in detail in chapter 
2. 
Conversely, the full list of meta-analysis results was also supplied to the 
oPOSSUM tool in order to test the up and down regulated gene sets for 
enrichment with regard to other transcription factors. 
 
5.5 Meta-analysis result gene sets 
 
The use of six different meta-analysis models identifying separate result lists for 
up and down regulated genes produces twelve separate gene lists. An individual 
assessment of their biological context even in compressed form would cause the 
generation of numerous and large tables, and while this would be the most 
complete and detailed approach, it would detract from an assessment of how much 
a microarray meta-analysis confirms or adds to biological knowledge, irrespective 
of quality differences between meta-analysis models. This motivates an 
aggregation of these lists into a single gene set (although still divided into up and 
down regulation). Following characterisation of the original gene lists, the 
aggregation process is described and discussed. 
 




5.5.1 Meta-analysis results prior to aggregation  
 
Prior to discussing the output of an aggregate list of meta-analysis “hits” or 
“discoveries”, a distinction is made between meta-analysis “model” and “model 
family”. This is based on most meta-analysis models not being fully independent 
of another, for example Rank Product meta-analysis: while these are three meta-
analyses that all use the same analytical framework of permuted rank-based 
statistics and therefore constitute a “model family”, the individual models work 
with different parameters, in this case each Rank Product meta-analysis model 
applies different weights to individual microarray studies. In case of meta-analysis 
based on effect size, only a random effect model was shown to be suitable and 
there is therefore no distinction between model family and model. 
For any of these lists, it must be emphasized that they do not contain all possible 
genes statistically identified to be differentially regulated under IFN-γ treatment, 
because most of these genes can readily be identified in the statistical analysis of 
individual studies. While those genes are of course biologically interesting (given 
that they will be associated with larger expression fold changes), the purpose of 
this chapter is to identify genes that a meta-analysis can identify beyond that set. 
Table 5.1 summarises the twelve original gene lists and various forms of overlap 
between these models and model families. It covers genes that have been 
identified as statistically significant (“discovered”) through meta-analysis alone, 
i.e. this does not include genes that were discoverable through statistical analysis 
of any individual study. After reduction of list to genes that were annotatable and 
not redundant in Ingenuity Pathway Analyzer, the table lists the number of genes 
discovered by each meta-analysis model or model family, those unique to a model 
(the number of genes identified with each model that were not identified through 




Table 5.1 Summary of meta-analysis-only discoveries 
a) Genes up regulated by IFN-γ treatment 
 Rank Product family Fisher family Effect size 















N 70 107 75 80 72 76 
Model 
family 133 (29) 135 (17) 76 
Unique to 




49 34 25 
Common to 






b) Genes down regulated by IFN-γ treatment 
 Rank Product family Fisher family Effect size 















N 66 158 145 175 74 121 
Model 
family 207 (38) 234 (15) 121 
Unique to 




112 87 41 
Common to 





For each meta-analysis model and model family, these tables count the number of 
statistically significant meta-analysis gene-probes for genes up-regulated (a) or down-
regulated (b) by interferon gamma. Table columns identify a given meta-analysis model 
and model family, table rows identify the method of counting. Counts shown exclude 
significant meta-analysis results that are already significant in individual microarray 
studies. Bracketed counts for model family give the intersection, i.e. genes in common to 
all models in a given model family.  
 
Table 5.1 describes differences in gene list sizes and gene list overlap depending 
on meta-analysis model and model family used. Two main features are the 
considerable differences between the gene list sizes under different meta-analysis 
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models and the difference between the relatively large number of genes identified 
by individual meta-analysis models (or model families) and the considerably 
smaller number of those genes that are in common to all models or model 
families). Both features confirm that considerable quantitative differences exist 
and that they may be related to the quality of a meta-analysis. This provides 
confirmation that the choice of meta-analysis matters and that it is therefore useful 
to work with aggregated (“consensus”) rather than individual lists as described in 
the next subsection.  
 
5.5.2 Consensus lists of meta-analysis results  
 
Several options for list aggregation were considered and discarded before final use 
of the two-out-of-three model families criterion. A union set of all genes that are 
identified by any of the meta-analysis models would be too large (214 up 
regulated genes and 392 down regulated) and include too many false positive 
results identified by lower quality meta-analysis models. An intersection set of 
genes common to all twelve meta-analysis models or common to all 3 meta-
analysis model does create a valuable high-confidence set of results (see table 5.2) 
but is also limited to the lowest common denominator in terms of performance of 
meta-analysis models. Using only result lists from the best-performing meta-
analysis model or model family would not be a fully objective set in that chapter 3 
identified no single model clearly superseding all others, resulting in good results 




Table 5.2 High-confidence gene lists 
Up regulated in IFN-γ  (n=24) Down regulated in IFN-γ  (n=18) 





13244; degenerative spermatocyte 
homolog 1 
 
Mertk 17289;  c-mer proto-
oncogene tyrosine kinase 
Sirpa 




16709; kinectin 1 
 
Map2k3 
26397; mitogen-activated protein 








27373; casein kinase 1, epsilon 
 
Atad1 
67979; ATPase family, 
AAA domain containing 1 
 
Orc5 




11416; solute carrier 
family 33 (acetyl-CoA 
transporter), member 1 
 
Fam134b 
66270; family with sequence 




ribosomal protein L13 
 
Reep5 
13476; receptor accessory protein 5 
 
Fbrs 14123; fibrosin Wdr48 
67561; WD repeat domain 48 
 
Abcc5 27416; ATP-binding 
cassette, sub-family C 
(CFTR/MRP), member 5 
 
Cyb5r3 
109754; cytochrome b5 reductase 3 
 
Dnajc13 235567; DnaJ (Hsp40) 









protein, Y-encoded-like 1 
 
Ppan 









10, NatA catalytic subunit 
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Genes contained in this table are meta-analysis “hits” in all 3 model families, meaning 
that even the worst performing meta-analysis model is able to identify these as statistically 
Klf3 








224250; claudin 25 
 
Pgrmc1 
53328; progesterone receptor 




viral oncogene 1 
 
Sptan1 





domain containing 17 
 
Eif2s3x 
26905; eukaryotic translation 
initiation factor 2, subunit 3, 
structural gene X-linked 
 
Tox4 
268741; TOX high 




68134; UPF3 regulator of nonsense 
transcripts homolog B (yeast) 
 
Tulp3 














110172; solute carrier 




56494; golgi SNAP 










381738; dynein regulatory 










significant. The second column for up or down regulated genes contains the EntrezGene 
ID and gene description. Genes highlighted in bold can be considered as even higher 
confidence, as these are meta-analysis hits in all twelve individual meta-analysis models. 
A large disadvantage in focusing all interpretation on only this gene set is the limitation to 
genes that even the worst performing meta-analysis model or model family can identify, 
making this a lowest-common-denominator set. 
 
 
While the genes presented in table 5.2 are clearly worth following up, they are also 
limited to the results of the least well performing meta-analysis. It therefore 
becomes necessary to define another alternative. This alternative is referred to as 
“consensus set” and is simply defined as those genes that are identified as meta-
analysis-only discoveries in at least two out of the three model families. To 
provide an example, this would include a gene that is contained in any of the Rank 
Product meta-analysis family and is also contained in one of the two Fisher 
models or in the single effect size model. This approach assumes that qualitative 
differences between model families are larger than those between the models 
within a model family. It also allows for one model family to perform worse than 
the other two without affecting the aggregated result. The Venn diagrams in figure 
5.2 outline details of consensus sets generation, which are all three blue-shaded 




Figure 5.2 Venn diagram defining consensus gene set 
 
Large circles refer to meta-analysis model family. Smaller circles inside large 
circles refer to individual models within the model family (where applicable). 
Only intersection counts are included, totals can be found in table 5.1. 
Consensus set: the union of blue shaded areas indicate selected set of genes, they 
are identified by meta-analysis only in any two of the three different model types. 
In set theory terms: (𝑅𝑃 ∩   𝐹) ∪ (𝑅𝑃 ∩ 𝐸𝑆) ∪ (𝐹 ∩ 𝐸𝑆) 
Where Ifng is up regulated with respect to controls, n=106 genes comprise the 
consensus set. 




After this aggregation, there are n=106 genes in the consensus set up regulated by 
IFN-γ, and n=152 down regulated. These were stored in a simple data sheet37 for 
the purpose of combining them with their known biological context as described in 
sections 5.3 and 5.4. The proteins associated with these genes can also be seen in a 
STRING interaction map in the appendix. 
 
5.5.3 Meta-analysis disagreement lists  
 
With the consensus list approach emphasizing what meta-analysis models have in 
common in terms of performance beyond individual study analysis, it is 
conceivable that some important differences between meta-analysis methods are 
overlooked. Whilst not discussed in this thesis, meta-analysis results unique to 
                                                
























Ifng up regulated with respect to controls Ifng down regulated with respect to controls 
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each of the twelve models were also extracted (matching the totals shown in line 
“Unique to model” in table 5.1) for separate investigation and candidate selection 
at a later stage and are only included as spreadsheets in supplementary material 
here38. 
 
5.6 Meta-analysis results in biological context 
 
Using meta-analysis consensus lists as described above, this section highlights 
biological context identified with reference to JAK-STAT pathway, known IFN-γ 
regulated genes, genes with predicted STAT1 binding sites (GAS motifs) in their 
promoter, relevant annotation and literature, and in-house experimental data. This 
supporting evidence is then combined into master lists in section 5.7. 
 
5.6.1 In the context of JAK-STAT pathway 
 
Only two canonical genes (including SOCS, PIAS and IRF modifiers in this 
definition) related to the IFN-γ activated JAK-STAT pathway are contained in the 
meta-analysis consensus results (Junb, Sfpi1). Given that these consensus lists 
explicitly exclude any genes that are easily identifiable (due to more pronounced 
changes in transcription levels on IFN-γ treatment) in the statistical analysis of 
individual microarray studies, this is an unexpected finding. The presence of these 
two genes is discussed at the end of this chapter. Most weight in terms of 
biological context of meta-analysis findings must therefore lie with genes 
stimulated by interferon (gamma), interactions with other signalling pathways or 
currently unconfirmed subtle modifiers of IFN-γ signalling. 
 
  
                                                
38  Available in supplementary material folder “MetaAnalysisResults”, files 
“UniqueResultsPerModel_down.txt” and “UniqueResultsPerModel_up.txt” 
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5.6.2 In the context of known ISGs 
 
Using the interferome database as reference, a simple table of known interferon 
stimulated genes (see table 5.3) shows that approximately 25% (up regulated) and 
18% (down regulated) of genes identified in meta-analysis are already known. If 
specifically limiting the overlap to known type II response genes, this drops to 
12% and 9%, respectively. 
 
Table 5.3 Meta-analysis results compared to Interferome.org ISGs  
 
Consensus list In Interferome Not in Interferome Total 
Up regulated in 
IFN-γ treatment 26 (I=25; II=13; 




27 (I=27, II=14, 
III=2) 125 152 
 
”In Interferome” identifies genes that are categorised as Type I, Type II or Type III 
interferon regulated genes in the Interferome database. Numbers listed in brackets show 
the breakdown by type of interferon, with categories not being mutually exclusive. 
 
Making an assumption about full genome size (~20000 genes) and factoring in 
that the Interferome database defines 10% of these (~2000 genes) as regulated by 
interferome (of any type), results in table 5.3 exceed (at 25% and 18% of genes) 
random chance selection of IFN-γ regulated genes. This difference in observed 
proportion (21% if ignoring direction of regulation) and expected proportion 
(10%) is statistically significant at p=4.458x10-8 (by χ2-test comparing two 
proportions), of course with the important caveat that the above assumptions are 
not independently confirmed. Given that the meta-analysis results intentionally 
exclude any easily discovered responses to IFN-γ (captured in individual 
microarray study and not used here), this outcome still lends some support to the 
relevance of the full list of results. 
 
Meta-analysis results are also compared (table 5.4) to in-silico predictions of 
STAT1 target genes obtained through oPOSSUM. Of the 106 IFN-γ up regulated 
genes and 152 IFN-γ down regulated genes, 99 and 148 respectively have a unique 
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and valid Ensembl gene ID (required by oPOSSUM). Of these, 29 and 28 genes 
respectively contain a STAT1 binding site in their promoter region (when limiting 
searches to 5kb/2kb upstream/downstream). Under the same assumptions as for 
table 5.3, the proportion of meta-analysis results with GAS motif (57 out of 247 = 
23%, irrespective of direction or regulation) is at p=2.831x10-11 significantly 
larger than the proportion for the whole genome (10%, although the strength of the 
assumption of GAS motifs amongst the 2000 interferome database genes is not 
known). While this appears similar to the comparison against ISGs in the 
interferome database, the actual gene lists differ. Of the 29 genes with a STAT1 
binding site (GAS motif) in interferon down regulated genes, only 4 genes (Gps1, 
*Capn2, Hey1, *Tshb) are a known ISGs according to the interferome database. Of 
the 28 genes with a STAT1 binding site in IFN-γ up regulated genes, 9 are known 
ISGs (*Birc2, *Junb, *Rgs14, Arl6ip5, *Hnrnph2, Pnpla2, Ubr4, *Bcl3, Lpp). Of 
these, even fewer (see starred entries) are known to be stimulated via a type II 
response. In addition, when comparing in-silico predictions of STAT1 transcribed 
genes to the gene expression profiles of an independent time course study 
(MITCH12), very few predictions are confirmed for the down regulated set (4 out 
of 29 have a notably decreasing expression level), but half are confirmed for the 
up regulated set (14 out of 28 have notably increasing expression levels). Given 
that the GAS motif relates to genes transcribed by STAT1 rather than inhibited, 
this results may to some degree validate the in-silico approach, although it is far 
from conclusive. 
 
 Table 5.4 Meta-analysis results compared to in-silico ISGs  
 
Consensus list GAS motif No GAS motif Total 
Up regulated in 




29 120 149 
 
”GAS motif” identifies genes that contain a binding site for STAT1 in their promoter 
region (searches include regions 5kb/2kb upstream/downstream). Up/Down regulated 
represent statistical results obtained through meta-analysis (and condensed to consensus 
lists). Row totals do not match actual meta-analysis list sizes because of identifier 
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Conversely, if oPOSSUM is used to identify enrichment for any transcription 
factors in the list of meta-analysis-only discoveries, STAT1 is featured but does 
not rank as one of the statistically best matches. A summary figure relating 
significance to GC content in sequence is included in supplementary material, a 
ranked list of significant transcription factors is provided in list form here (table 
5.5), limited to those matching the default opossum significance threshold.  
 




Significant transcription factors 
within set of genes identified as 
up regulated by IFN-γ 
Significant transcription factors 
within set of genes identified as 
down regulated by IFN-γ 
1 SPIB ELK1 
2 ELF5 SPI1 
3 MZF1_1-4 GABPA 
4 Mycn ELF5 
5 ZEB1 Zfx 
6 Klf4 MZF1_1-4 
7 Nkx2-5 YY1 
8 Anrt::Ahr ARID3A 
9 MZF1_5-13 FEV 
10 GABPA SPIB 
11 SPI1 Esrrb 
12 USF1 ZEB1 
13 Nkx3-2 Arnt::Ahr 
14 Myc CEBPA 
15 ELK1 Stat3 
16 AP1 Klf4 
17 FEV NF-kappaB 
18 ZNF354C EBF1 
19 MAX RELA 
 
 
While many transcription factors are ubiquitous in their range of functions, a 
cursory examination of table 5.5 shows several transcription factors important to 
MAPK signalling (SPIB, Myc, ELK1), JAK-STAT signalling (GABPA, SPI1) or 
other immune related function (RELA – part of NF-kappaB complex, AP1 – 
cytokine response, Ahr::Arnt – inhibition of inflammatory response, ZEB1 – 
repressor of IL2 expression). However, a simple enrichment analysis for 
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transcription factor binding sites cannot equate the presence of a binding site with 
their biological role (where the GAS promoter is only the primary event upon 
STAT binding, resulting in expression of other proteins like IRF3 that in turn 
cause secondary events by binding to IRF promoters etc.). It is therefore unclear 





5.6.3 New candidate ISGs based on existing annotation 
 
This category covers genes that meta-analysis of multiple microarray studies 
identifies as regulated with statistical significance, but are not identified by 
interferome.org and may either have some relevant annotation or literature 
associated with them, or have other experimental evidence behind them. As 
described earlier, annotation information was obtained through GeneCards.org and 
literature searches. For each gene, an annotation category was subjectively decided 
on as follows: 
Category 1. “Known Ifn related”. Is the gene already known to be 
related to interferon regulation? This information was 
obtained from the interferome database, see 5.2.1. 
Category 2. “Potential Ifn related”. Is there otherwise any explicit 
mention of interferon or associated genes/processes in the 
pathway (e.g. Stat1, NFκb, immune response, …) of any 
form that could mean it could be relevant to interferon 
regulation? 
Category 3. “No obvious relation to Ifn”. Does the gene have annotation 
that is not obviously related to the previous two categories? 




With regard to existing annotation for genes not already known to be ISGs, table 
5.6 suggests a further 12 (9 for up and 3 for down regulation) genes as ISGs, based 
on existing annotation.  
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Table 5.6 New ISGs suggested by existing annotation  
 









Up regulated in 




27 3 89 33 152 
 
“Known Ifn related” indicates that a gene has been flagged as type I, II, or III interferon 
regulated in the Interferome.org database. “Potential Ifn related” indicates that a gene’s 
existing annotation contains explicit or implicit hints to involvement with interferons. “No 
obvious relation to Ifn” indicates that a gene has existing annotation but this does not 
appear to be related to the interferon pathway”. “Lack of annotation” indicates that there 
is virtually no existing annotation for a gene.  
 
The candidates in question are listed here, including some of the relevant 
annotation: 
Bcl2a1 (direct transcription target of NFκb in response to inflammatory     
mediators) 
Casp12 (stimulated by IFN-γ in fibroblasts, may reduce cytokine release, involved 
in reducing activity of NFκb) 
Cd47 (inhibits cytokine production by mature dendritic cells, may be activated by 
IFN) 
Igbp1 (depletion enhances induction of Stat1 dependent genes) 
Ikbke (regulates balance between type I and type II interferon responses) 
Itga4 (induced by IFN-γ, part of MAPK signalling) 
Raf1 (key component of MAPK cascade, involved in macrophage proliferation 
and activation, affected by bacterial host infection) 
Tbk1 (activates interferon regulatory factor 3, Irf3) 
Txndc17 (modulates TNFa signalling and NFκb activation)  
 
For IFN-γ related gene down regulation it is 3 genes: 
Lrrfip1 (regulates TLR signalling) 
Map2K3 (IL-12 induced IFN-γ activation) 
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Mapk1 (transcriptional repressor of interferon signalling) 
 
 
An unresolved complexity in establishing known ISGs is of course that the 
validation set used here is based on microarray transcription studies. This means 
that in some cases the “new” ISG candidates are already implicated as ISGs or 
modifiers of IFN-γ signalling, through proteomic or other work. Nonetheless, here 
they are identified through microarray transcription studies and appear to be 
influencing or be influenced by IFN-γ signalling, but are currently not confirmed 
as transcription-derived ISGs.  
 
5.6.4 New candidate ISGs based on time course data 
 
For the purposes of validating meta-analysis candidates against experimental 
evidence, gene expression profiles in a microarray time course (“MITCH12”) 
were classified by their overall expression trajectory across the full 12 hours, with 
each category chosen as described in table 5.7. 
 
Table 5.7 New ISGs suggested by IFN-γ microarray time course study  

































Categories are subjectively defined as follows: Rising (expression profile 
trajectory over most of the 12 hours goes from low expression to high expression, 
where the minimum differential between low and high is ~2 fold and does not 
include profiles within signal noise levels below ~100). Dropping (opposite 
criteria to Rising). Peak (expression profile trajectory rises and drops considerably 
once over the course of 12 hours). Trough (expression profile trajectory drops and 
rises considerably once over the course of 12 hours). Unremarkable (gene 
expression never changes across the 12 hours, or fluctuates without a clear pattern, 
or has single time-point peaks or troughs only, or is entirely within an arbitrarily 
defined region of signal noise below 100). Not Found (the gene does not appear 
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to be represented on this microarray platform). Numbers and percentages should 
be considered tendential rather than precise, because the categorisation of 
expression profiles is subjective.  
 
 
With hit confirmation rates of 54% and 43%, respectively (combining all profiles 
that are not unremarkable or not found), there appears to be a reasonable amount 
of congruency between meta-analysis results and independent microarray time 
course. This is particularly reinforced by the matching regulation direction, with 
IFN-γ up regulated genes in the meta-analysis results primarily matching rising 
profiles in the time course experiment, and vice versa. 
  
While all genes in the first three categories constitute potential candidates, 
amongst them are those with a weaker justification and those that are notable 
examples in both up and down regulation in terms of large systematic changes 
(generally larger than two-fold, and at higher and therefore more reliable levels of 
measurement) in the microarray time course that were also (and only) identified by 
meta-analysis of the two-condition microarray studies. 
 
From the above set, the most (visually and subjectively) notable genes up 
regulated by IFN-γ and amongst the meta-analysis results are listed below, with 
highlighted gene symbols indicating the strongest expression profiles. A starred 
entry indicates this gene does not feature in the list of known ISGs in the 
interferome database and as such has higher value for follow-up as a novel 
candidate. 
 
*Ahrr (aka Cyp1a1, involved in cholesterol/sterol/lipid synthesis) 
Arl6ip5 (regulated by type I IFN, according to Interferome.org) 
Bcl3 (regulated by type I/II IFN, according to Interferome.org) 
*Capza2 (interacts with Calm1, which is known to interact with type I IFN) 
Cd47 (Receptor for SIRPA, binding to which prevents maturation of 
 immature dendritic cells and inhibits cytokine production by mature 
 dendritic cells. May be involved in membrane permeability changes 
 induced following virus infection) 
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Cflar (regulated by type I IFN, according to Interferome.org) 
*Clic4 (nuclear translocation regulates macrophage deactivation) 
*Ehd1 
Junb  (regulated by type I/II IFN, according to Interferome.org) 
Ly6a (regulated by type I IFN, according to Interferome.org) 
*M6pr (high degree of co-localisation with STAT1 and HPIV1 C proteins, but 
 not STAT2) 
Mafk (regulated by type I IFN, according to Interferome.org) 
Mertk (important role in inhibition of TLR-mediated innate immune 
 response by activating STAT1; regulated by type I IFN, according  to 
Interferome.org) 
*Ms4a4b 
Mxd1 (regulated by type I IFN, according to Interferome.org) 
*Rnf14 (gene promoter contains Nfkb transcription factor binding site) 
Rgs14 (regulated by type I/II IFN, according to Interferome.org) 
Rsad2 (regulated by type I/II/III IFN, according to Interferome.org) 
Sfpi1 (regulated by type I IFN, according to Interferome.org)  
*Stard3 (involved in cholesterol traffic and steroid synthesis) 
*Usp12 
 




*Csnk1e (may act as a negative regulator of circadian rhythmicity by 
phosphorylating PER1 and PER2) 
Elk3 (regulated by type I/III IFN, according to Interferome.org) 
*Hyal2 




In terms of formulating hypotheses for the addition of novel candidate ISGs to 
already known biology, the most promising are those genes identified as 
significant by meta-analysis, exhibiting a notable gene expression profile over 
time, and not already known as an ISG. From the above list, these are Clic4, 
Ms4a4b, Stard3, Ahrr, Capza2, Ehd1, M6pr, Obfc2a, Rnf14, Usp12, Cdt1, 
Hyal2, Ptpre, Csnk1e and Snrk (see figure 5.3). This list intentionally ignores the 
use of up or down regulation, as this is only evidenced by the meta-analysis, 
whereas the gene expression profiles of the time course experiment may show 
much more complex patterns depending on time frame. Although many of these 
genes have been shown to play some role in the IFN-γ signalling cascade or more 
general immune response to pathogens, the evidence is not conclusive and not 
specific to the effect of IFN-γ in mouse macrophages, making them a suitable 
proposition for further hypothesizing and experimental follow-up. 
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Figure 5.3 Expression profiles of  selected new identified ISGs
 
Gene expression profiles for 15 genes (one of which is represented by two gene probes) 
which are significant in the consensus result set of meta-analyses, have strongly changing 
expression profiles in an independent microarray time course of IFN-γ treatment in mouse 
macrophages (MITCH12), and which are not already known to be interferon stimulated 
genes (according to Interferome.org). The X-axis represents 25 measurement time points 
from 0 to 720 minutes in 30-minute intervals. The Y-axis represents absolute linear-scale 
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transcription level after data processing and normalisation. Graphs are organised by 
expression profile pattern: 9 graphs in top section and 2 graphs in the middle section 
containing genes which are up regulated in meta-analysis results (here visually separated 
by straightforward up regulation and peaking expression in MITCH12); 5 graphs in 
bottom section are down regulated in meta-analysis results, although in MITCH12 down 
regulation is notably transient. 
 
 
5.6.5 Candidate ISGs based on other evidence 
 
While the previous sections cover the context of meta-analysis findings using 
selected primary sources, results were also tied into published and on-going 
research in our group covering immune response to pathogens in immune cells. 
For these, one can use the results obtained in meta-analyses to emphasize these 
genes. 
 
A recent paper (Kropp, Robertson et al. 2011) identified interactions between type 
I and type II immune responses as a contribution to the activation state of 
macrophages following viral infection. Using IFN-γ treatment and subsequent 
withdrawal of IFN-γ treatment, this study identified 163 genes that require 
continuous IFN-γ stimulation in order to maintain their transcription response to 
viral infection. This number of results would usually be difficult to follow up, but 
congruency of this set of results with meta-analysis results may help in focusing 
further investigation. Of the 163 genes identified, 148 are unique genes, and 10 of 
these show subtle but consistent (that is, identified by meta-analysis alone) gene 
expression increases in response to IFN-γ treatment. These are Klf3, Tox4, 
Kiaa0247, Rnf14, M6pr, Ahrr, Ankib1, Pnpla2, Stx4, and Hivep2. Notably, there 
are no matches against the consensus list of genes down regulated by IFN-γ, which 
conforms to expectations as the list of 163 genes is only concerned with reversible 
up regulation of genes. 
 
More in-house research (Blanc 2013, Watterson, Guerriero et al. 2013) suggests 
links (in response to viral infection) between IFN-γ signalling and sterol 
biosynthesis, with the former down regulating the latter. This research focuses on 
the primary sterol biosynthesis pathway consisting of 23 genes. Of these, only two 
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are also significant in microarray meta-analysis, one each for genes up regulated 
by IFN-γ (Ebp) and genes down regulated by IFN-γ (Mvd, a target of Srebp2). 
While this outcome does not help in further prioritisation of research, it 
independently verifies it and adds confidence to this analysis and its consistency. 
New hypotheses on the interaction between IFN-γ and sterol biosynthesis are 
included in the discussion section of this chapter.  
 
 
5.7 Master lists of identified candidate genes 
 
As a primary outcome in this thesis, master lists of novel genes identified by 
microarray meta-analysis and with independent supporting evidence available are 
included as tables 5.8 and 5.9. A complete list of meta-analysis-only discoveries 
(consensus lists) irrespective of supporting evidence is included in the 
supplementary material39. 
 
For tables 5.8 and 5.9, list inclusion criteria apart from significant meta-analysis 
outcome are: supporting evidence in form of MITCH12 time course expression 
profiles, relevant literature, STAT1 binding site (GAS motif) in the gene’s 
promoter region, known reversible inhibition of virus replication by IFN-γ. Novel 
IFN-γ regulated genes are identified as rows without shading (row shading 
indicates genes are known as stimulated by IFN-γ type I, II, or III). Ordering of 
genes in theses tables is based on the number of pieces of supporting evidence 
(equal weight assumed), although this does not imply genes with less supporting 






                                                
39 Folder “MetaAnalysisResults”, file “CategorisedCumulatedGeneList.xlsx” 
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M6pr Y  Y Co-localises with Stat1 and HPIV proteins, allowing virus to block IFN signalling (Schomacker, Hebner et al. 2012) 
Rnf14 Y Y Y  
Stx4 
(Stx4a) Y  Y 
Rate-limiting step of TNFa production in macrophage activation 
(Pagan, Wylie et al. 2003) 
Tbk1 Y Y  Induction of Ifn-beta, IRF3 through TLR (Hemmi, Takeuchi et al. 2004, Perry, Chow et al. 2004) 
Abcc5 Y Y   
Ahrr Y  Y  
Batf  Y  
Inhibits AP-1 activity and affects T-cell proliferation (Thornton, 
Zullo et al. 2006). Induced by STAT3 (Senga, Iwamoto et al. 
2002). Protein forms complex with IRF4 and JUNB (Tussiwand, 
Lee et al. 2012) 
Cd47 Y   Binds macrophage SIRPa (Oldenborg, Gresham et al. 2001). Listed as ISG (de Veer, Holko et al. 2001) 
Clic4 Y   
Regulates M0 deactivation (Malik, Jividen et al. 2012). In 
bacterial M0, induced by LPS and positive regulator of LPS (He, 
Ma et al. 2011) 
Ehd1 Y Y   
Igbp1 Y   Depletion enhanced induction of STAT1-dependent genes (Fielhaber, Han et al. 2009) 
Ikbke Y   
Critical for regulation of IFNb and ISGs (Takeuchi, Hemmi et al. 
2004). Restores RIG-I dependent antiviral response on HepC 
infection (Breiman, Grandvaux et al. 2005). Regulates balance 
between type I and type II interferon responses (Ng, Friedman 
et al. 2011). 
Klf3  Y Y  
Lgals8  Y  Inhibition of IL-6 production in M0 (Yang, Jiang et al. 2011) 
Marcks  Y  Candidate biomarker for interferon therapy response (Huang, Tu et al. 2008) 
Psen1 Y Y   
Raf1  Y  Component of MAPK cascade (Farrar, AlberolaIla et al. 1996, Jesenberger, Procyk et al. 2001) 
Stard3 Y   Cholesterol transport (Strauss, Liu et al. 2002) 
Tmod3 Y Y   
Tpm3 Y Y   
Ankib1   Y  
Arf3  Y   
Atad1 Y    
Capza2 Y    
Casp12    Stimulated by IFN-γ in fibroblasts (Kalai, Lamkanfi et al. 2003) 
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Fbrs - Y   
Fxc1  Y   
Gosr2    In HepG2 cells, TNFa up-regulates Gosr2 (Pandey, Munjal et al. 2010) 
Hivep2   Y  
Inpp1 Y    
Itga4    Induced by IFN-γ in monocytes (Waddell, Popper et al. 2010) 
Kiaa0247 -  Y  
Ktn1 Y    
Lrp10 
(Lrp9) Y    
Mrpl13  Y   
Ms4a4b Y    
Obfc2a - Y   
Ppap2a Y    
Slc35b1 Y    
Tox4 -  Y  
Txndc17 - Y   
Usp12 Y    
Vcan - Y   
Bcl3 Y Y  
Protein is known to interact with p50 and p52 subunits of NF-
kappaB (Schwarz, Krimpenfort et al. 1997). Suppresses p53 
activation and induced apoptosis (Kashatus, Cogswell et al. 
2006). Inhibits IL-10 expression in M0 (Riemann, Endres et al. 
2005) 
Birc2 Y Y  
Up 
regulation protects B cells from deletion, allows for IgA secretion 
(Husain, Holodick et al. 2006) 
Junb Y Y  STAT3 binds to Junb promoter (Oh, Kim et al. 2009) 
Pnpla2 Y Y Y  
Arl6ip5 Y Y   
Cflar Y   Controls NF-kappaB activation in DCs (Golks, Brenner et al. 2006) 
Lpp Y Y   
Ly6a Y   T-cell proliferation, regulated by TNFa (Henderson, Kamdar et al. 2002) 
Mertk Y   
Regulates TNFa and M0 activation (Camenisch, Koller et al. 
1999, Sather, Kenyon et al. 2007).Innate immunity (Behrens, 
Gadue et al. 2003) Stat1 activation. 
Mxd1 Y   Induced by IFN-γ, inhibits M0 mitogenesis (Dey, Kim et al. 1999) 
Rgs14 Y Y   
Sfpi1 Y   
Blocks T-Cell development. Regulates macrophage 
differentiation in response to cytokines. Regulates transcription 
of IL7Ra (DeKoter, Walsh et al. 1998, DeKoter, Walsh et al. 
1998, Anderson, Weiss et al. 2002) 
Hnrnph2 - Y   
Mafk Y    
Ubr4 - Y   
Genes in this table are up regulated (statistically significant) by IFN-γ microarray meta-
analysis, where this result is also supported by independent evidence. Independent 
supporting evidence is defined as the gene having a notable expression profile in the 
MITCH12 microarray time course study (identified through GEViSE tool), containing a 
STAT1 binding site (GAS motif, identified through oPOSSUM software) in its promoter 
region, having been identified as reversible inhibitor of viral infection through IFN-γ 
(Kropp, Robertson et al. 2011), or having had literature related to immune responses - 
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irrespective of a specific relation to type II response in murine macrophages – published 
(identified through PubMed with combined searches of the official gene symbol and 
“interferon”). The number of pieces of supporting evidence are also used to sort genes 
within the table, with equal weight given to all evidence sources. Gene symbols in bold 
font are those that can be considered high-confidence findings on merit of their 
identification through all three meta-analysis model families. Shaded rows indicate that a 
gene is already known as regulated by IFN-γ through the Interferome database 
(irrespective of it being known as a type I, II, or III regulated gene). A horizontal dash in 
the MITCH12 column indicates that the gene was not found within the MITCH12 


































































Ptpre Y Y  
Inhibits JAK-STAT signalling in leukaemia cells (Tanuma, 
Nakamura et al. 2000). Up-regulated during differentiation 
and/or activation of macrophages, and its overexpression 
suppress IL-6 and IL-10-induced JAK-STAT signalling (Tanuma, 
Shima et al. 2001) 
Csnk1e Y   Control of circadian rhythm through PER2 degradation (Eide, Woolf et al. 2005) 
Dbi Y   Regulated by SREBP-1c in hepatocytes (Neess, Kiilerich et al. 2006) 
Galnt6 Y Y   
Hyal2 Y   
Entry receptor for a sheep retrovirus. Disassociation from RON 
allows activation of Akt and MAPK cascade (Danilkovitch-
Miagkova, Duh et al. 2003) 
Lta4h Y   Proinflammatory lipid mediator (Billharz, Zeng et al. 2009) 
Map2k3  Y  
Essential for TNF-stimulated p38 MAPK activation (Brancho, 
Tanaka et al. 2003). Related to IL-12 activated immune 
response pathway through p38 and STAT4 (Watford, Hissong et 
al. 2004) 
Map4k4  Y  Activation of TNFa promoter (Mack, Von Goetz et al. 2005) 
Nfatc1  Y  May express IL-4 independent of Stat6 (Wang, Kusam et al. 2006) 
Nfya  Y  Reduces induction of JunB by IL6 (Sjin, Krishnaraju et al. 2002) 
Nisch Y Y   
Pde7a  Y  In T-cells, increase correlates with IL2 (Li, Yee et al. 1999) 
Pgrmc1  Y  Putative steroid-binding protein (Nolte, Jeckel et al. 2000). Binds to SCAP and Insig-1 ( both part of a complex in sterol 
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biosynthesis) (Suchanek, Radzikowska et al. 2005) 
Sirpa Y   Cd47 binds macrophage Sirpa protein and suppresses phagocytosis (Oldenborg, Gresham et al. 2001) 
Vamp3  Y  Related to macrophage phagocytosis (Allen, Yang et al. 2002) 
Arid2  Y   
Asxl1  Y   
Atp6V0a1 Y    
Cdt1 Y    
Dnajc11  Y   
Dock7  Y   
H1fx  Y   
Isca1 - Y   
Lrrfip1    
Repressor of TNFa (Suriano, Sanford et al. 2005). siRNA 
against LRRFIP1 was found to inhibit type I IFN production 
induced by [listeria] (Rathinam and Fitzgerald 2011, Thompson, 
Kaminski et al. 2011) 
Mapk1    Transcriptional repressor of interferon (gamma) signalling (Hu, Xie et al. 2009) 
Mvd Y    
Nudt5  Y   
Pik3r2 Y    
Ppan Y    
Prpf19  Y   
Ptp4a1  Y   
Reep6  Y   
Rrp1b - Y   
Snrk Y    
Snx21 - Y   
Synj2 Y    
Tspan5 Y Y   
Usp2  Y   
Usp48  Y   
Wdr48 Y    
Capn2  Y   
Degs1 Y    
Elk3 Y   (note: strong MITCH12 expression profile, but up-regulated in time-course while down-regulated in meta-analysis) 
Gps1  Y   
Hey1  Y   
Rab11a    Promotes phagocytosis in M0 (Cox, Lee et al. 2000) 
Tshb  Y   
Genes in this table are down regulated (statistically significant) by IFN-γ microarray 
meta-analysis, where this result is also supported by independent evidence. Independent 
supporting evidence is defined as the gene having a notable expression profile in the 
MITCH12 microarray time course study (identified through GEViSE tool), containing a 
STAT1 binding site (GAS motif, identified through oPOSSUM software) in its promoter 
region, having been identified as reversible inhibitor of viral infection through IFN-γ 
(Kropp, Robertson et al. 2011), or having had literature related to immune responses - 
irrespective of a specific relation to type II response in murine macrophages – published 
(identified through PubMed with combined searches of the official gene symbol and 
“interferon”). The number of pieces of supporting evidence are also used to sort genes 
within the table, with equal weight given to all evidence sources. Gene symbols in bold 
font are those that can be considered high-confidence findings on merit of their 
identification through all three meta-analysis model families. Shaded rows indicate that a 
gene is already known as regulated by IFN-γ through the Interferome database 
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(irrespective of it being known as a type I, II, or III regulated gene). A horizontal dash in 
the MITCH12 column indicates that the gene was not found within the MITCH12 





This chapter aims to answer the primary question if meta-analysis of a modestly-
sized set of similarly-themed small microarray transcription studies can reveal new 
biological research spotlights that cannot be obtained by the analysis of the 
individual studies alone. Before discussing outcomes related to specific genes, a 
number of issues relating to the information and interpretation methods in this 
chapter require consideration. 
 
5.8.1 Discussion of issues relevant to result interpretation 
 
Complete type II interferon response. An alternative and worthwhile pursuit for a 
more biological thesis would consist of a complete analysis of all genes regulated 
directly and indirectly by IFN-γ. This would be accomplished by considering all 
genes with a statistically significant meta-analysis result, irrespective of a gene 
also being identified as statistically significant in the analysis of any one of the 
microarray studies. However, in this thesis the emphasis must lie on the statistical 
performance of meta-analysis beyond the prospects of single-study analyses. That 
is, what biology does a meta-analysis uncover that cannot be uncovered by an 
individual study? Given this focus, the results in this chapter cannot cover the 
complete transcriptional response to IFN-γ and will lack well-known actors or 
modifiers of the type II response, because these will almost by definition be those 
genes showing strong transcriptional responses to IFN-γ stimulus, and therefore be 
among the first discoveries made in any microarray study (or other platform). This 
affects reference comparisons, where gene list overlap with known ISGs would 
likely be much higher if individual study results were included. It also affects 
summary output in form of STRING (Franceschini, Szklarczyk et al. 2013) protein 
interactions within the identified gene lists, with many potential interactants 
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missing. This is one of the major considerations to be aware of in any reading of 
this chapter. 
 
Biological framework. All microarray studies used in meta-analysis are 
investigating the effect of IFN-γ (with different doses and time points) on murine 
macrophages. This is a more specific framework than the research into interferon 
stimulated genes (ISGs) here used as reference in form of the interferome database 
and in-silico STAT1 binding site identification, because the latter also covers type 
I and type III responses and distinctions are not always clear. This is not 
necessarily a crucial factor to be taken into account, as many interactions between 
these signalling pathways continue to be found. Because interferons of all types 
may have an effect on or be influenced by a type I interferon response, it is here 
not considered useful to remove findings not obviously related to type II 
interferon. A similar argument applies to accepting reference findings from cell 
types other than macrophages, because aspects of JAK-STAT or other signalling 
found in immune cells other than macrophages may also apply to macrophages but 
lack current confirmation, encouraging further laboratory testing of hypotheses. 
 
Interferome database. Although probably the largest resource of ISGs, this 
database cannot be considered comprehensive. While it may have considerable 
overlap with ISGs other research groups have arrived at through proteomic, single-
gene or other laboratory platforms, there is little doubt that numerous important 
candidates are not included. This does lessen the interpretation of “candidate 
ISGs” used in this chapter, in that a gene may not be contained in the interferome 
database and on cursory investigation not known to a given researcher, but it may 
be an obvious and known ISG to others, based on published research they are 
familiar with. 
 
Objective standards. The statistical meta-analysis of microarray studies can be 
considered objective, but there are two areas in the biological interpretation of 
their results that can suffer from subjectivity. One is the use of temporal gene 
expression profiles as provided by MITCH12 (see 5.4.1). Measured across 12 
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hours, few genes exhibit entirely straightforward expression level changes. The 
interpretation of those is therefore dependent on an individuals’ perception of what 
constitutes a clear rise, drop, peak or trough, or what constitutes an overall profile 
of interest. In order to alleviate this, the results discussed in more detail in this 
chapter are limited to expression changes that are above 2-fold (up or down). 
Summary tables will also contain information of lower confidence. The second 
area is gene annotation, where a compromise must be found between thoroughness 
of investigation and inclusiveness of results. Because of the number of genes 
involved, not all available sources of annotation or literature can be assessed for 
each gene. Information provided here is therefore based on a subjective 
assessment of relevance. This includes annotation for genes obtained for the 
human rather than mouse genome, implying homologous function which is not 
necessarily true. 
 
Gene sets. A by-product of comparing multiple meta-analysis models is the 
number of gene lists this produces. While it is possible to broadly assess their 
differences and features (chapter 3), it makes a thorough look at biological context 
of each list difficult. The gene list consolidation into one list of 106 IFN-γ up 
regulated and 152 down regulated genes was therefore necessary but will of course 
not allow further conclusions on which meta-analysis provides the most 
biologically relevant results. In that context, an interesting but here omitted list 
(included in supplementary material) are those genes only identified by a single 
meta-analysis model to the exclusion of all others. 
 
Transcriptomics. A general complication of “omics” approaches is the discrepancy 
between hypothesis driven and data driven research. Microarray studies are not 
initialised with one or just a few hypotheses regarding the role of particular genes 
in a system in question. This thesis covers the analysis of such data and will 
therefore always provide data driven (potential) answers to questions that were not 
posed. Apart from the use of highly domain-specific knowledge allowing 
immediate identification of interesting (where this entirely depends on the 
operator) genes amongst results, the optimum achievable results are usually gene 
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lists with varying amounts of prioritisation. It is always the case that these require 
experimental follow-up in prospective laboratory studies, and this thesis is no 
exception. 
 
Overlap between meta-analysis and known biology. The biological context of 
microarray meta-analysis results appears to be relevant to the biological question 
of transcriptional responses to IFN-γ stimulation of cells. This statement is 
supported by non-random overlap between differentially regulated genes obtained 
through meta-analysis and genes already known to be part of IFN-γ signalling and 
transcription. This point is strengthened by the fact that gene lists obtained through 
meta-analysis do (by design) not contain any of the statistically significant results 
that are discovered in any individual microarray studies. One side effect of this is 
ineffectiveness of gene set enrichment tests. While tools such as DAVID40 are 
often used to identify significant clusters of functional annotation categories with 
submitted gene lists, this is here problematic because meta-analysis consensus lists 
(with 106 up and 152 down IFN-γ down regulated genes) do not contain any of the 
genes statistically discovered in individual studies and are therefore “de-enriched” 
for direct IFN-γ transcriptional responses. Additionally, with these consensus lists 
expected to produce IFN-γ stimulated genes as yet unconfirmed by other research, 
existing gene annotation categories may not reflect their function within type II 
responses. Use of DAVID in this case results in a majority of genes without 
current annotation classes, with the remainder of genes belonging to significant 
clusters of important but unspecific nature, for interferon up regulated genes these 
are transcription regulation, intracellular transport, protein localisation, membrane, 
transmembrane and nucleotide binding, for interferon down regulation these are 
phosphorylation, kinase activity and membrane. 
 
5.8.2 Discussion of genes in biological context 
 
Interactions between interferon signalling and sterol biosynthesis. Several of the 
potential new ISGs suggested by meta-analysis correspond to a recently suggested 
                                                
40 http://david.abcc.ncifcrf.gov/ 
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role of interferon as a regulator of antivirally acting 25-hydroxycholesterol 
production in macrophages (Blanc 2013). Mvd and Ebp are already verified 
interactors in sterol biosynthesis and meta-analysis here confirms opposite but 
significant reactions to IFN-γ (with Mvd down regulated and Ebp up regulated). 
However, meta-analysis also provides novel genes for interactions between type II 
interferon signalling and sterol biosynthesis. Stard3 is identified as up regulated by 
IFN-γ, which is strongly confirmed in the MITCH12 time course study. Literature 
suggests a role for Stard3 in cholesterol transport (Strauss, Liu et al. 2002) and an 
only unimportant role in sterol biosynthesis (Kishida, Kostetskii et al. 2004). In 
macrophages Stard3 overexpression does not affect SREBP2 transcription but 
represses lipogenesis (Borthwick, Allen et al. 2010). However, these studies do 
not cover interferon signalling in response to infection, making this a worthwhile 
hypothesis for further laboratory work.  
Pgrmc1 (here down regulated by IFN-γ and tendentially but not conclusively 
confirmed by the time course study) has been shown to directly interact with 
SCAP and Insig-1 (Suchanek, Radzikowska et al. 2005) and to promote sterol 
biosynthesis in embryonic kidney cells (Hughes, Powell et al. 2007). If these roles 
can be confirmed in macrophages, a new hypothesis would consist of IFN-γ down 
regulating Pgrmc1, and therefore affecting the SCAP, Insig-1, SREBP complex in 
its regulation of sterol synthesis. 
Two additional new hypotheses linking IFN-γ signalling with sterol biosynthesis 
could be based around the expression pattern similarity of both Itga4 and Obfc2a 
to Ch25h (STAT1 induced, couples interferon response to 25-hydroxycholesterol) 
when analysed by a clustering algorithm in a microarray time course study (not the 
MITCH12 study used for validation in this chapter) involving 8 hours of treatment 
with IFN-γ. This information is obtained from table S1 and figure 6 of Blanc et al 
(Blanc 2013) but is not verifiable through the MITCH12 time course and as such a 
weaker proposition. 
Lrp10 (alias Lrp9) as a membrane protein may serve in the uptake of apoE-
containing lipoproteins (Sugiyama, Kumagai et al. 2000) and SREBP2 protein 
mediates Ldlr gene transcription in hepatic cells (Huang, Zhou et al. 2008) and in 
humans Ldlr protein has been shown (Brodeur, Theriault et al. 2012) to have a 
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subfamily containing Lrp10 (Lrp9 in mice).  While this is far from conclusive, 
strong up regulation by IFN-γ is confirmed in MITCH12, pointing to a possible 
hypothesis around Lrp10 taking part in the interaction between interferon 
signalling and sterol biosynthesis over SREBP2. 
Three further meta-analysis outcomes related to recent research into sterol 
biosynthesis are Galnt6, Rab11a and Golga4, all down regulated by IFN-γ 
(Golga4 is not part of the master table due to lack of supportive evidence in the 
used references) but awaiting further research. 
Another IFN-γ induced (as identified by meta-analysis and verified by MITCH12 
time course data) gene is Ehd1, its protein has been suggested to associate with 
fibroblast LDL receptor and regulate cholesterol uptake (Naslavsky, Rahajeng et 
al. 2007) and be involved in the transport of Rab11 containing vesicles 
(Naslavsky, Rahajeng et al. 2006), which would have relevance to the above 
mentioned Rab11a in our in-house research on crosstalk between type II interferon 
immune response and sterol, especially since there appears to be no published 
research on Ehd1 in context of cytokine activation available at this time. 
 
Crosstalk between type I and type II interferon signalling. Meta-analysis here 
confirms potential mechanisms of crosstalk between these two pathways as 
described in Kropp et al (Kropp, Robertson et al. 2011). Induction of a known type 
I interferon signalling gene - Tbk1 – identified in that study under low IFN-γ dose 
is here confirmed by meta-analysis of several studies. Although the meta-analysis 
includes the microarray study used in that paper, it is not statistically identified in 
that study (due to more stringent criteria). However, the effect of IFN-γ on Tbk1 is 
consistent across microarray studies (ranging from low dose to very high dose of 
IFN-γ) and therefore identified through meta-analysis.  
Not an outcome related to the Kropp et al study, Ikbke (alias IKKε or IKK-i) is a 
known regulator of antiviral signalling and has recently been proposed (Ng, 
Friedman et al. 2011) as a regulator of the crosstalk between type I and type II 
interferon pathways in that by phosphorylating STAT1 it suppresses formation of 
STAT1 homodimers and thus shifts the transcriptomic response to type I 
interferon. Meta-analysis would here underline the fact that in absence of viral 
 199 
infection, treatment with IFN-γ does lead to small but consistent up regulation of 
Ikbke where the question would be if this is to regulate type I interferon stimulated 
genes and/or to act as feedback control for type II interferon stimulated genes. 
Ikbke is also suggested to be functionally equivalent (production of interferon beta 
through IRF3 or IRF7) to Tbk1 (Ikeda, Hecker et al. 2007). The presence of both 
Tbk1 and Ikbke in meta-analysis-only results implies that in many transcriptional 
studies they will not be identified as statistically significant, which is reinforced by 
their absence from the (microarray-based) Interferome database. This would 
support a closer investigation into their combined effect on type I- type II 
crosstalk. 
 
Batf. It has been shown that IFN-γ suppresses IL10 production by suppressing AP-
1, thus augmenting TNFa induction (Hu, Paik et al. 2006). With BATF known as 
an inhibitor of AP-1 mediated gene expression (Deppmann, Thornton et al. 2003), 
consistent up regulation by IFN-γ in microarray meta-analysis may suggest that 
this regulation is involved in crosstalk between type II interferon and IL10 
signalling pathways. 
 
Clic4 is known to be up regulated through LPS or combined LPS and IFN-γ 
treatment (Malik, Jividen et al. 2012), although its function is still under 
investigation. He et al (He, Ma et al. 2011) investigated its role in infection and 
found the Clic4 gene to be induced by LPS and to act as a positive regulator of 
LPS signalling through IRF3 phosphorylation. The induction of Clic4 in 
macrophages is here confirmed by microarray meta-analysis (and reinforced by 
the MITCH12 time course), using a range of treatment times and doses. Notably, 
none of the microarray studies use LPS in their treatment regime, suggesting that it 
is not only LPS signalling through TLR receptors that is involved, but that type II 
interferon alone may have downstream effects on IRF3 through Clic4.  
 
In meta-analysis, Ptpre is found to be down regulated by IFN-γ, in the MITCH12 
time course this is also true for the first six hours, after which it returns to original 
levels. In published research, a cytosolic isoform of its protein has been found to 
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inhibit IL-6 and IL-10 induced JAK-STAT signalling (Tanuma, Shima et al. 2001) 
by preventing phosphorylation of STAT3. The same research also suggested that it 
does not affect STAT phosphorylation by type I or type II interferon signalling. 
While this research was not in macrophages, it may allow to hypothesize that IFN-
γ down regulation of Ptpre could aid in the induction (or prevention of inhibition) 
of JAK-STAT signalling, and based on MITCH12 data, that this effect is transient. 
 
Csnk1e is a known circadian clock gene (PER2 associated), and limited research 
into the interactions between cytokine signalling and clock genes has shown that 
TNFa and IL-1b suppress clock genes (including Per2) in mouse fibroblasts 
(Cavadini, Petrzilka et al. 2007); that murine macrophages contain an intrinsic 
clock that may regulate innate immune responses (Hayashi, Shimba et al. 2007); 
and that antiviral responses could be under circadian control via the JAK-STAT or 
NF-kB pathway in human T-cells (Bollinger, Leutz et al. 2011). It is currently not 
clear how extracellular IFN-γ suppresses circadian clock associated gene Csnk1e 
but the outcome from this study would suggest that it contributes to the antiviral 
state through immediate-early mechanisms, with MITCH12 showing that it starts 
returning to original expression levels after 4 to 5 hours after IFN-γ treatment. 
 
Down regulation. While the initial set of genes that meta-analysis identifies as 
IFN-γ down regulated is larger than the set of up regulated genes, the amount of 
available corresponding evidence (or lack thereof) is less and may be related to 
common research biases favouring up regulation as reported outcomes. While this 
makes prioritisation of research spotlights problematic in general, confirmation for 
down regulation is still provided by the independent time course microarray study, 
possibly raising the importance of also following through research on IFN-γ down 
regulated genes. It is also notable that all of the genes identified as down regulated 
by meta-analysis and strongly confirmed by MITCH12 time course have a 
transient down regulation and reverse to their original expression levels by 12 
hours after treatment (figure 5.3). It is unclear if this is a chance finding, if it is 
related to the nature of observable down regulation in microarray studies; or 
indeed if this is biologically meaningful.   
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JAK-STAT. Two unexpected results in terms of their presence in the meta-
analysis-only results are Sfpi1 (a known regulator of STAT) and Junb (known to 
be induced by STAT1 or STAT3). In theory, these should have been identified as 
statistically significant in some of the individual microarray studies as well as 
meta-analysis and therefore not be present in these results. This indicates 
inconsistent responses to IFN-γ treatment across microarray studies, possibly 
brought about by different treatment regimes. It is also possible that the use of 
different measurement time points results in those probes as sometimes up, 
sometimes down regulated, for which there is a slight indication in the microarray 
time course data (where expression levels fall and rise again over time).  
 
Conclusion. Many priority (higher up in the master tables) genes identified would 
appear to fit directly into interferon-related processes or into processes which have 
recently been identified within the Ghazal lab or elsewhere to be relevant to the 
interferon response (sterol pathway, type I interferons). With meta-analysis 
identifying genes of lower transcriptional activity than those in the main IFN-γ 
response (which were subtracted from these results prior to interpretation), the 
mechanism by which individual genes fit into the established JAK-STAT pathway 
and set of ISGs is not easy to identify. If one assumes that meta-analysis was 
successful in identifying novel gene functions, then their ultimate confirmation 
within the system of interest (type II immune response in murine macrophages) 
relies on prospective laboratory studies, with existing research on these genes 
often only confirming relevance if allowing for entirely different treatments, cell 
types or organisms. This chapter demonstrates that a statistical meta-analysis of 
even a small and heterogeneous set of microarray studies can provide results that 
match the expected biological framework and provide novel hypothesis for 
experimental validation. However, statistical meta-analysis results are not self-
evident or free of false positives, making a secondary review of results with a 
biological emphasis a necessity. This requires analysts to either obtain a sufficient 
amount of specialist biological knowledge or to collaborate very closely with 








This chapter test the ability of an enhanced network analysis to identify genes or 
gene sets with coordinated activity over time, and develops a hypothesis for 
Trafd1 involvement in sterol biosynthesis upon IFN-γ activation of macrophages. 
 
A network analysis of IFN-γ microarray time course data is complementary to the 
case-control nature of microarray studies used in meta-analysis. Where meta-
analysis in this thesis can only combine snapshots (with individual study design 
prescribing different doses and different measurement time points) of the effect of 
IFN-γ treatment on macrophages, a time course allows identification of potential 
causal relationships between genes by measuring their co-expression levels over a 
period of time. While lacking the statistical rigour of meta-analysis, network 
analysis provides a nuanced data set for validation and discovery of new biology. 
 
The work in this chapter is motivated by a) the availability of time course 
microarray data with a relatively large number of time points, b) the use of the 
same data (although only the IFN-γ time course) for direct validation of meta-
analysis results (see chapter 5), and finally c) the supposition that a methodical 
(although not objective or statistically rigorous) network analysis can identify 
meaningful gene set expression patterns in a time course study. An attempt is 
made to reduce common network (and clustering) analysis bias in form of guiding 
the analysis towards expected biological results, by avoiding trial-and-error 
parameter choices that are judged on expected biological outcomes. Instead, 
parameters are chosen based on the computational ability of the applied processing 
steps. This chapter does not propose a correct or optimal set of parameters 
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applicable to other data sets, but a general multi-step approach that in this case 
leads to interesting high-level results. 
 
Gene expression profiles obtained from this microarray time course study into the 
time-dependent effects of IFN-γ or murine cytomegalovirus were also used as part 
of the independent validation of meta-analysis results (chapter 5), but in a purely 
gene-by-gene approach. This chapter expands on the results by utilising similarity-
structures across genes in a time course (network analysis). 
 
6.1 Macrophage activation and function 
 
Established models for classical and alternative macrophage activation are 
introduced in chapter 1, and here supplemented by further pathway information 
relevant to gene transcription network analysis. 
The activation and function of macrophages is a complex process, centred on 
intricately coordinated networks of gene and protein expression that balance the 
level and duration of anti-inflammatory and pro-inflammatory macrophage 
functions in order to maximise harmful effects towards pathogens while 
minimising harmful effects towards the host. Many immune cells can produce 
multiple cytokines and chemokines, and cytokines and chemokines can be 
produced by multiple types of cells. Many cells will produce proteins that can both 
boost and reduce further immune responses (such as type I IFN). Classical 
activation of macrophages includes not just cytokine-mediated activation 
(primarily type II IFN signalling), but also activation through pathogen 
recognition (TLR signalling) and activation through immune receptors of other 
immune cells (ITAM signalling). While many aspects of signalling cascades and 
downstream products of individual signalling pathways are understood, less is 
known about the complex crosstalk between them (Hu, Chen et al. 2007). 
Feedback loops, crosstalk and overlapping cell functions result in highly complex 
scenarios driven by many factors (time, expression levels, location). The 
description provided below can therefore only serve as a simplifying overview. 
 
 204 
Macrophages can be activated by recognition of host factors (cytokines, primarily 
IFN-γ), recognition of pathogens by TLRs or recognition of other immune 
receptors (e.g. present on B or T cells). Respectively, these invoke IFN signalling, 
TLR signalling and ITAM signalling in the macrophage. 
Member genes and proteins of signalling pathways differ and the downstream 
effect of macrophage activation depends on many factors, but it can be 
summarised as production of cytokines (TNFα, IFNα, IFNβ, IL-1b, IL-6, IL-10, 
IL-12, IL-18), cell surface molecules (MHC), growth factors (TGFβ), and other 
molecules (nitric oxide, reactive oxygen). These four groups affect, respectively, 
inflammatory processes, antigen presentation, tissue repair and killing of 
pathogens. While this grouping may suggest mutual exclusivity of function, this is 
not necessarily the case (e.g. nitric oxide can activate transcription factor NF-kB). 
Products of activated macrophages drive both pro-inflammatory and anti-
inflammatory processes, where the proportion will depend on the stage or level of 
infection, with the aim of mounting a sufficiently sized response to pathogens 
before returning cytokines to homeostatic levels after pathogen eradication and 
tissue repair.  
This fine-tuning of increasing or decreasing inflammatory processes depends on 
positive and negative feedback loops and interactions between TLR, ITAM and 
IFN signalling, and the balance between macrophage-activating and macrophage-
suppressing factors. A prominent example of the latter is the balance between 
IFN-γ and IL-10, with IFN-γ inhibiting IL-10 production and driving expression of 
pro-inflammatory genes via activation of STAT1, and with IL-10 suppressing 
TLR signalling and driving expression of anti-inflammatory genes via STAT3. 
 
Gene co-expression analysis of a microarray time course study in theory enables 
global identification of coordinated gene expression as it occurs where a) 
macrophages are immune-activated without presence of a pathogen (treatment 
with IFN-γ), b) macrophages are activated by pattern recognition receptors 
through viral infection in the absence of (initial) IFN-γ and c) IFN-γ activated 
macrophages are challenged with the same viral infection. Gene co-expression 
measured for these three conditions would be expected to identify different 
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patterns of regulation, with condition (a) initially only engaging type II signalling, 
but viral recognition (b) engaging TLR signalling. The study described here is 
referred to as MITCH12 and described below. 
 
6.2 Microarray time course study 
 
MITCH12 is a microarray study consisting of three independent time courses, 
which measure the effect of IFN-γ, the effect of murine cytomegalovirus 
(MCMV), and the combined effect of IFN-γ and MCMV. For each time course, 
expression level measurements are taken over 12 hours, in 30-minute intervals and 
starting at 0 hours (i.e. 25 time points per time course). The study is described in 
detail and with a graphical overview in chapter 2, section 2.8.2. 
 
Classical macrophage activation is achieved when both an IFN-γ signal and 
pathogen recognition (LPS signal) occur, which in case of MITCH12 is provided 
only by the third condition. However, even this experiment condition does not 
establish full macrophage function, due to completely missing interactions with 
other types of immune cells. Therefore, this study’s aims are in the identification 
of isolated signalling pathways and limited interactions between them in the 
absence of full system complexity. 
 
 
6.3 Network analysis introduction 
 
It is common in microarray studies to identify genes that behave similarly across 
samples (or samples that behave similarly across genes) in terms of their measured 
expression level. When using gene (or sample) expression profiles to determine 
relatedness of genes, network analysis has the goal of identifying co-expressed 
sets of genes (or samples). Unlike related methods (clustering algorithms like K-
Means or Support Vector Machines), network analysis accepts more diverse 
inputs, such as defining relationships between genes in other ways than expression 
profile distance/similarity (e.g. known interactions between their proteins). 
Partitioning into gene sets is performed by topographical rather than clustering 
 206 
algorithms, that is, genes are visually arranged in a 2D or 3D view based on their 
measure of relatedness, genes are represented as single nodes rather than gene 
expression profiles, and the strength or nature of relatedness between genes is 
indicated as lines (edges) between those nodes. 
In this chapter, visual co-expression networks are identified on the basis of gene-
gene correlation. The entirety of all gene-gene Pearson correlations is referred to 
as adjacency matrix or correlation matrix, with the resulting network often referred 
to as a “guilt-by-association” network. The adjacency matrix is here enhanced to 
remove redundant gene-gene relationships (Partial Correlation & Information 
Theory, described in detail below) and the gene networks visually laid out through 
a topographical algorithm contained in Cytoscape (see discussion). The use of 
simple adjacency matrices (characterised by measuring similarity rather than 
distance between genes) is externally motivated in that Pearson correlation (as an 
R analysis function) has previously been parallelised (coded for use on large 
computing systems with multiple CPUs) in collaboration41 between DPM and the 
Edinburgh Parallel Computing Centre, with the purpose of facilitating 
computation of large adjacency (or distance) matrices as they can occur with high-
throughput biological platforms. 
 
6.4 Network analysis 
 
6.4.1 Input data 
 
The input microarray data set was processed (background corrected, normalised 
and log2 transformed) as described in chapter 2, and performed by another 
member of DPM for a previous analysis (Mizanur Khondoker, unpublished work). 
This also included a non-specific filtering step to reduce the number of gene 
probes from the original full set of 22393 gene probes to 14299 gene probes with 
“non-flat” expression profiles (also excluding control probes).  
 
                                                
41 www.r-sprint.org 
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6.4.2 Computation of adjacency matrices 
 
For each microarray time course, Pearson’s product-moment correlation 
coefficient r is computed for all possible gene-gene pairs (14819 x 14819 = 
219,602,761) across 25 time points. This identifies positive or negative linear 
relationships between gene expression profiles or vectors, with r= 1 signifying 
identical profiles and r=-1 signifying exactly opposite profiles. It should be noted 
here that the use of correlation coefficients means the absolute expression level of 
a gene is irrelevant and it is only the “shape” of the expression profile that 
determines the correlation coefficient.  
 
6.4.3 Size reduction of adjacency matrices 
 
An arbitrary but necessary (for computation efficiency of the following and other) 
step is introduced to remove genes that do not correlate well with any other gene. 
In order to remain in the adjacency matrix, a gene has to satisfy a minimum 
requirement of |r|>=0.95 for correlation with at least one other gene. 
 
6.4.4 Removal of redundant gene-gene correlations through PCIT 
 
At this stage, the gene adjacency matrix contains all (filtered) gene-gene Pearson 
correlation coefficients, but the absence of any weighting means that if one were 
to draw a network of all these genes now, it would contain both essential and 
redundant information. “Redundant” here amounts to a lack of causal inference 
regarding the correlation of any two genes, or technically, the association between 
two genes depends on a common third (correlated to both of those genes). For 
example, if gene X is correlated with gene Y, and a gene Z is correlated with both 
X and Y, the question arises if the correlation between X and Y is causal in itself 
or if the real causal relationship is between X and Z and Y and Z. Rather than 
imposing further arbitrary correlation thresholds to separate “good” from “bad” 
correlations and increase direct causal relationships in the data, approaches have 
been developed that aim to empirically determine this distinction from the data 
and therefore lead to better (but not perfect) causal relationship content in the 
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resulting gene network. This is here done using PCIT, a partial correlation and 
information theory algorithm (Reverter and Chan 2008). Briefly, for each trio of 
genes, this calculates the original 3 Pearson correlation coefficients between them, 
in addition to the 3 partial correlation coefficients (correlation between two genes 
with removal of the effect exerted by a third gene). The average ratio between 
original (0th order) correlation coefficients and partial (1st order) correlation 
coefficients is then used to inform a threshold based on which an association 
between the two genes in questions is judged significant or not. This is repeated 
for each possible gene trio, meaning that each gene-gene pair is tested for the 
influence of any other individual genes in the data set. An example of this is 
provided in figure 6.1.   
 
Figure 6.1 Overview of PCIT algorithm
 
PCIT combines partial correlations with a information-theory approach in order to remove 
indirect gene-gene relationships. A) For any trio of genes (this example uses genes X,Y,Z) 
in the microarray data set, the three possible Pearson correlation coefficients are 
computed, denoted as rxy, rxz and ryz. They contain no information about the linear 
association between two genes with respect to the contribution of a third gene to this 
association. B) Partial correlation coefficients are computed for the same gene-gene 
associations, taking into account their possible dependence on a third gene. The new 
coefficients are denoted as rxy.z, rxz.y and ryz.x ,where the last letter indicates the gene used 
for conditioning. C) Ratios between the partial correlation coefficient and full correlation 
coefficient are computed for each gene pair and subsequently averaged as “tolerance 
































based on the original correlation exceeding ε in the other two gene pairs, in this case 
leading to removal of the edge between X and Y. The process is repeated for all possible 
gene trios in the data set. 
 
6.4.5 Basic visualisation of all remaining gene-gene associations 
 
Before assessing visual networks based on remaining correlation coefficients 
between gene pairs, general correlation structure is assessed through clustered 
heatmaps of the adjacency matrix. 
 
6.4.6 “Guilt-by-association” networks 
 
Adjacency matrices for each time course were reformatted for import into 
Cytoscape, with correlations serving as edge weights in 2D networks. Apart from 
colour-labelling and graph rotation, all node positioning was entirely left to the 
topographical algorithm, that is, no further manual manipulations (e.g. individual 
node repositioning) were applied to the algorithm-generated network layout. 
 
 
Code for processing of data prior to network analysis can be found in R script 




Before constructing a co-expression network, global structures in the three time 
courses are visualised through a heatmap showing clustered scaled gene 
expression levels. The full data set cannot be used for this purpose because a) 
computational capacity to perform clustering is usually limited to ~2000 genes (on 
the computer used for analysis) and b) noise in form of genes never changing 
expression levels (low variation) or never exceeding some expression threshold 
(low intensity) obstructs clustering algorithms. Here, the 2000 most variable genes 
(standard deviation, measured across all three time courses) are further reduced to 
exclude genes without a single expression level measurement above the maximum 
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of all 75 sample medians, resulting in 1377 gene probes for clustering shown in 
figure 6.2. 
 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Expression data (scaled across all 75 samples) 
 [red=virus, blue=Ifng, black=both] 
 n=1377 highest variance genes with min 1 sample above grand median






















Agglomerative hierarchical clustering of 1377 genes probes with high variation and 
above-median intensity in at least one sample. Genes in rows, samples in columns. Time 
courses are identified by the colour bar on top of the graph (red=virus, blue=IFN-γ, 
black=virus+IFN-γ) and arranged in chronological order from 0h on the left to 12h on the 
right. Genes expression values are scaled (across all 75 samples, mean=0, standard 
deviation=1), the resulting z-score is represented by colours: red cells= expression above 
mean for this gene, blue cells= expression below mean for this gene. The added 
annotation on the right indicates subjective gene clusters of interest, with A= genes down 
regulated over time, B=genes with transient down regulation, C= up regulated genes, D= 
different regulation patterns between time courses, and E=C. 
 
Figure 6.2 is here added to provide a general data overview. While there are 
clusters of interest amongst the most variable genes, such as distinct sets of up 
(C,E) and down regulated genes (A,B) and in particular sets of genes with 
different expression patterns in the three conditions (D), this is part of a general 
analysis and not part of the network generation as discussed in this chapter. 
The general overview can further be elaborated on by finding indications for how 
the three treatments differ, and a summary graph of genes expressed above a given 
threshold at each time point and for each condition is presented in figure 6.3. 
Based on the evidence from highly-expressed genes, gene activation is time-
dependent and all three conditions are reasonably similar (within about 50 genes 
difference at all time points). In terms of a conventional analysis looking at high 
expression and high expression changes, this would conceivable limit analytical 
results to a relatively small set of genes. This serves as partial motivation to 
investigate if the use of gene correlation patterns can provide more information. 
 
Figure 6.3 Count of highly-expressed genes per time-point 
 
For each sample (= time point), z-scores were calculated for each gene probe. Highly 
expressed genes were defined as those for which expression levels are greater than or 







equal to three standard deviations above the sample mean (z>=3). X-axis is divided into 
25 half-hourly time points, Y-axis is the count of highly expressed genes at that time point 
(the scale shown ranges from 100 to 200). Red line represents the virus time course, blue 
line the IFN-γ time course and dotted black line the combined virus+IFN-γ time course. 
Horizontal reference lines are the time course average counts across all 25 time points 
(top=IFN-γ, middle=virus, bottom=virus+IFN-γ). 
 
 
6.5.1 Size reduction of initial adjacency matrices has notably different 
effects on the IFN-γ time course 
 
Initial filtering of genes reduces the starting set of 14299 genes in the three time 
courses to 1779 (IFN-γ), 2834 (MCMV) and 2911 genes (combined interferon 
treatment and MCMV), respectively. This simple filtering out of genes without at 
least a single correlation to another gene better than r=|0.95| reduces the 
computational burden from 204 million gene pair correlations to 3.2, 8.5, and 8 
million, respectively. It should be noted that adjacency matrix of course contain 
self-to-self and duplicated (reversed) gene-gene correlation pairs, meaning the 
above sizes are n2 (where n is the number of individual genes in data set), but from 
a network point of view only !
!!!
!
 are unique and required. However, the full 
number of computations is still necessary due to the following processing step 
requiring a complete correlation matrix as input. Subsequent removal of redundant 
gene-gene correlations identified by PCIT further reduces the size of adjacency 
matrices (which is the number of gene-gene correlations) to 0.8, 2.5 and 3.6 
million, respectively. While PCIT has considerably reduced the number of gene-
gene correlations based on objective criteria and therefore enriched a potential co-
expression network for direct relationships, the resulting matrix sizes are still too 
large to serve as input for Cytoscape (see discussion). A further reduction of 
matrix sizes is therefore required, with a correlation strength threshold chosen to 
reduce the (largest) adjacency matrix to a size that can be accepted by Cytoscape 
when run on a 4-core MacPro with 9Gb of RAM). This reduction is here achieved 
by retaining a gene-gene correlation pair only if the absolute correlation 
coefficient |r| ≥0.9. Unfortunately, this also removes lower-valued correlations that 
still may be significant as identified by PCIT (a perceived advantage of that 
approach). Table 6.1 summarised the initial number reductions. 
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Table 6.1 Adjacency matrix size reduction steps 







Initial data set 204 204 204 
After 1st filtering 3.2 8 8.5 
After PCIT 0.8 3.6 2.5 
Cytoscape input 0.07 0.16 0.13 
This table states (unit=millions) the number of pair-wise gene correlations that make up 
an adjacency matrix (a square matrix of Pearson correlation coefficients measured for 
every possible combination of two genes’ linear similarity of expression profiles across all 
time points in a time course data set). For example, if the full input of 14299 genes are 
used for correlation, this results in 142992=204,461,401 correlation coefficients computed. 
First filtering refers to removal of genes that are not highly correlated (|r|>= 0.95) with at 
least one other gene (excluding itself). PCIT removes gene-gene pairs based on their 
statistical independence from a common third gene. “Cytoscape input” refers to a further 
necessary filtering step to reduce the adjacency matrix to a size that can be handled by 
Cytoscape, every time-course only precedes with those gene-gene correlations better than 
|r|>=0.9 (i.e. the threshold is the same for all three time courses and based on the 
necessary size reduction for the largest set). 
 
 
With identical (even if arbitrary for correlation thresholds) criteria applied to each 
time course, early indications are the IFN-γ treatment is different from the other 
two conditions, affecting (reducing) the number of observed gene-gene 
similarities. 
 
6.5.2 Gene cross-correlation maps show structural differences 
between the three time-courses 
 
Prior to exporting data to Cytoscape (and thus reducing the size of the adjacency 
matrices), a useful visualisation of the existing gene correlation matrices (after 1st 
filtering and PCIT) is a simple plot of all correlation coefficients, as shown in 
figure 6.4 below. It should be noted that gene-gene correlations highlighted in 
green are those manually set to 0 because they did not pass the PCIT identification 
of significant correlations. As already clear from table 6.1, IFN-γ has notably 
fewer gene-gene correlations, but the visually observable differences also suggest 
that IFN-γ affects the coordination of genes that can be seen in virus-infected 
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macrophages. In IFN-γ treated macrophages, fewer genes are co-expressed, but in 
distinct gene sets. The combination of virus infection and IFN-γ treatment would 
appear to display an intermediate scenario. Although this cannot be assumed to be 
of statistical or biological significance, it gives cause to speculation (not tested in 
this thesis) that the virus is actually coordinating gene expression, and that this can 
be disrupted by IFN-γ. Taking all three outcomes into account, this implies there 
could be intrinsic differences between initial IFN-γ receptor signalling (IFN-γ 
treatment) and initial toll-like receptor signalling (on virus recognition).  These 
may be due to induction or inhibition of different downstream genes (and pro- or 
anti-inflammatory cytokines) but technical shortcomings of viral infection cannot 
be discounted. That is, at Multiplicity-Of-Infection 1.0, work within the Ghazal 
group (data not shown) has shown that 30-40% of macrophages do not go on to 
express viral genes, which will affect measured mRNA transcription on the full 
macrophage population. 
Also of interest here are negative gene-gene correlations, that is genes with a given 
expression trajectory that is seen inverted in other genes. In virus-infected 
macrophages, these can be described as a small number of genes negatively 
correlated with a large number of other genes. In IFN-γ treated macrophages, a 
small number of genes is negatively correlated with a small number of other 
genes. 
In interpretation it is important to keep in mind that adjacency matrices (and later, 
networks) may portray visually compelling structures but lack numerical 
indicators for their significance. 
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Figure 6.4 Gene cross-correlation maps  
 
This graph visualises the gene adjacency matrices for each time course. Rows and 
columns represent the same set of genes and are sorted by a clustering vector derived from 
genes’ correlation coefficients. Each graph pixel is the Pearson correlation coefficient for 
a pair of genes. The diagonal indicates self-self correlations of a given gene. Pixels in the 
red colour spectrum are positively correlated, pixels in the blue spectrum are negatively 






here. The maps contain 0.8, 3.6 and 2.5 million correlation coefficients for IFN-γ, Virus 
and IFN-γ+Virus, respectively. 
 
 
A closer look at structural properties is obtained by transforming the gene 
correlation matrices into gene co-expression network graphs, representing gene 
similarity by edges drawn between gene nodes, and the overall layout informed by 
strength of correlation, number of correlated genes and other parameters useable in 
the visual arrangement of nodes. As a point of procedure, a perceived expression 
level increase for many genes at the 90 minute time point (which could in theory 
be biological fact or technical artefact) was separately tested for its influence on 
network structure, but the removal of this time point had no discernible effect on 
the resulting graphs (data not shown) or outcomes discussed here. 
 
6.5.3 Cytoscape gene co-expression networks show structural 
differences between the three time courses as well as particular gene 
“hubs”	  
 
To examine gene co-expression patterns in greater detail, topographical gene co-
expression networks generated in Cytoscape (figures 6.5a-c) are based on a layout-
algorithm that determines the visual organisation of genes (nodes) through the 
supplied correlation coefficient information. The IFN-γ time course exhibits a 
remarkably different network structure, with three distinct “subnetworks” 
separated by a few “hub” genes that have similarities to genes in two subnetworks 
but do not fully match expression profiles in either. Interpreted at the highest level, 
these networks are (naturally) similar in information content to the structure 
revealed in figure 6.4, with virus-infected macrophages resulting in a dense 
network of closely correlated genes. If topological layouts are assumed to have a 
basis in the underlying biology (and this cannot here be confirmed), it could be 
suggested that this infection either coordinates gene expression of this set, or does 
not affect homeostatic coordinated gene transcription at all (although the latter is 
less likely given that the combined infection+treatment time course displays an in-
between state that would not exist if virus infection had no effect on 
macrophages). In contrast, in interferon-gamma treated macrophages this tight 
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network is disrupted, with treatment causing genes to follow different expression 
trajectories over 12 hours. The actual expression profiles (data not shown) of 
genes in these subnetworks are not prominent in themselves (e.g. slow expression 
increases with some variability), which suggests that applying a standard 
clustering algorithm (Partitioning-Around-Medoids, PAM) would likely result in 
ignoring these gene sets in favour of those with strong expression changes, in 
effect favouring expression level over gene-gene relationships. 
 
6.5.4 Cytoscape gene co-expression networks show alignment with 
meta-analysis results	  
 
Highlighted gene nodes (red = up regulated by IFN-γ, blue = down regulated by 
IFN-γ) on figures 5a-c identify significant meta-analysis results that overlap with 
the MITCH12 time course microarray study. The limited number of highlighted 
genes is solely caused by genes not passing the correlation strength limits set by 
the network analysis. That is, where meta-analysis may identify an individual gene 
of consistent but low transcriptional changes, network analysis may exclude them 
because their expression is not sufficiently similar or independently correlated to 
another gene. All IFN-γ up regulated genes (n=20) are part of the immune 
response subnetwork, with down regulated genes (n=3) not stringently associated 
with any single subnetwork. Discussed in chapter 5 and amongst the notable 
matches between meta-analysis and network analysis are Stard3, Cd47, M6pr, 
Clic4, Lrp10, Tbk1, Mxd1 (all up regulated) and Ptpre (down regulated). For these 
genes, it would appear sensible to consider co-expressed genes into any 
formulated hypotheses. Notably, many of these genes (e.g. Stard3, Clic4, Tbk1, 
Lrp10) maintain strong co-expression (to other genes) when non-activated or 
activated macrophages are challenged with cytomegalovirus (figures 5b and 5c). 
In these other two biological conditions, expression trends are roughly similar to 
that of the IFN-γ activation alone, but they are by no means identical across the 
entire 12-hour period. In terms of interpretation, maintaining co-expression levels 
with other genes does not indicate that expression levels or patterns are not 
affected by the biological condition in question. 
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Figure 6.5a IFN-γ treatment, gene co-expression network 
 
Gene co-expression network generated with Cytoscape (v2.8.0), using as input ~70,000 
gene-gene correlation coefficients. Nodes are genes, orange edges between nodes 
represent high positive correlation between the two connected genes, black edges 
represent high negative correlation. Highlighted nodes are genes identified as significant 
in meta-analysis (red=up regulated by IFN-γ, blue = down regulated by IFN-γ). 
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Figure 6.5b Virus-infection, gene co-expression network
 
Gene co-expression network generated with Cytoscape (v2.8.0), using as input ~160,000 
gene-gene correlation coefficients. Nodes are genes, orange edges between nodes 
represent high positive correlation between the two connected genes, black edges 
represent high negative correlation. Highlighted nodes are genes identified as significant 




Figure 6.5c Combined virus+IFN-γ, gene co-expression network
 
Gene co-expression network generated with Cytoscape (v2.8.0), using as input ~130,000 
gene-gene correlation coefficients. Nodes are genes, orange edges between nodes 
represent high positive correlation between the two connected genes, black edges 
represent high negative correlation. Highlighted nodes are genes identified as significant 
in meta-analysis (red=up regulated by IFN-γ, blue = down regulated by IFN-γ). 
 
 
6.5.5 Cytoscape gene co-expression networks may indicate different 
biological functionality.	  
 
Using IPA (Ingenuity Pathway Analyzer), the gene sets contained in the major 
IFN-γ subnetworks were tested for significant overrepresentation of gene ontology 
annotation categories. The uppermost subnetwork is significantly enriched for 
immune response, stress response and cell division genes, the middle subnetwork 
is enriched for general cellular processes, and the lowermost subnetwork for G-
Protein coupled receptor activity, olfactory receptor activity and transmembrane 
receptor activity. Given the larger number of cross-correlated genes in the viral 
time course, enrichment is less specific and mainly limited to protein binding 
events. The time course with combined virus infection and IFN-γ treatment has 
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two distinct subnetworks that match IFN-γ, with the two small rightmost 
subnetworks enriched for G-Protein and olfactory receptor activity. These results 
are here listed only as general pointers of interest, since interpretations of large 
gene co-expression networks are not free of subjective bias. 
 
6.5.6 Trafd1 (alias Fln29) 	  
 
Trafd1 is anti-correlated to sterol biosynthesis genes. Recently, sterol metabolism 
has been shown to be part of an intrinsic component of interferon signalling 
(Blanc 2013). In this context, the single node that in IFN-γ treated macrophages 
connects the uppermost subnetwork (“immune response”) to the middle 
subnetwork (“cellular processes”) is Trafd1 (of the multiple probes representing 
this gene, the most highly expressed is the one in question here). While it would 
be an over-interpretation to assume that Trafd1 has an actual biological coupling 
function between two distinct gene sets (because co-expression does not 
automatically imply biological function), their distinct location in the 
topographical layout motivates a closer examination. 
Trafd1 It is positively correlated to 86 genes in the middle subnetwork and 138 
genes in the upper subnetwork, but of particular interest are 19 genes with which it 
is negatively correlated in the upper subnetwork. Simple examination of these 
genes flags up Sqle and Sc4mol, both of which are participants in the sterol 
biosynthesis pathway and interact with SREBP2. This generates enhanced interest 
in Trafd1 because research within the Ghazal group (Blanc 2013) had identified a 
likely link between an interferon induced antiviral response (mediated through 
STAT1) in macrophages and the synthesis of 25-hydroxycholesterol (which acts 
downstream of the above two genes and proteins). However, Trafd1 was not 
known in this context.  Its 12 hour expression profile in the IFN-γ time course is 
presented in figure 6.6 and includes the expression profiles of Srebf2 (activator of 




Figure 6.6 Trafd1 and Srebf2 expression profiles on IFN-γ treatment of 
macrophages 
 
Following IFN-γ treatment, 12-hour expression profiles of Trafd1 (red), showing anti-
correlation to Srebf2 (orange, dotted) and Srebf1  (blue, dashed). X-axis shows 25 half-
hourly time points (starting at 0 hours and ending at 12 hours), Y-axis shows normalised 
absolute log2 scale expression level. 
 
 
Expanding the interest in anti-correlation to the full sterol pathway (Table 6.2, 25 
genes) shows that there is a general tendency for down regulation (indicated by 
anti-correlation with up regulated Trafd1) of these genes, even if they do not pass 











Acat1 acetyl-Coenzyme A acetyltransferase 1 -0.06 
Hmgcl 3-hydroxy-3-methylglutaryl-Coenzyme A lyase 0.25 
Hmgcs1 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 -0.86 
Hmgcr 3-hydroxy-3-methylglutaryl-Coenzyme A reductase -0.54 
Mvk mevalonate kinase -0.08 
Pmvk phosphomevalonate kinase -0.01 
Idi1 isopentenyl-diphosphate delta isomerase -0.67 
Mvd mevalonate (diphospho) decarboxylase -0.53 
Fdps farnesyl diphosphate synthetase -0.54 
Ggps1 geranylgeranyl diphosphate synthase 1 0.70 
Ggps1 geranylgeranyl diphosphate synthase 1 0.72 
Dhdds dehydrodolichyl diphosphate synthase -0.53 
Fdft1 farnesyl diphosphate farnesyl transferase 1 -0.84 
Sqle squalene epoxidase -0.91 
Lss lanosterol synthase -0.63 
Tm7sf2 transmembrane 7 superfamily member 2 -0.02 
Ebp phenylalkylamine Ca2+ antagonist (emopamil) binding protein 0.06 
Sc5d sterol-C5-desaturase (fungal ERG3, delta-5-desaturase) homolog (S. cerevisae) -0.72 
Dhcr7 7-dehydrocholesterol reductase -0.88 
Dhcr24 24-dehydrocholesterol reductase -0.47 
Dhcr24 24-dehydrocholesterol reductase -0.78 
Cyp51 cytochrome P450, family 51 0.13 
Sc4mol sterol-C4-methyl oxidase-like -0.90 
Nsdhl NAD(P) dependent steroid dehydrogenase-like -0.06 
Hsd17b7 hydroxysteroid (17-beta) dehydrogenase 7 -0.66 
 
 
This assessment of negative correlation promotes further investigation of Trafd1. 
Firstly, its expression in IFN-γ stimulated macrophages is experimentally verified, 
passively through an existing other microarray time course study and actively 
through qPCR and siRNA experiments carried out in the Ghazal group for this 
purpose.  Secondly, existing knowledge on Trafd1 is summarised. 
 
Trafd1 significant in multiple microarray studies. Trafd1 is significantly (to 
several decimal places, and by any statistical test) up regulated by IFN-γ in all four 
microarray studies that form part of the meta-analysis in chapter 3. It is therefore 
also significant in meta-analysis, but not included amongst results in chapter 5 
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because its significance in individual studies means it does not match the criterion 
of meta-analysis-only discovery. 
 
Trafd1 up regulation confirmed in independent time course study. A study of the 
effects of IFN-γ on macrophages was carried out within the Ghazal research group 
(subsequently to and independently of MITCH12), utilising a different microarray 
platform and experimental protocols. The retrieved expression profile for Trafd1 
(figure 6.7) suggests 2-fold up regulation (or higher, if considered relative to a 
mock condition) over a period of 7 hours, broadly confirming the trajectory 
observed in MITCH12. 
 
Figure 6.7 Trafd1 expression in an independent time course study 
 
Graph of the absolute log2 scale expression levels (Y-axis) of Trafd1 in a time course of 
IFN-γ treated murine bone marrow derived macrophages. Y-axis represents time periods 




Trafd1 up regulation confirmed through real time quantitative PCR. A 
quantitative real time PCR experiment carried out (in triplicate) in validation of 
Trafd1 confirms up regulation by IFN-γ in wild type mouse macrophages, where 
this is further established by IFN-γ not being up regulated in Stat1 knock-outs. 





Figure 6.8 Trafd1 mRNA expression validation 
 
Graphs show levels of mRNA expression of Trafd1 in response to IFN-γ treatment 
(100u/ml), shown in relation to mock treatment. Each treatment was measured at 6 and 24 
hours in bone marrow derived macrophages (BMDM) cultured from either wild-type 
mice, interferon alpha receptor (IFNAR1) knock-out mice or Stat1 knock-out mice. Bars 
represent the means ± standard error of the mean of n=3 biological replicates (=mice).  
These experiments were performed using Real Time quantitative Reverse Transcription 
PCR (qRT-PCR) based on TaqMan Applied Biosystems, with experiments run and 
analysed by Mathieu Blanc within the Division of Pathway Medicine. The TaqMan qRT-
PCR and the treatment protocol used has been described previously (Blanc, Hsieh et al. 
2011)  and only differs in the use of the gene tested, which is here Trafd1 (TaqMan primer 




siRNA assay of Trafd1 suggests but does not confirm anti-viral effects. A 
validation study of Trafd1 knocked down (figure 6.9) by four different siRNAs 
(each done in triplicate) shows increased viral growth relative to RISC control, 
suggesting that Trafd1 may have a direct or indirect role in restricting viral 
growth, although the strength of this evidence is not beyond doubt. This may be 
due to this type of siRNA assay lacking sensitivity to detect increases rather than 
decreases, with observations (within the Ghazal group) up relative increase 

















incomplete until a larger number of replicate runs (10-12) are performed beyond 
the three shown here. 
 
Figure 6.9 Trafd1 laboratory validation in siRNA knock-down
 
Experiment data provided by Wayne Hsieh, Ghazal group. Four different (in terms of 
sequence) siRNA probes are used to knock down Trafd1 in order to observe the effect on 
viral growth. Each knock down is performed in triplicate, but error bars are not added to 
this graph because it has not reached the final experiment size of 10-12 replicates. 
Construction of the GFP-encoding Murine Cytomegalovirus (MCMV-GFP, originally 
named: pSM3fr-rev) used in this study was previously described (Angulo, Ghazal et al. 
2000, Angulo, Ghazal et al. 2000). The virus was propagated in mouse NIH-3T3 
fibroblasts. For Trafd1 experiments, 1.5×104  primary murine embryo fibroblasts cells 
(pMEF) in 80 µl of DMEM 10% CS medium lacking antibiotics was added to the 
siRNA:Dharmafect 1 complexes. Growth medium was removed and 100 µl of the siRNA: 
Dharmafect 1 liposomes were added. 48h post transfection, the transfection media was 
first removed. Cells were then infected with GFP tagged murine cytomegalovirus 
(MCMV-GFP) [multiplicity of infection (MOI = 0.05] for 1h at 37° C.	  Virus replication 
was monitored as a function of eGFP fluorescence hours post-infection (24-72h for 
MCMV) using the POLARstar OPTIMA plate reader (BMG Labtech). Virus replication 
slopes over the linear phase were calculated and normalised to Risc Free transfected cells, 
and the mean replication was calculated.  M54 siRNA was used as a positive control as it 




Known or proposed Trafd1 functions. Trafd1 is suggested to be a negative 
regulator of the innate immune response and modulation of inflammatory function 
in macrophages. Specifically, Trafd1 is known as interferon-inducible and LPS-
inducible, with its induction STAT1-dependent (Mashima, Saeki et al. 2005). 
Sanada et al (Sanada, Takaesu et al. 2008) identified Trafd1 as a negative 
feedback regulator of TLR, suppressing TLR4-mediated NF-kappaB activation by 
binding to TRAF6. Others (Richards and Macdonald 2011) also suggest binding to 
TRAF3, but in either case the binding interrupts anti-viral signalling, with the 
actual mechanism unknown. A summary of this information is provided in figure 
6.10. There appears to be no known function of Trafd1 (or its binding partner 
Traf6) relating to sterol biosynthesis. 
 
Figure 6.10 Schematic overview of known Trafd1 function 
 
Pathways drawn with yED graph editor. Dotted lines indicate binding with the effect of 
inhibition of the targeted signalling pathway, although the mechanisms remain unknown. 
 
 
Other “hubs”. Based on the amount of supporting evidence available through 
annotation, biological interest in Trafd1 has here outweighed interest into that of 
the other subnetwork-connecting genes in the IFN-γ network, and these are 
Olfr1116 and Wdfy2. For these, little is known about their functionality, although 
the protein of Wdfy2 has been shown to interact with Foxo1 protein (Foxo1 is a 
transcription factor) for a putative function in promoting adipogenesis (Fritzius 
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and Moelling 2008) and Foxo1 has been identified as an inhibitor of cellular 
antiviral responses and IFN-β (Lei, Zhang et al. 2013). If their status as “hubs” is 
of similar relevance to that of Trafd1, validation of this functionality would 




Network analyses. As already recognised in the early days of microarray 
technology (Quackenbush 2003) and discussed to this day (Gillis and Pavlidis 
2012), guilt-by-association networks have some promise but are far from optimal 
in their ability to reliably identify biologically significant (rather than statistically 
or numerically significant) gene networks. Much of this is related to experiment 
design, which often does not capture true biological variation because the number 
of samples or biological conditions is too small. The selection of dis(similarity) 
metric is also of importance, and Pearson correlation was here only chosen on the 
basis of it having been the focus of a supercomputing-based collaboration. Time-
course studies have an advantage in that their interpretation is more 
straightforward (coordinated gene expression over time) than that for gene-
association analyses in studies with multiple biological conditions (if a gene 
maintains correlation in different biological settings, what does this signify). 
However, major drawbacks remain in form of assigning biologically significant 
function to genes or gene sets, requiring thorough follow-up work to verify results. 
 
Gene filtering. The addition of PCIT to the workflow is an attempt to reduce the 
final gene co-expression networks to only those genes that have a direct 
expression association and excluding those associations that can be readily 
explained by a common third gene. This approach does not ensure a causal-links-
only gene network, but should be enriched for it.  In theory, this is an 
improvement over simply choosing gene-similarity thresholds (in this case, 
correlation coefficients) with the assumption that all indirect gene-gene 
associations will have lower correlation levels. PCIT allows “weaker” gene-gene 
associations to remain in the data as long as they are statistically proven to be 
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independent of a third gene, making for a less objective threshold. In practice, the 
effect cannot be easily assessed on unknown data (i.e., outside simulations on data 
sets with known outcomes), and the improvements achieved may be diminished by 
a need for further massive reductions in data size due to computational limits. In 
this case, PCIT decreases gene-gene correlation matrices by a factor of around 2 to 
3 (table 6.1), but these considerable reductions still exceeds Cytoscape’s 
computational limitations on the available hardware. The therefore necessary 
arbitrary reduction to gene-gene correlations |r|≥0.9 excludes a large number of 
low but significant gene-gene associations. 
  
New hypotheses related to Trafd1. Prior research (Blanc, Hsieh et al. 2011, Blanc 
2013) has identified that the TLR signalling, interferon type I and type II 
signalling pathway may interact with the sterol metabolic, expanding the role of 
lipogenic transcription factors (SREBP-1, SREBP-2) from nutrient level 
regulation to responses to bacterial and viral infection. The evidence in this 
chapter is insufficient to suggest that Trafd1 has a causal relationship to reduction 
of sterol synthesis that is parallel to its role as negative regulator of TLR4 
signalling to prevent runaway innate immune responses. It is also unclear if the 
reverse may be a possibility, with reduced sterol synthesis leading to up regulation 
of Trafd1 and therefore reduction of TLR4-mediated responses. The (verified) 
evidence obtained in this chapter is limited to the statements that Trafd1 is induced 
by interferon-gamma mediated JAK-STAT signalling and that its induction and 
mRNA increases strongly (and coincides in terms of time points) with decreases in 
Sqle and Sc4mol (also Srebf1 and Srebf2) gene transcription. Taken together with 
Ghazal group findings on STAT1 being the link between interferon signalling and 
sterol biosynthesis, this warrants prospective experiments to confirm a role for 
Trafd1 beyond negative regulation of LPS-signalling. 
 
Comprehensiveness of analysis. This chapter provides only an isolated analysis, 
further analyses have been carried out (expression thresholding, fuzzy clustering, 
statistical tests for gene periodicity) and are planned (statistical test for time-
dependent gene expression changes). These have identified separate aspects (genes 
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involved in autophagy, genes potentially related to circadian rhythms, genes 
related to vesicular transport) that do not overlap with findings discussed in this 
chapter. The network analysis itself is also not fully comprehensive, in this chapter 
favouring the development of a particular targeted hypothesis over a complete 
listing of results, which includes complete sets of enrichment tests performed on 
subnetworks (using IPA or DAVID). This chapter also omits network-specific 
metrics regarding degree of node-connectedness, average path lengths, other 
methods of gene hub identification etc., mainly because interpretation of such 
outcomes cannot easily be associated with biology. The use of Cytoscape for 
generating network graphs is an additional limitation in the analysis workflow 
used here. Other R-based42 or external43 network graph tools may allow for higher 
maximum node or edge numbers, enabling relaxation of the here used final step of 
gene-gene correlation strength (|r| ≥ 0.9).  
 
Value of network analyses. While this chapter shows that explorative methods 
(cluster and network analyses) can be successful in identifying broad biology 
(here, global effects of IFN-γ treatment) and potentially interesting candidate 
genes (here, Trafd1), they remain very subjective in their use. That is, a different 
set of parameters and values (different gene-gene distance metrics, correlation 
thresholds, processing algorithms) may lead to equally valid but entirely different 
new findings and hypotheses. In this instance, care was taken to choose processing 
steps on the basis of computational limitations rather than on the basis of 
biological expectations, avoiding user bias. The work in this chapter was initially 
(before result interpretation) independent of the Ghazal groups work on sterol 
synthesis and results were therefore not guided towards these outcomes. Result 
interpretation is inevitably biased towards prior domain knowledge, which is 
unavoidable for “omics” type data, where algorithm-based (explorative or 
statistical) prioritisation of genes still produces sizeable gene sets that require 
either the prior domain knowledge mentioned above or sufficient means to 
investigate each constituent gene. Network analysis has here also demonstrated 




that it may in some cases surpass the usefulness of clustering approaches like K-
means or PAM, which do not highlight the role of individual genes and would not 
have called for further investigation of the mildly interesting expression profile or 
the set of genes anti-correlated to it. However, this does not mean network 
analyses can be taken at face value. It is in fact risky to do so, given that a gene 
co-expression network’s topographical layout is dependent on small differences 
that may not represent true biology because there are not sufficient numbers of 
samples or replicates to reliably recognise small differences. Additionally, any 
gene-gene correlation coefficients can be due to both (causal) biology or (non-
causal) random matches.  
 
Conclusions. Viral infection and IFN-γ activated macrophages appear to be 
distinct in their genome-wide coordinated responses, with the level of viral 
infection used here possibly controlling or negating expression of a large 
proportion of macrophage genes (resulting in high co-expression numbers). IFN-γ 
activated macrophages present an image of modular coordination, with immune 
response genes forming a separate subnetwork from genes with other or more 
generic functions. When infection is measured in activated macrophages, a 
visually intermediate scenario presents itself, and if representative of actual 
biology, this may come closest to a naturally occurring response (activated 
macrophages dealing with infection). While these are not unexpected findings as 
such, the results here encourage further work on detailed content of subnetworks 
identified in the IFN-γ and combined treatment/infection regimes. However, this 
work is outside the scope of this chapter and would also benefit from analysis 
methods with a less global approach, e.g. statistical analyses of the differential 
regulation between the treatment regimes, using specific gene sets of interest only. 
Trafd1 as a single gene hypothesis is attractive for further research, as it fits into 
(but does not stem from) a current research theme within the Ghazal group, and 
also shows some promise in identifying a further factor in the crosstalk between 
IFN-γ (which Trafd1 is not known for but here obviously present) and TLR 
signalling (which Trafd1 is known for as a negative regulator, but with direct TLR 
signalling or LPS treatment not used in this study). 
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With the above limitations in mind, an objectively applied (without expected 
outcomes in mind) network analysis can identify promising and otherwise 
unnoticeable biological hypotheses to pursue. Unlike statistical analyses they do 
not provide probabilistic results or predetermined significance thresholds. 
Combined with the above-mentioned risk of too much confidence in the quality or 
meaning of gene-gene correlations, successful outcomes require strong 








This research set out to investigate if the use of statistical meta-analysis techniques 
on a limited collection of small microarray studies can identify otherwise masked 
transcriptional changes in the IFN-γ activation of macrophages. Although the 
newer technology of high-throughput next generation sequencing is set to replace 
microarray technology in time, microarray meta-analysis remains an important 
subject given the continuing use of microarray technology and the availability of 
large numbers of legacy microarray data sets in public repositories. Additionally, 
despite a wealth of research into macrophage signalling pathways and interferon-
stimulated genes by microarray and other techniques, the field remains open for 
statistically powered solutions that are able to detect weaker but important genes 
involved in macrophage type II interferon signalling or by extension for other 
biological hypotheses such as a viral challenge in type II interferon signalling. 
 
The investigation of the primary research hypothesis above was converted into a 
framework of four research questions aimed to provide an increased understanding 
of which genes are involved in the type II interferon response in macrophages and 
how to detect them. 
- Firstly, can statistical meta-analysis provide meaningful biological results when 
applied to a heterogeneous (in terms of experiment design, not subject matter) and 
restricted set of small microarray studies? 
- Secondly, can existing meta-analysis models be improved? 
- Thirdly, can the potential scope of microarray meta-analyses be increased by 
imputing gene expression values that are missing due to merging of different 
microarray platforms? 
- Finally, can the existing body of knowledge with regard to IFN-γ-mediated JAK-




7.1 Research conclusions 
 
Taken together, this research has demonstrated that statistical meta-analyses are a 
suitable and improvable tool for primary identification of gene candidates in type 
II interferon signalling in macrophages, and that with the aid of biological domain 
knowledge these can be developed into novel biological hypotheses. 
Relevant findings are outlined below on the basis of the above stated research 
questions. Details on these are provided as part of section 7.2. 
 
Can statistical meta-analysis provide meaningful biological results when applied 
to a heterogeneous and restricted set of small microarray studies? 
All evidence obtained in chapters 3, 5 and 6 supports a positive answer to this 
research question. Chapter 3 provides quantitative evidence that a statistical meta-
analysis results in gene transcription discoveries not made in any individual 
studies and also points to clear advantages for non-parametric methodology (Rank 
Product meta-analyses and Fisher’s meta-analysis based on Rank Product tests). 
Chapters 3 and 5 corroborate that this quantitative improvement in terms of 
numbers of significant results can be biologically verified, both broadly against 
lists of interferon-stimulated genes in any experimental setting, and specifically 
against independent macrophage experiment data. A detailed investigation of final 
meta-analysis result lists provides clear and novel candidate hypotheses to be 
tested in a macrophage activation system. 
 
Can existing meta-analysis models be improved? 
Improvement of models was shown to be of utility for a set of heterogeneous 
microarray studies. Quantitative evidence suggests that the alternative weighting 
scheme (proportional study weighting) for the Rank Product meta-analysis shows 
favourable performance with increasing stringency of the alpha criterion (figure 
3.6), that is, lowering of the p-value significance threshold enables this method to 
identify more true positive genes than other methods. This trend is less clear for 
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the equal study weighting alternative, but both suggested methodology advances 
are an improvement over the original Rank Product meta-analysis, where this 
interpretation must currently be limited to cases in which the selected microarray 
studies are very unbalanced in terms of sample size. Moreover, in the selection of 
per-study analysis methods when applying Fisher’s combination of probabilities, 
to a heterogeneous data set, a Rank Product test should be favoured over a 
parametric test. 
 
Can imputation of missing gene expression values increase the scope of 
microarray meta-analyses? 
Remarkably, while not very sensitive or useful to obtain estimates of biological 
expression, statistical estimation of large numbers of gene expression 
measurements (which are missing not due to random errors or caused by other 
variables, but due to not all genes being represented on all microarray platforms) is 
more successful at recovering known statistical outcomes than analysis with 
missing values or, obviously, not analysing these genes at all. 
 
Can the existing body of knowledge with regard to IFN-γ-mediated JAK-STAT 
signalling in macrophages be expanded? 
Meta-analysis has identified (depending on model) 70 to 107 IFN-γ up regulated 
and 66 to 175 IFN-γ down regulated genes with expression too low or variable to 
be identified in any individual microarray study. Subsequent aggregation reduced 
this list to 106 up regulated and 152 down regulated genes, and corroboration 
against independent data sources specified priority lists for experimental 
validation, consisting of 58 up regulated and 47 down regulated genes, previously 
not known or strongly confirmed to have a role in type II interferon signalling in 
murine macrophages. In confirming better than random overlap between meta-
analysis results and known biology, biological and bioinformatical follow-up has 
highlighted several gene transcription hypotheses open to prospective testing. 
Many of these concern possible crosstalk between type I and type II interferon 
signalling (Tbk1, Ikbke, Clic4), between type II interferon signalling and IL-10 
signalling (Batf, Ptpre), are of interest in linking type II interferon signalling to 
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sterol biosynthesis in the macrophage (Stard3, Pgrmc1, Itga4, Obfc2a, Lrp10, 
Ehd1), or provide further possible insights in the regulation of between immune 
responses by the circadian clock (Csnk1e). 
 
7.2 Implications of research outcomes 
 
This research has implications at the level of statistical methodology as well as 
macrophage biology, and these are here discussed in context of existing 
knowledge. 
 
In terms of statistical methodology, this research is supportive of prior research 
(Rhodes, Barrette et al. 2002, Choi, Yu et al. 2003, Hong and Breitling 2008) in 
that the combining of multiple studies provides notionally more power to identify 
differential expression differences in case-control microarray studies. Where the 
cited studies have assessed this outcome mostly quantitatively and with only a 
very limited amount of biological validation, the research here has provided both 
numerical and biological evidence for the relevance of meta-analysis. 
 
Research findings here also support the conclusion (Hong and Breitling 2008) that 
non-parametric meta-analyses (Rank Product or Fisher’s model based on rank 
statistics) have advantages over parametric methodology (effect size models, 
Fisher’s model based on parametric test results) when using a small heterogeneous 
set of microarray studies. Earlier cases made for the use of parametric models 
(Choi, Yu et al. 2003) only find agreement here in terms of absolute numbers (in 
that any meta-analysis improves on single-study analyses), but not in terms of 
relative numbers when compared to non-parametric approaches. However, it is 
unknown how the Bayesian model proposed by Choi et al would fare in 
comparison to non-parametric models given the data sets used here. 
 
The research here also suggests that one particular improvement to Rank Product 
meta-analysis is beneficial over the standard model in cases of large study size 
heterogeneity. The here proposed proportionally weighted Rank Product meta-
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analysis has not been suggested before, and partially this may be due to previous 
research (Rhodes, Barrette et al. 2002, Choi, Yu et al. 2003, Hong and Breitling 
2008) having pragmatically or intentionally limited their real, standard or 
simulated microarray data sets to approximately balanced study sizes only; in 
these scenarios, similar study sizes mean the issue is less relevant. Clearly, as 
evidenced by the microarray studies available for type II interferon activation of 
macrophages, the issue exists, and the alternative weighting scheme proposed 
should be a primary choice in such cases. 
 
Large-scale imputation of a particular type of missing gene expression values in 
microarray meta-analyses has not been subject to research before, presumably 
because the notion of generating gene expression estimates for genes that are not 
included on a given microarray platform is not intuitive. However, the large 
number of genes which have to be omitted from a meta-analysis (or are subject to 
reduced power) for this reason have driven an actual investigation into this issue 
and found that in terms of statistically significant results, imputation recovered a 
larger proportion than simply accepting missing values (figures 4.5 and 4.6), with 
BPCA or a simple sample-wise regression leading to the best imputation 
estimates. This usefulness does not extend to reliability of differential expression 
measurements using imputed values. While showing more promise than expected, 
it requires dedicated further research to establish if this approach works well for 
microarray data sets with other characteristics than the ones used here, and for that 
reason its application to the meta-analyses performed in this thesis was considered 
premature. 
 
Meta-analysis has identified genes that are consistently regulated by IFN-γ in 
macrophages, with their characterisation for example pointing to a role in sterol 
metabolism. 
Concurrent but independent work within the Ghazal group of STAT1-mediated 
links between interferon response and sterol biosynthesis (Blanc, Hsieh et al. 
2011, Blanc 2013) suggests that the association of these genes with IFN-γ 
signalling should motivate prospective testing of the following hypotheses. 
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Up regulation of Stard3 by IFN-γ suppresses lipogenesis. A role in cholesterol 
transport (Strauss, Liu et al. 2002), sterol biosynthesis (Kishida, Kostetskii et al. 
2004) and repression of lipogenesis (Borthwick, Allen et al. 2010) has been 
previously identified outside an immune response context, but no literature 
currently supports its regulation by IFN-γ.  
Down regulation of Pgrmc1 by IFN-γ inhibits sterol biosynthesis via SCAP and 
Insig-1. As a direct interaction partner of SCAP and Insig-1 (Suchanek, 
Radzikowska et al. 2005), this gene is strongly associated with sterol biosynthesis 
and promotes sterol biosynthesis in some cells (Hughes, Powell et al. 2007), but 
this has not been shown in macrophages and no literature currently supports its 
regulation by IFN-γ. 
Up regulation of Lrp10 by IFN-γ is mediated by SREBP2 protein.  Evidence exists 
for Lrp10 to be indirectly mediated by SREBP2, although this has only been 
shown for human hepatic cells (Huang, Zhou et al. 2008) and it assumes that 
Lrp10 is a subfamily of LDLR protein as has been shown for humans (Brodeur, 
Theriault et al. 2012). No literature currently supports the (independently 
validated) meta-analysis finding of a relation to IFN-γ signalling. 
Up regulation of Ehd1 by IFN-γ regulates cholesterol uptake. Independent 
research suggests that Ehd1 regulates cholesterol uptake in fibroblasts and is 
involved in the transport of vesicles containing Rab11 (Naslavsky, Rahajeng et al. 
2006, Naslavsky, Rahajeng et al. 2007), where Rab11 itself is known to promote 
phagocytosis in macrophages (Cox, Lee et al. 2000) and meta-analysis here 
suggests its up regulation by IFN-γ. 
 
Meta-analysis has also identified genes that are consistently regulated by IFN-γ in 
macrophages, but where literature evidence only points towards type I interferon 
signalling, suggesting possible crosstalk between type I and type II interferon 
signalling. 
Up regulation of Tbk1 and Ikbke by IFN-γ causes a negative feedback loop 
enhancing type I interferon signalling over type II interferon signalling. Tbk1 is a 
known inducer of IFN-β and IRF3 through TLR signalling and type I interferon 
signalling (Hemmi, Takeuchi et al. 2004, Perry, Chow et al. 2004). The meta-
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analysis finding of Tbk1 regulation by IFN-γ is corroborated through a matching 
up regulation of Ikbke, where this gene has previously been found to be 
functionally equivalent to Tbk1 (Ikeda, Hecker et al. 2007). Ikbke has also been 
found to be a crosstalk regulator between type I and type II interferon signalling 
by phosphorylating STAT1 and preventing the formation of STAT1 homodimers 
and therefore shifting gene transcription towards type I interferon signalling (Ng, 
Friedman et al. 2011), while no such hypothesis has as yet been proposed for 
Tbk1. 
Clic4 is up regulated by IFN-γ and involved in macrophage deactivation through 
IRF3. Clic4 has been proposed as a regulator of macrophage deactivation in 
response to nitric oxide induction and LPS or LPS and IFN-γ signalling (He, Ma et 
al. 2011, Malik, Jividen et al. 2012). Through phosphorylation of IRF3 it may 
positively regulate LPS signalling, although the results of meta-analysis suggest 
LPS activation is not required as a primary trigger. 
 
Meta-analysis has further highlighted genes related to IL-10 signalling. 
Down regulation of Ptpre by IFN-γ induces or prevents inhibition of JAK-STAT 
signalling through phosphorylation. An isoform of the protein has been found to 
inhibit (in myeloid cells) IL-6 or IL-10 induced JAK-STAT signalling by 
preventing phosphorylation of STAT3. While meta-analysis suggests down 
regulation by IFN-γ, the above paper finds Ptpre not involved with STAT 
phosphorylation through type I or type II interferon responses. 
Batf up regulation by IFN-γ directly or indirectly inhibits IL-10 production.  In 
human macrophages, AP-1 (transcription factor required for IL-10 production) can 
be inhibited by BATF protein (Deppmann, Thornton et al. 2003) and it has been 
shown that IFN-γ also suppresses AP-1 (Hu, Paik et al. 2006). 
 
Meta-analysis has identified a potential role for IFN-γ in regulating molecular 
clocks. 
Csnk1e is down regulated by IFN-γ and directly or indirectly regulates the 
molecular clock in macrophages. The circadian or molecular clock has been found 
relevant to macrophages in their regulation of immune responses (Hayashi, 
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Shimba et al. 2007), with anti-viral responses under circadian control via JAK-
STAT signalling in human T-cells (Bollinger, Leutz et al. 2011). Csnk1e is a 
circadian clock gene associated with PER2, and although TNFa and IL-1b have 
been shown to suppress clock genes including Per2 in mouse fibroblasts 
(Cavadini, Petrzilka et al. 2007), no previous evidence supports the meta-analysis 
result of Csnk1e down regulation by IFN-γ. 
 
Network analysis of type II interferon signalling has shown meaningful overlap 
with meta-analysis results and emphasized biological importance and implications 
of negatively correlated gene expression patterns, here identifying a gene 
negatively correlated to sterol biosynthesis genes. 
In an independent validation of meta-analysis results, an objective network-
analysis of a microarray time-course study has shown that such data-driven 
methods (as opposed to hypothesis-driven meta-analyses) can lead to new 
biological insights despite a lack of probabilistic metrics and with explicit 
avoidance of bias in the various processing steps (i.e. not guiding results based on 
prior knowledge). In this case new biological insight has been identified in a 
topological network link (Trafd1) between two subnetworks as a possible direct or 
indirect connection between type II interferon signalling and the sterol 
biosynthesis pathway. The highlighting of Trafd1’s potential relevance to sterol 
biosynthesis is rooted in negative correlation patterns. Its general pattern of up 
regulation by IFN-γ over time is the inverse of that observed for two important 
sterol genes (Sqle and Sc4mol), and this negative correlation was obvious in a 
network graph but is unlikely to be found by other methodologies, although a 
complete listing of all highly anti-correlated gene pairs would of course contain it. 
In general terms, this should encourage closer investigation of strong negative 
correlation patterns within time course data, because related gene function may not 
always be indicated by positively correlated co-expression. In follow-up, a high 
proportion of other sterol pathway genes were also found to be negatively 
correlated (anti-correlated) to Trafd1 (table 6.2), including the activator of 
cholesterol biosynthesis (Srebf2, figure 6.7). In conjunction with recent findings 
(Blanc 2013) of a likely link between an interferon induced antiviral response  (via 
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STAT1) and synthesis of 25-hydroxycholesterol acting downstream of Sqle and 
Sc4mol genes and proteins, this resulted in a new hypothesis that Trafd1 may be a 
relevant actor in this link. This hypothesis is refined by existing research on 
Trafd1 as a negative regulator of TLR-mediated NF-kappaB activation (Sanada, 
Takaesu et al. 2008, Richards and Macdonald 2011) and inducible by interferon 
and LPS (Mashima, Saeki et al. 2005).  
 
Although there are limitations, if this research is generalised to other biological 
hypotheses and slightly different data compositions, it should provide a strong 
incentive to utilise large amounts of free and publicly available microarray data for 
formal, automatic and cost-effective meta-analyses, where an additional level of 
biological follow-up work by the analyst or a close collaborator is strongly 
indicated in order to propose laboratory-testable hypotheses. Given the observed 
advantages in combining statistical results with biological validation efforts, the 
results obtained in this thesis should also encourage inter-disciplinary learning.  
 
7.2 Limitations of research outcomes 
 
The biological hypothesis and meta-analysis approaches used in this thesis are 
subject to narrow parameters, with any conclusions not necessarily transferrable 
beyond the specified treatment (IFN-γ), the mouse bone marrow derived 
macrophage system, meta-analysis model and data set characteristics. In the 
strictest sense, these limit the interpretation of this thesis to the following 
statement: “Rank-Product and proportionally weighted Rank-Product meta-
analysis is clearly able to provide novel hypotheses for type II interferon signalling 
in murine macrophages if applied to a set of four differently-sized and Affymetrix-
based microarray studies investigating the effect of a range of doses of IFN-γ 
measured at different time points in the activation of macrophages”. 
 
Study selection. Although any of the meta-analyses used in this thesis are easy to 
apply on a prepared set of microarray studies, particular challenges are posed in 
the correct identification of suitable studies, the matching of gene probes between 
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studies and the processing of individual studies. These concerns are particularly 
applicable if microarray data sets are based on different platforms, raising issues 
of different measurement scales (dual-colour hybridisations versus single-colour 
hybridisations), probe representations (single 30-70mer oligonucleotide sequences 
or multiple small 11-mer or small oligonucleotides), and single-study analysis 
strategies. Although chosen for their experiment design similarities, the level of 
such similarity is difficult to define and does make no attempt to test the 
implications of mouse background (C57Black/6 or Balb/c), macrophage activation 
or development state. While the broad question “what effect does IFN-γ have on 
murine macrophages” is answered, different conclusions would likely be obtained 
if study selection were either more or less specific. 
 
Data simulation. Often, meta-analysis models (or any other new statistical 
approaches) are tested on “standard” data sets or simulated data. This was 
considered here, but those schemes were ultimately replaced by systematic 
biological assessments of results because a) standard data sets are only standards 
for historical reasons rather than purposefully generated, b) simulation would have 
to cover a prohibitively large parameter space (study size, variance, missing 
values, scale, proportions of high-fold-change-genes etc.) in order to truly 
generalise any results, and c) biological assessments can be seen as a reasonable 
compensation for the (albeit artificial) generalisation obtained through simulated 
or unrelated biological data. Here, the non-existent (for simulation) or very limited 
(for using standard data sets) biological validation is replaced by in-depth 
biological assessments of results in a global context (chapter 3) and in a system-
specific (chapter 5) context. As a consequence, findings in this thesis cannot 
support the use of Rank-Product meta-analysis as a suitable choice for all small 
collections of microarray studies, but as a choice that has been shown to work well 
in this example. 
 
Type II interferon signalling. While meta-analysis can provide a deeper 
understanding of IFN-γ initiated JAK-STAT signalling in macrophages, it is 
important to note that a complete characterisation of this pathway is not a goal in 
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the research carried out here. To address the main hypothesis of identifying small 
transcriptional changes otherwise masked by data variance in individual 
microarray studies, only those results were considered that are unique to meta-
analysis, that is, genes that are already significant in any individual studies were 
excluded from interpretation (see figure 7.1). This does for example dismiss 
Trafd1 (identified through network analysis) from discussion in chapter 5, as it is 
found to be significant in all of the individual microarray studies. However, if 
complete pathway characterisation is a goal and individual study results are 
included in the assessment of IFN-γ induced or regulated genes, limitations would 
still apply in that the studies used do not model the biological effects of other 
signalling pathways activated through pathogen recognition or through stimulation 
by other immune cells. 
 
Figure 7.1 Genes of relevance to this thesis 
 
The area enclosed in red represents (not to scale) genes identified through statistical 
testing (single-study inference tests or meta-analysis), where this number is dependent on 
data variance and number of studies. Microarray data with high gene expression variance 
increases difficulty to statistically identify differentially expressed genes, and a single 
microarray study has limited power to identify small expression changes with statistical 
significance. The shaded area contains those genes that are discovered only through the 
application of meta-analysis. The unshaded areas are statistically significant results 
obtained in single microarray studies and also form part of the response to IFN-γ 
macrophage activation, but their lower variance facilitates easier statistical identification 












Meta-analysis significance. Although probabilistic analyses are more objective 
than machine learning approaches, ultimate results are still dependent on choice of 
models and parameters, which is here relevant in two ways. Firstly, it is a given 
that acceptance of a less stringent (e.g. p<= 0.05 instead of p<=0.01) false positive 
error threshold would have led to a larger number of genes identified as significant 
and may have produced further biological hypotheses. Secondly, the use of a 
multiple testing correction algorithm could also have performed the role of a more 
stringent alpha level, and would be recommended for citing significance levels in 
publication, but for comparing meta-analysis results this would have introduced a 
further element of complexity in that the correction methods commonly used 
differ for the three meta-analysis models, and would also differ for statistical 
testing performed in individual studies. Although not used here because the issue 
multiplies the outputs to be assessed, a separate investigation could be included in 
future research. 
 
Sensitivity analysis. The definition of “combinable” studies to be used for meta-
analysis is elastic and sensitivity analyses are a useful tool in standard meta-
analysis theory to address this. Sensitivity analyses ask the question of “how 
robust is a meta-analysis with respect to different meta-analysis models, study 
size, study quality, or inclusion criteria”. They are usually applied by repeatedly 
performing meta-analyses for different combinations or selections of the above 
parameters and then interpreting the spread of outcomes so obtained. Extending 
this concept to microarray meta-analysis in the particular instance of this thesis, 
meta-analyses could be repeated by permuting the number and size of studies 
considered, by including further studies that use other treatments (e.g. IFN-β), 
other cell types (e.g. fibroblasts, monocytes), other organisms (e.g. human, rat), or 
other platforms (e.g. Illumina arrays, custom-printed arrays). While this is 
desirable and the full set of studies already collected could make this technically 
feasible, it is extremely complex: A) sensitivity analyses have to be performed for 
each gene, B) in the absence of detailed biological interpretation (such as that done 
in chapter 5) it is not clear how to interpret a finding of more or fewer genes 
achieving a given (or changed) overall effect size, C) at the level of RNA 
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expression and with respect to the characteristics of different cell types or 
signalling pathways within a cell, the experiment factors listed above will likely 
defy simple explanations. With these issues perhaps making a sensitivity analysis 
for those biological factors impractical, a sensitivity analysis excluding different 
studies in turn could be feasible in order to detail the effect of study sizes and 
study numbers. The practical ability to do so technically exists after code solutions 
for meta-analyses and outcome assessments are implemented, but the additional 
effort in assessing this type of meta-analysis robustness was considered secondary 
to assessing the biological implications of results (chapter 5), where robustness is 
characterised by comparisons against known biology and independent 
experiments. Additionally, as a comparison of meta-analysis model outcomes is 
the purpose of chapter 3, section 3.4 is in effect a sensitivity analysis for the effect 
of using different meta-analysis models, although not named as such.  
 
Network analysis. In contrast to statistical probabilistic models for testing 
inference, network analysis is a comparatively subjective tool, that is, depending 
on user choices for parameters and parameter values (primarily scale of data 
values, distance/similarity metric thresholds, type of distance/similarity metric, 
clustering algorithm) the obtained results may be meaningful but only represent 
one possible outcome out of many. Although this research attempts to use 
objective and consistent parameter values to avoid results fully guided by user-
expectations, the obtained gene co-expression networks will represent only an 
incomplete picture of the biological effects measured in the system. 
 
7.3 Future research 
 
A major consideration of this thesis was the interfacing between different 
expertises, and this is planned to remain a future research focus in light of 
biological data becoming more rather than less complex. Future research therefore 
pursues both the promotion of a deeper understanding of the biological system 
through combining data from multiple sources, as well as improvements to meta-
analysis methodology to facilitate this. 
 246 
To this end, follow-up research to this thesis is planned or has already been 
initiated, as outlined below and going beyond intended publications of the 
proportionally weighted Rank Product model, biological results, network analysis, 
and (requiring further simulation work) missing data imputation. Future research 
on the basis of this thesis centers on follow-on experimental validation of results, 
the use of meta-analysis for biological hypotheses, enhancements and alternatives 
to meta-analysis models, and outreach to make basic meta-analysis approaches 
widely accessible. 
 
Follow-up testing of biological hypotheses. Analyses in this thesis have identified 
several hypotheses (discussed in section 7.2) on transcriptional changes induced 
by type II interferon activation of macrophages. Firstly, collaboration with 
experimentalists will be sought for independent validation of induction by IFN-γ 
(partially already in progress in form of siRNA screens and real-time quantitative 
PCR). Secondly, funding will be sought to prospectively perform studies testing 
the newly identified hypotheses and assigning mechanisms of action, with 
particular preference for the linking of type II interferon responses in macrophages 
to sterol biosynthesis and type I interferon response. Thirdly, a later stage may 
include validation of and research into those genes that are significant by meta-





Meta-analysis and cloud computing. Research into the technological aspects of 
future application of meta-analyses to new or legacy microarray data sets has been 
initialised by the Edinburgh Parallel Computing Centre (Alastair Hume) and me. 
Initially, the research question will be addressed by an MSc student, with research 
question and guidance provided by me on the basis of this thesis: Can meta-
analyses be remotely applied to microarray data sets stored in the “cloud” (remote, 
internet-accessible data and software storage)? If successful, further collaboration 
will be sought with microarray data set providers, with the aim of exploiting large 
amounts of new or legacy microarray data for simplified remote meta-analyses by 
non-statisticians. 
 
Applied meta-analyses. Meta-analysis has shown great utility for gaining deeper 
insights into type II interferon signalling in macrophages, which permits 
expansion of this methodology to an expanded view of this system. Further 
research is therefore set to exploit the initial set of candidate studies collected for 
potential meta-analysis, comprising a total of 30 studies. These meta-analyses will 
be aimed to provide a different view of immune responses to that pursued in this 
thesis, and consist of a) responses to type I interferon, b) responses to full 
macrophage activation (both IFN-γ and LPS signal), c) responses in human 
macrophages, and d) responses by other immune cells than macrophages.  
 
Network analyses. Although not a central hypothesis of this thesis, the presence of 
anti-correlated gene networks in the substantiation of meta-analysis results by 
network analysis has uncovered relevant biology and implies higher value than is 
currently acknowledged. In addition to negative correlation, secondary results (not 
included in this thesis) also pointed to limitations of (dis)similarity based networks 
by excluding part correlations (in the sense of breaking a time expression profile 
down into smaller time windows) that nonetheless share a biological relation. It is 
therefore planned to extend formal investigations (using alternative distance 
metrics and identifying probabilistic statistics for network relevance) into the 
identification and meaning of anti-correlated and part-correlated gene networks, 
using existing time course microarray data in the department. 
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Meta-analysis advances. This research has shown that improvements to existing 
meta-analysis models can be beneficial, and future research is set to build on this. 
Firstly, the proportionally weighted Rank Product meta-analysis will undergo 
further comparative testing and biological application within the plans outlined in 
the previous paragraph. Secondly, following refinements and further testing of 
missing value imputation, this approach will also be incorporated and introduced 
to the research community if successful. Thirdly, time courses are a frequent 
design with biological microarray studies, and a future focus will be their use for 
meta-analytical approaches, where this will require comparison to other data-
integration methods. Lastly, high-throughput next-generation-sequencing 
technology is set to become a new standard for post-genomic experiments, and it 
will be a priority to investigate if and how meta-analysis can also be relevant in 
this context. 
 
7.4 Final thoughts 
 
Prior to this research, meta-analysis had been shown to have promise in combining 
microarray study results, but the lack of biological verification in statistical 
research, the lack of meta-analysis methodology comparisons in biological 
research, and the as yet incomplete understanding of transcriptional outcomes in 
type II interferon signalling have driven the research question and research 
methodology in this thesis. 
The number, confirmed biological relevance and inclusion in prospective research 
of findings only attributable to microarray meta-analysis points towards it being a 
very useful research tool for even small sets of heterogeneous microarray studies. 
An obstacle to their use may be the identification of suitable microarray studies 
(which is difficult for analysts) and the merging of data and application of meta-
analyses (which are difficult for biologists). Another obstacle may simply be that 
there is insufficient awareness in the biological research community of statistical 
meta-analysis models and their merits. This is only addressable by outreach 
activities (which this thesis and planned future work is part of), and can only have 
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positive consequences for research, given the availability of very large numbers of 
publicly available microarray data sets that often complement one another. 
There is also little doubt that the value of supplementing statistical methodology 
with biological domain knowledge is real, and that this can not only be achieved 
through close research collaboration, but perhaps maximised through professionals 




















A1- Protein network (STRING), down regulated genes 
(Based on genes that 2 out of 3 meta-analysis model families identified as 






A2 - Protein network (STRING), up regulated genes 
(Based on genes that 2 out of 3 meta-analysis model families identified as 











A3 – QQ plot for deciding on effect size model 
Quantile-Quantile (QQ) plot of theoretical chi-squared distribution quantiles 













A4 – ROC plots for NCBI-derived gene reference lists 
ROC plots for assessing overlap between meta-analysis results and 
computationally generated lists (A,C,D) and manually curated (DPM) interferon-






Reference list A Reference list C 
Reference list D DPM “gold standard” 
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A5 – Sensitivity and specificity summary 
Summary graph of sensitivity and specificity estimates when comparing overlap 
between statistical results (individual studies and meta-analysis, by any of the used 
methods, and for a given significance threshold) and biological reference lists 




A6 – Reversed IDR plots, Fisher’s meta-analysis 
Independent Discovery Rate (IDR) plots reversed, i.e. number of statistical results 







A7 – Reversed IDR plots, Effect Size meta-analysis 
Independent Discovery Rate (IDR) plots reversed, i.e. number of statistical results 






A8 – Reversed IDR plots, Rank Product meta-analysis 
Independent Discovery Rate (IDR) plots reversed, i.e. number of statistical results 





A9 – Reversed IDR plots, Rank Product meta-analysis, 
proportional weights 
Independent Discovery Rate (IDR) plots reversed, i.e. number of statistical results 





A10 – Reversed IDR plots, Rank Product meta-analysis, 
equal weights 
Independent Discovery Rate (IDR) plots reversed, i.e. number of statistical results 





A11 – Transcription factor enrichment of aggregated 
meta-analysis results 
oPOSSUM enrichment analysis, testing for transcription factor binding site 



















































































A12 – DPM gene reference list (“gold standard”) 
 
This  list has been manually curated by the Division of Pathway Medicine and the 
Ghazal group and reflects the core interferon gamma transcriptional network. 
 
MGI Gene 
Symbol Gene Description 
Entrez 
Gene ID 
Ciita class II transactivator [Mus musculus]  12265 
Ccl5 CHEMOKINE (C-C MOTIF) LIGAND 5 20304 
Fasl FAS LIGAND (TNF SUPERFAMILY, MEMBER 6) 14103 
Gbp1 GUANYLATE NUCLEOTIDE BINDING PROTEIN 1 14468 
H2-Aa HISTOCOMPATIBILITY 2, CLASS II ANTIGEN A, ALPHA 14960 
H2-Ab1 HISTOCOMPATIBILITY 2, CLASS II ANTIGEN A, BETA 1 14961 
H2-Bl HISTOCOMPATIBILITY 2, BLASTOCYST 14963 
H2-DMa HISTOCOMPATIBILITY 2, CLASS II, LOCUS DMA 14998 
H2-DMb1 HISTOCOMPATIBILITY 2, CLASS II, LOCUS MB1 14999 
H2-Ea HISTOCOMPATIBILITY 2, CLASS II ANTIGEN E ALPHA 14968 
H2-Eb1 HISTOCOMPATIBILITY 2, CLASS II ANTIGEN E BETA 14969 
H2-M10.1 HISTOCOMPATIBILITY 2, M REGION LOCUS 10.1 14985 
H2-M3 HISTOCOMPATIBILITY 2, M REGION LOCUS 3 14991 
H2-M9 HISTOCOMPATIBILITY 2, M REGION LOCUS 9 14997 
H2-Oa HISTOCOMPATIBILITY 2, O REGION ALPHA LOCUS 15001 
H2-Q1 HISTOCOMPATIBILITY 2, Q REGION LOCUS 1 15006 
H2-Q10 HISTOCOMPATIBILITY 2, Q REGION LOCUS 10 15007 
H2-Q2 HISTOCOMPATIBILITY 2, Q REGION LOCUS 2 15013 
H2-Q5 HISTOCOMPATIBILITY 2, Q REGION LOCUS 5 15016 
H2-Q7 HISTOCOMPATIBILITY 2, Q REGION LOCUS 7 15018 
H2-T22 HISTOCOMPATIBILITY 2, T REGION LOCUS 22 15039 
H2-T23 HISTOCOMPATIBILITY 2, T REGION LOCUS 23 15040 
H2-T24 HISTOCOMPATIBILITY 2, T REGION LOCUS 24 15042 
H2-T3 HISTOCOMPATIBILITY 2, T REGION LOCUS 3 15043 
Il12b INTERLEUKIN 12B 16160 
Il15 INTERLEUKIN 15 16168 
Irf1 INTERFERON REGULATORY FACTOR 1 16362 
Irf2 INTERFERON REGULATORY FACTOR 2 16363 
Psmb9 
PROTEOSOME (PROSOME, MACROPAIN) SUBUNIT, BETA 
TYPE 9 (LARGE MULTIFUNCTIONAL PEPTIDASE 2) 16912 
Socs1 SUPPRESSOR OF CYTOKINE SIGNALING 1 12703 
Socs3 SUPPRESSOR OF CYTOKINE SIGNALING 3 12702 
Stat1 
SIGNAL TRANSDUCER AND ACTIVATOR OF 
TRANSCRIPTION 1 20846 
Tap1 
TRANSPORTER 1, ATP-BINDING CASSETTE, SUB-FAMILY 
B (MDR/TAP) 21354 
Nfkbia 
nuclear factor of kappa light polypeptide gene enhancer in B-
cells inhibitor, alpha  18035 
Tnf tumor necrosis factor 21926 
Tlr2 toll-like receptor 2 24088 
CCl4 chemokine (C-C motif) ligand 4 20303 
Gbp5 guanylate binding protein 5  
Cxcl10 chemokine (C-X-C motif) ligand 10 15945 
Gbp3 guanylate binding protein 3 55932 
Ifit1 interferon-induced protein with tetratricopeptide repeats 1 15957 
Ifit3 interferon-induced protein with tetratricopeptide repeats 3 15959 
Mx2 myxovirus (influenza virus) resistance 2 17858 
Adar adenosine deaminase, RNA-specific 56417 
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Stat2 signal transducer and activator of transcription 2 20847 
Ddx58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58  
Ccl3 chemokine (C-C motif) ligand 3 20302 
Cd274 CD274 antigen 60533 
Oasl1 2'-5' oligoadenylate synthetase-like 1 231655 
Oas2 2'-5' oligoadenylate synthetase-like 2 23962 
Gbp2 guanylate binding protein 2 14469 
Gbp6 guanylate binding protein 6 229900 
Tlr3 toll-like receptor 3 142980 
Ifih1 interferon induced with helicase C domain 1 71586 
Ifit2 interferon-induced protein with tetratricopeptide repeats 2 15958 
Ifi205 interferon activated gene 205  226695 
lsg20 interferon-stimulated protein 57444 
Zbp 1 Z-DNA binding protein 1 58203 
Gbp4 guanylate binding protein 4  
H2-D1 histocompatibility 2, D region locus 1 14964 
Irf3 interferon regulatory factor 3 54131 
Irf4 interferon regulatory factor 4 16364 
Irf5 interferon regulatory factor 5 27056 
Irf6 interferon regulatory factor 6 54139 
Irf7 interferon regulatory factor 7 54123 
Irf8 interferon regulatory factor 8 15900 
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